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ABSTRACT 
 
Introduction 
Intrauterine growth restriction (IUGR) is a common obstetric condition causing significant perinatal 
morbidity and mortality. A phenomenon known as brain sparing occurs in IUGR fetuses whereby 
blood is preferentially diverted to supply the developing brain often at the expense of other organs.  
However, although this supposedly neuroprotective mechanism exists, children that were growth 
restricted in utero have a higher incidence of long term neurodevelopmental sequelae. 
This thesis therefore aims to explore the brain redistribution phenomenon in detail by investigating 
cerebral volume blood flow and the metabolic profile of the IUGR brain using high resolution 
ultrasound and proton magnetic resonance spectroscopy respectively. 
Methods 
150 appropriately grown and 78 IUGR fetuses had volume blood flow assessed longitudinally using 
high resolution ultrasound and power Doppler in multiple fetal vessels. The metabolic status of the 
brain was then assessed in 46 appropriately grown and 26 growth restricted fetuses using Proton 
Magnetic Resonance Spectroscopy. 
Results 
IUGR fetuses had a generalised increase in vessel diameter in comparison with appropriately grown 
control fetuses, and when standardised for weight, increased volume blood flow was noted in the 
middle cerebral, renal, umbilical and carotid arteries and the ascending aorta.  No difference in flow 
was noted in the descending aorta. 
N-acetylaspartate:Choline and N-acetylaspartate:Creatine ratios were reduced in IUGR fetuses and 
lactate was present in the developing brains of both appropriately grown and growth restricted fetuses. 
Conclusions 
Volume blood flow is significantly altered in IUGR fetuses, likely to be mediated by alterations in 
vessel diameter. This may be secondary to alterations in circulating vasoactive factors or as a 
result in alterations of the composition of vessel walls.  The metabolic status of the brain tissue is 
also altered which may in part explain the higher incidence of neurodevelopmental sequelae in some 
fetuses that were growth restricted in utero. 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Introduction 
 
Intrauterine growth restriction (IUGR) is a common and challenging obstetric condition, 
associated with significant perinatal morbidity and mortality[1].  Even if survival beyond 
infancy occurs, associations between in utero growth restriction and childhood and adult 
disease are well reported[2].  A phenomenon known as ‘brain sparing’ occurs in growth 
restricted pregnancies, whereby blood is preferentially diverted to supply the developing 
brain.  However, even though this supposedly neuroprotective mechanism exists, individuals 
that were growth restricted in utero are at higher risk of neurodevelopmental sequelae[3].   
 
Much of the current knowledge regarding IUGR is derived from animal studies and 
ultrasound assessment of human fetuses.  However, many aspects regarding the 
pathophysiology of the condition and its association with long term outcome have not been 
fully elucidated.  Currently there are no effective preventive or therapeutic strategies and 
clinical management focuses on the correct identification of IUGR fetuses and appropriate 
timing of delivery[4].  Therefore, a thorough understanding of the pathophysiology of the 
condition will form the basis for preventative and treatment options in the future. 
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1.2 Definition and Prevalence of IUGR 
 
A precise definition of IUGR is crucial to the appropriate clinical management and optimal 
perinatal outcome[4].  However, there is a lack of uniformity in diagnostic criteria, and 
reported studies in the literature often do not distinguish between the terms ‘small for 
gestational age’ (SGA) and IUGR.  A threshold of the 10th centile for birth weight and/or 
abdominal circumference is generally used to define the SGA fetus[5].  This, however, is a 
purely statistical definition and will encompass constitutionally small but healthy fetuses.   
 
Chard et al proposed that true IUGR encompasses fetuses that fail to reach their genetic 
growth potential; where growth velocity slows or ceases due to inadequate oxygen and 
nutritional supply.  It is this subgroup that are at the highest risk of the sequelae associated 
with poor in utero growth[6].   
 
Bobrow and Soothill further refined the definition of IUGR proposing a categorization based 
on aetiology[7]: 
 
1 normal SGA: where fetuses have no structural anomalies, normal liquor volume 
and normal distribution of blood flow: 
2 abnormal SGA: where fetuses have evidence of structural or genetic 
abnormalities: 
3 IUGR: where fetuses have impaired placental function, identified by abnormal 
blood flow within the fetus and reduced growth velocity. 
 
The incidence of true fetal growth restriction is difficult to determine but it has been reported 
that as few as 15% of SGA fetuses have true IUGR[8].  True growth restriction will be the 
focus of this thesis. 
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1.3 Aetiology 
 
Fetal growth is a complex interaction of the pre-determined genetic growth potential of the 
fetus, which may be predicted from parental characteristics[9] and modifying factors 
including: maternal, fetal, placental and external conditions.  Factors which may contribute to 
IUGR are outlined in Table 1.  There is often an overlap between conditions resulting in 
IUGR, and risk factors may also interact synergistically[10].  The most common causes of the 
condition will be outlined in more detail below. 
 
1.3.1 Fetal Causes of IUGR 
Genetic abnormalities are associated with 5-20% of cases of IUGR.  Trisomies, 18 and 13 
can result in growth restriction through a reduction in the number of small muscular arteries 
in the tertiary stem villi of the placenta[11].  Single gene disorders, partial chromosomal 
deletions, specific placental mosaics and uniparental disomy have also been associated with 
abnormal fetal growth[11-12]. 
 
A reduction in growth velocity is also a common finding in fetal infections, accounting for 
10% of cases of IUGR.  Examples include: cytomegalovirus, rubella, syphilis, toxoplasmosis 
and malaria[8].  Cytomegalovirus causes direct cytolysis and loss of functional cells, rubella 
results in vascular insufficiency by damaging the endothelium of small vessels and by 
reducing cell division, syphilis causes vasculitis, thrombosis and villous oedema of the 
placenta and malaria results in activation of immune mediated inflammatory processes and 
causes platelet deposition in the vascular system resulting in vessel obstruction[11]. 
 
The risk of IUGR is dependent on the number of fetuses present as well as chorionicity of the 
pregnancy.  Overall 3% of cases of IUGR are associated with multiple gestations, 
monochorionic twins have a 40% risk of developing IUGR compared with 20% of 
dichorionic twins.  When the condition does arise, morbidity and mortality is higher among 
twin IUGR fetuses than singletons.  As in singleton pregnancies IUGR may be a marker for 
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structural or genetic abnormalities, placental dysfunction or infection but in monochorionic 
twin pregnancies it may also reflect twin to twin transfusion syndrome[11]. 
 
1.3.2 Maternal Causes of IUGR 
There is extensive evidence which has correlated prenatal smoking with low birthweight and 
IUGR[13].  This effect is also noted with women exposed to passive smoking whilst 
pregnant.  The underlying mechanisms of the association are unclear but may be related to a 
combination of increased fetal carboxyhaemoglobin levels[8], culminating in decreased 
oxygen carrying capacity and impaired uterine blood flow[11].  Other maternal conditions 
also cause a reduction in oxygen carrying capacity including lung disease, anaemia, cyanotic 
heart disease and life at high altitude [11].   
 
In the past thrombophilia was considered a risk factor for the development of IUGR.  
Associations have been reported with specific genetic mutations leading to a maternal 
thrombophilic state resulting in an increased risk of placental thrombosis[14].  However, a 
meta-analysis by Facco et al found there was a statistically significant association only 
between factor V Leiden and IUGR and this was in case control-studies only[14].  Further, 
research needs to be undertaken to assess true associations between thrombophilia and IUGR 
to eliminate the effects of publication bias. 
 
1.3.3 Placental Causes 
A compromised supply of nutrients and oxygen through the placenta to the fetus is the 
commonest cause of IUGR; this has been reported to account for up to 90% of cases[15].  
Placental dysfunction results in a reduction in fetal cell size.  If the onset of IUGR is early in 
gestation cell number may also be affected[10].   
 
Placental dysfunction is associated with another pregnancy specific condition - pre-
eclampsia.  This is a multisystem disease and can result in increased systemic vascular 
resistance, increased platelet aggregation, endothelial dysfunction and activation of the 
coagulation system[16].  Pre-eclampsia can manifest as an entirely maternal condition but it 
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can be found in association with fetal growth restriction, as the two conditions share common 
pathophysiology[16].  This will be discussed in more detail below (see page 32). 
 
Although there is considerable overlap in the aetiology of IUGR this thesis will focus on 
placental causes in singleton pregnancies, excluding fetuses with evidence of karyotype 
abnormalities or congenital infections.   
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Factor Example 
Maternal Malnutrition 
Maternal age <16 
Parity 
Low socio-economic status 
Chronic hypertension 
Pre-eclampsia 
Diabetes 
Renal disease 
Antiphospholipid syndrome 
Inherited thrombophilias 
Fetal Chromosomal abnormalities 
Genetic conditions 
Congenital malformations 
Intrauterine infections 
Multiple pregnancy 
Placental Abnormal placentation 
Chronic placental abruption 
Uterine abnormalities 
Confined placental mosaicism 
Environmental Smoking 
Alcohol 
Drug usage 
High altitude 
Irradiation 
 
Table 1 Risk Factors for Intrauterine Growth Restriction 
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1.4 Physiology of Fetal Growth 
 
The placenta is a critical structure in the aetiology of IUGR.  The development of the normal 
placenta will first be outlined, followed by abnormalities which contribute to the 
development of growth restriction. 
 
1.4.1 Normal Development of the Placenta 
Placentation commences with implantation of the blastocyst to the uterine epithelium 6-7 
days post fertilization.  The blastocyst comprises of an inner cell mass, a fluid filled cavity, 
the blastocele and an outer layer of mononucleated epithelial cells, trophoblasts (Figure 1). 
The trophoblast gives rise to the majority of the placenta and fetal membranes, and the inner 
cell mass results in the embryo proper, umbilical cord and the placental mesenchyme. 
 
 
Figure 1 Blastocyst 
The trophoblast overlying the inner cell mass attaches to the uterine endometrium and upon 
contact polar trophoblast differentiates into two layers: inner mononucleated cells, the 
cytotrophoblast, and an outer multinucleated zone with indistinct cell boundaries, the 
syncytiotrophoblast.  Implantation also involves characteristic changes in the histology of the 
uterine endometrium including the replacement of uterine epithelial cells with epithelised 
stromal cells or decidual cells.  These changes are known as the decidual reaction.  Local 
oedema also occurs in the stroma surrounding the blastocyst due to increased vascular 
permeability.  Inflammatory cells migrate to the site of implantation and restructuring of the 
connective tissue matrix, blood vessels and uterine glands occurs. 
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The syncytiotrophoblast has an invasive role and penetrates the uterine epithelium.  The 
embryo becomes embedded in the decidual stroma with the syncytiotrophoblast providing a 
complete covering.  The cytotrophoblast cells engage in mitotic activity, rapidly dividing and 
undergoing membrane-membrane fusion with the syncytiotrophoblast culminating in its 
expansion.  By day 9 vacuoles develop within the syncytiotrophoblast which fuse to form 
lacunae, resulting in an inter-communicating network.  These are the spaces into which the 
maternal blood supplying the placenta flows.   
 
The cytotrophoblast cells form cellular columns which penetrate into, and are surrounded by 
syncytiotrophoblast.  These cellular columns have a number of functions.  Within the first 
four weeks of pregnancy cytotrophoblast cells placed distally at the ends of the columns 
migrate outwards into the uterine tissue as extravillous cytotrophoblast, attaching to and 
invading the uterus and its arterioles.  Two distinct populations of extravillous trophoblast 
exist: interstitial cytotrophoblast which invade the decidual stroma and superficial 
myometrium and the endovascular cytotrophoblast which invade the lumen of spiral arteries, 
destroying the elastic and muscular components of the vessel wall and replacing them with 
fibrous tissue.  The endovascular cytotrophoblast thereby converts the muscular spiral arteries 
of the uterus into wide, flaccid vessels which can accommodate the increase in maternal 
placental blood flow and form a high flow, low resistance vascular conduit which perfuses 
the lacunar spaces and forms a primitive circulation. 
 
The actual columns of cytotrophoblast cells within the placenta form primary villi.  Primary 
villi obtain a mesodermal core, growing towards the decidua, thus forming secondary villi.  
From day 20 mesodermal cells within the core of the villus differentiate into blood cells and 
blood vessels creating the villous capillary system and forming a tertiary villus (Figure 2).  
During the first and second trimesters villous vascularisation is determined by sprouting and 
branching angiogenesis.  By the end of the second trimester expansion of the fetal placental 
vascular system is by non branching angiogenesis resulting in elongated terminal capillary 
loops.  These form the capillary network of the mature terminal villi which are responsible 
for nutrient and gas exchange[17]. 
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Figure 2 Tertiary Villus 
The syncytiotrophoblast is in direct contact with the intervillous space (see Figure 3).  It has a 
crucial role as it is the location of a variety of receptors, transporters and enzymes facilitating 
regulation of maternal-fetal exchange[18].  Following formation of the maternal-fetal 
circulation, placental transport capacity is the major determinant of fetal growth.  Transport 
capacity is increased as the surface area of the villous membrane increases which is 
associated with an increased density of carrier proteins for glucose, amino acids and fatty 
acids. 
 
Villous trophoblasts are highest during the third trimester.  Apoptosis of these cells is part of 
normal pregnancy[19] and is normally compensated for by increased cytotrophoblast 
proliferation and differentiation[20].  The nuclei of the syncytiotrophoblast aggregate with 
condensation of chromatin forming syncytial knots and protrude into the intervillous 
space[21].  
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Figure 3 Longitudinal Section through a Villus, Illustrating Maternal and Fetal 
Circulations 
 
Multiple angiogenic growth factors, cell adhesion molecules, cytokines, growth factors, 
matrix metalloproteinases (MMPs) hormones and transcription factors are also necessary for 
effective placentation.  Invasion of the uterus requires attachment of trophoblast cells to the 
extracellular matrix (ECM) and subsequent migration.  As the trophoblast differentiates into 
cytotrophoblast and syncytiotrophoblast cells, changes in the expression of cell adhesion 
molecules (CAMs), cadherins and integrins, occur.  Villous cytotrophoblast cells express E-
cadherin which is involved in intercellular junctions and cell polarity and the α6 and β4 
integrin subunits which form receptors for the extracellular matrix component laminin.  
Syncytiotrophoblast and extravillous cytotrophoblast cells express cadherin 11.  Down 
regulation of extravillous cytotrophoblast α6 and β6 subunits and upregulation of the α5β1 and 
α1β1 integrins which are fibronectin and collagen/laminin receptors respectively also occurs.  
Culture studies have shown that α1β1 laminin/collagen interactions promote invasion whereas 
α5β1 fibronectin interactions restrain it.  Therefore, differential expression of cell adhesion 
molecules is integral to normal placentation.  Following successful attachment to the uterus, 
degradation of the extracellular matrix is facilitated by proteinases, such as matrix 
metalloproteinases, that are expressed by extravillous cytotrophoblast.  Expression is 
maximal in the first trimester and diminishes in the second trimester. 
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Growth factors and cytokines have also been implicated in the regulation of placentation, 
including transforming growth factor (TGF) β1, insulin like growth factor (IGF) II, epidermal 
growth factor (EGF), activin and interleukin (IL) 1.  IGF II, activin, and IL 1β and EGF 
stimulate invasion of isolated cytotrophoblasts.  In contrast TGFβ inhibits the invasiveness of 
first trimester cytotrophoblasts by inducing production of tissue inhibitors of matrix 
metalloproteinases and promoting fusion of the cells to form syncytiotrophoblast, effects 
mediated by the high affinity receptor endoglin. 
 
The development of the placental villous tree is also regulated by a number of growth factors 
and their receptors.  Vascular endothelial growth factor (VEGF) is expressed in villous 
trophoblast and stromal macrophages.  Expression declines with advancing gestation and its 
transcription is induced under hypoxic conditions by the transcription factor hypoxia 
inducible factor (HIF) 1, expressed in the human placenta.  VEGF exerts its actions via two 
2-tyrosine kinase receptor isoforms: Vascular Endothelial Growth Factor Receptor (VEGF-
R)1 and VEGF-R2.  VEGF-R2 binding by VEGF induces endothelial cell proliferation while 
binding to VEGF-R1 stimulates endothelial tube formation.  These events combined result in 
branching angiogenesis[22].  In later pregnancy VEGF secretion decreases but another 
growth factor Placenta-like growth factor (PlGF) secretion increases.  PlGF shares 53% 
sequence homology with VEGF and binds exclusively to VEGF-R1 culminating in tube 
formation.  PlGF mediates its angiogenic activity by heterodimer formation with VEGF.  The 
shift in balance from the actions of VEGF to PlGF may explain the change in villous 
angiogenesis from branching to a non branching pattern; this results in the formation of 
terminal villi, as well as, the inhibition of the expansion of the feto-placental capillary tree 
necessary for early placental growth[23]. 
 
The local environment in different regions of the endometrium may also play a role in the 
control of cytotrophoblast proliferation and differentiation.  Culture of cytotrophoblast cells 
under hypoxic conditions promotes proliferation but not differentiation, whereas in normoxic 
culture the opposite occurs. 
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The placenta continues to grow and during the third trimester placental villi show 
maturational changes including larger capillaries that lie closer to a thinner 
syncytiotrophoblast.  Most cells of the cytotrophoblast disappear facilitating diffusional 
exchange.  As the villous tree grows the decidual tissue forms placental septa which divide 
the placenta into 15-20 convex areas called cotyledons.  Placental septa do not extend to the 
chorionic plate maintaining the maternal circulation between cotyledons. 
 
1.4.2 Placental Development in IUGR 
Analyses of placentas of pregnancies complicated by IUGR indicate abnormalities of 
maternal spiral arterioles, angiogenesis and development of the villous tree, and increased 
fibrin deposition[24].  Placental dysfunction, and structural abnormalities culminate in a 
reduction in nutrient transfer to the fetus.  These mechanisms will be outlined in more detail 
below. 
 
Abnormal invasion of myometrial segments of maternal spiral arterioles occurs in IUGR 
pregnancies as trophoblast are more proliferative and less invasive.  This creates high 
resistance vessels with persistent smooth muscle histology predisposing to placental hypo-
perfusion, hypoxia, oxidative stress, reperfusion injury, and evidence of villous tree 
malformation in the latter stages of pregnancy[20].  Altered expression of some CAMs[25] 
and a reduction in secretion of MMPs, resulting in reduced trophoblast invasiveness have 
been reported[26] and aberrant expression of growth factors and receptors in placental tissue 
may also contribute to the abnormal placentation associated with IUGR[27-28].  
 
Inadequately developed spiral arterioles may result in oxidative stress and the formation of 
reactive oxygen species[20].  IUGR placentas show signs of oxidative stress with reduced 
protein translation and reductions in key signalling proteins[29].  Hypoxia/re-perfusion of the 
placenta has been shown to induce greater trophoblast damage than hypoxia alone[30].  This 
may not be completely attributable to reactive oxygen species but also due to abnormal 
complement activation[20]. 
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Maternal factors which prevent vascular remodelling may contribute to the pathogenesis of 
IUGR.  Such conditions may include vascular disease resulting in local tissue hypoxia, 
genetic polymorphisms associated with abnormal vascular function, auto antibodies against 
maternal endothelium and failure of uterine natural killer cells to produce trophic cytokines in 
response to some MHC-C alleles[24].  Thrombosis of poorly transformed spiral arteries can 
also occur resulting in villous placental ischaemia and infarction.  This may interfere with the 
diffusion capacity of the placenta and impair nutrient exchange[22]. 
 
Early onset IUGR is associated with abnormal development of the villous tree which can 
result from a severe reduction in uterine blood flow.  A reduction in branching angiogenesis 
and decreased placental vascularisation results in a reduction in villi number with poor 
capillary formation.  Peripheral villi which contain slender unbranched and uncoiled capillary 
loops have also been reported.  This results in a reduction in surface area available for 
maternal-fetal nutrient transport[17].  A lack of oxygen extraction and consumption by the 
IUGR fetuses means that the oxygen content of maternal blood exiting the placenta is close to 
arterial values.  Increased PlGF versus VEGF expression has been found in early onset IUGR 
fetuses which further perpetuates a reduction in branching angiogenesis and abnormal villous 
tree formation[22]. 
 
Late onset IUGR demonstrates increased branching angiogenesis secondary to deficient 
remodelling of the spiral arteries.  Uteroplacental hypoxia is thought to be due to increased 
expression of factors which stimulate branching angiogenesis[17].  IUGR in late pregnancy is 
also associated with increased maturation of the placenta (Grannum grade 2 or 3) and a 40% 
increase in capillary fraction volume[31].   
 
Nutrient transfer has also been shown to be altered in IUGR placentas, with a reduction of 
activity and expression of essential amino acid and ion transporters[32].  System A is a 
sodium dependent transporter which transports neutral amino acids with short side chains 
including alanine, serine, proline and glycine.  Sodium independent systems L and y+ 
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transport branched chain amino acids and lysine.  Both of these systems show a reduced 
maximum rate in IUGR indicating a decreased number of transporter molecules[33]. 
 
Apoptosis of villous trophoblasts increases during pregnancy and villous injury may not be 
accompanied by an increase in cytotrophoblast proliferation and differentiation.  This 
imbalance of injury and repair may contribute to IUGR[34].  Pregnancies with IUGR 
demonstrate enhanced sensitivity to undergo cell death both in response to hypoxia and 
cytokines when compared with control pregnancies[35].  Syncitial knots, indicative of 
syncytiotrophoblast apoptosis, are increased in comparison with normal control 
placentas[36].  p53 has been implicated in apoptosis regulation in the IUGR placenta[20]. 
 
Increased apoptosis in villi from IUGR placentas is also indicated from increased cleavage 
products of caspase including cytokeratin 18 cleavage products[37].  Where there is a breach 
in the syncytiotrophoblast, cytokeratin 18 cleavage products and nuclei with condensed 
chromatin, indicative of apoptosis, are evident on the villous surface.  The discontinuity in 
the syncytium is marked by fibrin containing deposits which can be seen ultra structurally on 
the trophoblastic basement membrane.  Increased injury of the villous trophoblast would 
reduce the surface area of the syncytiotrophoblast thereby limiting nutrient transport[37]. 
 
1.4.2.1 IUGR and Pre-eclampsia 
As described on page 22, IUGR is often found concomitantly with pre-eclampsia[38] and 
both disorders involve abnormal placentation.  Pre-eclampsia and IUGR share many aspects 
of pathophysiology but there are also disparate components.  Accelerated endothelial 
dysfunction is a feature of both pre-eclampsia and IUGR.  A number of adhesion molecules 
are elevated in both conditions, although levels in pre-eclampsia often exceed those found in 
isolated IUGR[39].  Structural and cellular abnormalities in the placenta are also similar 
between the conditions.  Low levels of PlGF are observed in both IUGR and pre-eclampsia, 
mediated by down regulation due to hypoxia and HIF-1. 
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Pre-eclampsia, however, is associated with a greater degree of endothelial dysfunction and 
inflammation than IUGR in isolation.  Increased syncytiotrophoblast microparticles are shed 
into the maternal circulation in pre-eclampsia which are thought to be the stimulus of the 
systemic inflammatory response and endothelial damage responsible for the maternal 
condition.  These microparticles are not found to be elevated in cases of isolated IUGR[40]. 
 
It has recently been proposed that pre-eclampsia is a heterogeneous disorder and may be sub-
classified into separate aetiologies: early onset (less than 34 weeks) and late onset (greater 
than 34 weeks)[41].  Early onset pre-eclampsia is associated with 20 fold higher maternal 
mortality than term disease.  The pathophysiology of early onset disease differs from late 
onset with regards to neutrophil function[42] and cytokine levels[42].  It is likely that IUGR 
can also be separated into early and late onset disease as alterations in pathophysiology have 
been noted with regard to placental angiogenesis and placental transport mechanisms (see 
page 30). 
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1.5 The Fetal Response to Chronic Placental Insufficiency the Use of Animal Models 
 
Knowledge of both normal pregnancies and those complicated by IUGR has increased 
significantly over the last 50 years by means of ultrasound studies on human fetuses.  
However many questions regarding the progression and adaptation of IUGR fetuses to their 
environment cannot be addressed in human fetuses for ethical reasons.  Animal models 
therefore have provided a useful tool for further elucidating the pathophysiology and 
progression of IUGR.  No animal model of IUGR fully represents the human condition; 
however, IUGR can be induced in a number of species.  These models, and their specific 
advantages and disadvantages, will be outlined briefly below. 
 
Rodents were one of the first animals used to model IUGR by ligation of the uterine 
arteries[43].  Over 60% of animal model studies of IUGR currently use the rat model, 10% 
mice and 4% guinea pigs[44].  A number of other mechanisms can be used to induce growth 
restriction in the rodent including caloric restriction, glucocorticoid exposure and protein 
restriction[45].  Rodent models are convenient as they have a short gestation period and are 
useful for follow up studies.  The guinea pig model has a haemomonochorial placenta, and 
although labyrinthine which is highly invasive, it has similar growth patterns to that seen in 
humans.  They also deliver precocial neonates and have a similar IGF axis to that of 
humans[46].  Many similarities between the mouse and rat are seen with human physiology 
at the cellular and molecular level sharing similar genes and biochemical pathways.  Rodents 
are, however, altricial and the brain, renal, cardiovascular and endocrine/paracrine systems 
mature postnatally; whereas, in humans, this occurs prenatally[47].  Animals are also of a 
small size which limits any physiological studies which can be performed on them. 
 
Asymmetric growth restriction occurs spontaneously in runted piglets therefore avoiding the 
confounding impacts of artificial interventions to induce the condition.  Piglets are also of a 
sufficient size to facilitate ease of study, for example if daily blood samples are required.  
Developmental similarities also occur between the human fetus and the developing piglet 
including: a growth spurt during the perinatal period, energy metabolism, oxidative brain 
metabolism and cardiovascular and central autonomic functions[15]. 
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Non human primates are the closest analogue of human development and they are the only 
animals which have a discoidal, villous haemochorial placenta similar to that of humans[48].  
Marmoset monkeys (callithrix jacchus) have been used to assess the impact of nutritional 
restrictions on pregnancy and later health.  This species has a small size and is therefore easy 
to house and care for.  They also have a short average and maximum lifespan compared to 
other primates which makes them suitable for assessing the impact of the intrauterine 
environment on later health[49].  However, primate models of IUGR are extremely limited, 
partly due to their expense and need for stringent ethical approval. 
 
Ovine models account for 12% of IUGR animal models.  Advantages include comparable 
organogenesis to the human, occurring early in gestation and cardiovascular systems that are 
functionally mature during the late fetal period.  The ovine placenta also has a similar 
vascular structure[50] to the human placenta and the large size of sheep facilitates easy access 
for physiological samples.  IUGR can be induced by a number of mechanisms in the ovine 
model including: uterine carunclectomy, single umbilical artery ligation (not a suitable model 
for assessing late onset IUGR as all animals delivery early), placental embolisation (more 
suitable for studying late onset disease), high ambient temperature and overfeeding[47].  
However, sheep models are expensive, and different endocrine responses also occur in certain 
sheep models which differs from progression of the disease in human fetuses[47]. 
 
Animal models have not only facilitated assessment of the pathophysiology of IUGR where it 
is unfeasible to conduct experiments on the human fetus but they have also enabled validation 
of non invasive assessment techniques such as ultrasound which can then be utilised in the 
human fetus, both in the research and clinical setting[51]. 
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1.6 The Fetal Response to Chronic Placental Insufficiency 
 
A number of physiological adaptations occur in the growth restricted fetus in response to the 
adverse uterine environment as a result of placental insufficiency.  These adaptations which 
occur during the antenatal period are not just of significance in determining perinatal 
morbidity and mortality but may form the basis for disease in later life (see on page 61).   
 
1.6.1 Metabolic and Cellular Effects of IUGR on the fetus 
1.6.1.1 Oxygenation and Acid Base Status 
In healthy pregnancies fetal oxygen consumption is maintained at levels similar to those ex 
utero by the maintenance of high blood flow rates due to high fetal cardiac output. Other 
factors which are important in maintaining fetal oxygenation under normal physiological 
conditions include the high fetal haemoglobin concentration and the oxygen dissociation 
curve of fetal erythrocytes, which is shifted to the left when compared to that of adult 
haemoglobin.  This shift favours increased extraction in the placenta and increased delivery 
in fetal tissues (Figure 4). 
 
Figure 4 Graph of Fetal and Maternal Oxygen Dissociation Curves 
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The demands of the fetus can be met by increased fractional extraction when nutrient supply 
to the fetus is only mildly restricted[10].  Ovine models have demonstrated that in cases of 
growth restriction fetal hypoxemia and mild acidosis were common findings[52].  However, 
the sheep model has also demonstrated that moderately growth restricted fetuses do not 
always show significant reductions in fetal oxygen concentrations[53]. 
 
Studies on the human fetus utilising umbilical cord blood sampling have confirmed these 
findings[54-56].  Not all fetuses that had been classified as growth restricted showed 
alteration of metabolic parameters.  Pardi et al. found that: no fetuses with a normal heart rate 
pattern and normal Doppler velocimetry on ultrasound had evidence of hypoxia or acidaemia, 
where fetuses had a normal heart rate pattern but abnormal Doppler velocimetry, 17% had a 
moderate lactic acidosis, 4% had low pH and 13% were acidotic and where fetuses had 
abnormal heart rates and abnormal velocimetry, 64% had lactic acidosis, low oxygen content 
and low pH values.  The absence of end diastolic flow was also found to increase the risk of 
abnormal biochemical parameters[57].   
 
1.6.1.2 Carbohydrate Metabolism 
Maternal arterial glucose levels are unchanged in the ovine model of IUGR but fetal levels 
are significantly reduced[58].  Glucose transport between the mother and fetus is dependent 
on concentration gradients, occurring by facilitated diffusion through transporter proteins.  A 
sheep model, using tracer methodology to quantify fetal glucose utilization, found that fetal 
glucose utilization was not decreased compared with controls but the fraction of glucose 
oxidised was reduced.  The utilization rate in the fetus was higher than the uptake rate from 
the placenta implying fetal glucose production[59].  Levels of gluconeogenic enzymes were 
also found to be increased[59].  An explanation for this was an increased arterial plasma 
glucagon and norepinephrine concentrations both of which increased the expression of the 
gluconeogenic enzymes[60].  Glucose production in the fetus was reversible and was 
suppressed during a hyperglycaemic clamp[60].  The ovine IUGR fetus has reduced baseline 
and glucose stimulated arterial plasma insulin levels[59].  The fact that glucose utilization 
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rates are maintained despite a reduction in insulin levels indicates increased insulin 
sensitivity[59]. 
 
The findings in animal models have been supported in the human fetus by Marconi et al who 
analysed maternal and fetal glucose concentrations.  They found lower glucose levels in 
growth restricted fetuses and a higher maternal-fetal glucose difference compared to control 
pregnancies[61].  Findings of increased insulin sensitivity from animal models have also been 
confirmed in neonatal human studies.  Bazaes et al analysed the effect of low birth weight on 
glucose and lipid metabolism 48 hours after delivery.  They found lower glucose and insulin 
levels than appropriately grown controls and higher glucose/insulin ratios[62]. 
 
1.6.1.3 Protein Metabolism 
In healthy pregnancies increasing gestation requires increased nutritional demands, increased 
perfusion of the placenta and increased capacity of the placenta to transport nutrients.  
Maternal amino acid concentrations are directly related to placental amino acid transport in 
both normal and growth restricted pregnancies[63].  Fetal concentrations are often higher 
than maternal concentrations indicating that active transport is involved[64].  As nutrient 
supply to the growth restricted fetus deteriorates fetal hypoglycaemia becomes apparent, 
other energy sources are required and proteins can be catabolised to gluconeogenic amino 
acids[10]. 
 
Animal models have demonstrated that there are significant reductions in the placental flux of 
essential amino acids such as leucine and threonine.  In studies of hypoxic and 
hypoglycaemic sheep, fetuses with hypoxia and hypoglycaemia have reduced umbilical 
uptake of essential amino acids, but fetal essential amino acids are unaltered[65].  Cerebral 
levels of amino acids are however altered in growth restricted rat fetuses.  Under conditions 
of normoxia, the striatal concentration of aspartate was reduced and the level of alanine 
increased in comparison to appropriately grown fetuses[66]. 
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Studies on human fetuses have demonstrated that amino acid levels are higher in non 
pregnant women than pregnant women but this difference is less apparent in growth restricted 
pregnancies[33].  Maternal concentrations of some amino acids are increased in growth 
restricted pregnancies in comparison to normal pregnancies, including: lysine, histidine, 
valine, isoleucine, leucine, phenylalanine, arginine, alanine and tyrosine[67].  Under 
conditions of hypoxia and hypoglycaemia, although the uptake of essential amino acids is 
reduced absolute concentrations are comparable to normal controls[68].  It has been proposed 
that in the presence of relative hypoxia and hypoglycaemia, a hypometabolic state occurs, 
maintaining essential amino acid concentrations despite reduced uptake[65]. Placental 
transfer of amino acids is decreased even in cases of IUGR where oxygenation, acid base 
balance and placental blood flow are normal.  This may indicate that the reduction of fetal 
amino acid levels is a consequence of both a reduction in transport as well as increased 
protein breakdown to meet the energy requirements of the fetus. 
 
Elevated glycine to valine ratios have been reported in the cord blood of growth restricted 
fetuses at delivery[69].  This same effect can be observed in cases of calorie malnutrition in 
children[70] and it is possible that a similar mechanism of malnutrition occurs in the growth 
restricted fetus. 
 
1.6.1.4 Lipid Metabolism 
Lipids have a number of roles in the fetus: they are essential components of cell membranes, 
function as an important energy source as well as acting as precursors of cellular signalling 
molecules.  Lipid is present in a number of different forms: triglycerides, phospholipids and 
free fatty acids.  Free fatty acids in the fetal circulation may arise from placental transfer, de 
novo synthesis within the feto-placental tissue or from breakdown of triglycerides and 
phospholipids[71]. 
 
Absolute concentrations and relative proportions vary greatly between species[71].  However, 
a guinea pig model showed no alteration between IUGR and control fetuses in the 
incorporation of free fatty acids into triglycerides 45 minutes after an infusion of [1-14C] 
palmitic acid[72].  A rat model which specifically assessed hepatic fatty acid metabolising 
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enzymes in IUGR and control animals found a significant reduction in activity of acetyl CoA 
carboxylase, carnitine palmitoyltransferase and the alpha subunit of the trifunctional protein 
of β-oxidation[73].   
 
Human studies of lipid metabolism have focused on free fatty acid, triglyceride and 
lipoprotein concentrations in maternal and fetal blood as well as alterations in receptors and 
enzymes located within the placenta.  In humans essential fatty acids, linoleic acid and α-
linolenic acid and long chain polyunsaturated fatty acid derivatives (LCPUFAs) are important 
in fetal development.  LCPUFAs can be synthesised from essential fatty acids in adults[74]; 
however, significant venous arterial concentration differences in free fatty acids across the 
umbilical circulation at elective Caesarean section indicate significant placental transfer 
occurs for fetal supply[75]. 
 
Although total plasma lipid concentrations are not significantly altered in mothers and fetuses 
of IUGR pregnancies compared with appropriately grown control pregnancies, maternal:fetal 
ratios have been found to be deranged.  The fetal:maternal ratio of linoleic acid is higher in 
IUGR pregnancies, and the long chain polyunsaturated fatty acid docosahexaenoic acid and 
arachidonic acids are lower in comparison to controls.  This difference in relative amounts 
but not in the total plasma concentrations indicates inadequate transplacental supply and a 
lack of enzymes required for elaboration of these essential fatty acids[76].    
 
Fetal supply of maternally derived fatty acids requires lipase-mediated hydrolysis of 
lipoprotein borne triglycerides and phospholipids at the placental surface.  Lipoprotein 
receptors and lipoprotein lipases have also been shown to be abnormal in IUGR placentas[77-
78].  These findings may in part contribute to adult dyslipidemia (see page 61) associated 
with IUGR.  No alterations in total cholesterol, and high density lipoprotein C concentrations 
have been reported in umbilical venous blood of IUGR fetuses; however, triglyceride 
concentrations were found to be increased when compared to a control group[79].  This has 
been suggested to be indicative of altered triglyceride metabolism in IUGR fetuses[79]. 
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Leptin, a hormone implicated in regulating energy intake and expenditure, encompassing 
metabolism and appetite in later life has been found to be reduced in both animal models and 
human umbilical cord blood at delivery in growth restricted fetuses[80-81]. 
 
1.6.2 Endocrine Changes in the IUGR Fetus 
IGFs have a role in cellular proliferation and uptake of glucose and amino acids, and 
consequently play a significant role in fetal growth.  They interact with six binding proteins – 
Insulin-like growth factor binding proteins (IGFBP).   
 
Insulin-like growth factors are essential for cell growth and differentiation.  Mice that have 
null mutations of the IGF I or II genes weigh 60% less than normal birth weight[82].  Mice 
with aberrations of the IGF I receptor gene weigh 45% that of wild type indicating that both 
IGF I and II signal through IGF I receptor promoting fetal growth[83].  IGF II has a crucial 
role in the establishment of placental function as IGF II deficient mice have a 25% reduction 
in placental weight whereas IGF I deficient mice have normal placental weight[83].  
Circulating IGFBP is also implicated in the pathogenesis of IUGR.  Numerous animal models 
have demonstrated growth restricted animals are associated with raised levels of IGFBP-I due 
to increased production in the fetal liver[84].  This may limit IGF availability to its high 
affinity IGF receptors. 
 
Maternal serum IGF-I and IGF-II levels have been reported to be reduced with an increase in 
IGFBP from human pregnancies.  Fetal IGF I levels increase during gestation and there is a 
significant correlation with birthweight[33].  IUGR fetuses have lower levels in umbilical 
venous blood but IGFBP II and IGF II are similar to controls[85].  As gestation progresses 
levels of growth hormone decrease as levels of IGF I increase, indicating that IGF I has a role 
in the regulation of fetal growth and the inhibition of growth hormone production, although, 
the exact mechanisms by which these occur are yet to be elucidated[33].  Fetal IGF I levels 
have been found to be reduced in IUGR with a reduction in the expression of the IGF I 
receptor.  In humans birth weight is negatively correlated with IGFBP-1 levels in umbilical 
cord blood[86]. 
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The hypothalamic pituitary axis (HPA) has also been studied in IUGR fetuses.  The fetal 
HPA axis is similar to that of an adult.  Adrenocorticotrophic hormone (ACTH) is 
synthesised and secreted by the anterior pituitary in response to corticotrophic releasing 
hormone and adrenal vasopressin.  ACTH stimulates the release of cortisol.   
 
The fetal HPA axis is activated progressively throughout the latter part of gestation.  In 
healthy pregnancies throughout most of gestation glucocorticoid concentrations in the fetus 
are low and are derived from the mother following the materno-fetal concentration gradient 
which is maintained by the placental enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-
HSD-2).  In late gestation the fetal adrenal cortex becomes activated and the fetus is the 
primary source of circulating glucocorticoids which increases cortisol levels and the 
adrenocortical responsiveness to adverse conditions.  Glucocorticoid exposure in utero alters 
receptors, enzymes, ion channels and transporters in many cell types during late gestation.  
They also alter expression of growth factors cytoarchitectural proteins, binding proteins and 
components of intracellular signalling pathways[87].   
 
An ovine model has demonstrated that placental 11β-HSD-2 has been shown to have reduced 
activity and expression in IUGR pregnancies[79].  The sheep model has also been used to 
analyse specific components of the HPA axis, and has demonstrated that IUGR fetuses have 
increased levels of cortisol and ACTH. This indicates increased activation of the fetal HPA 
axis [47]. 
 
Increased levels of cortisol, ACTH and corticotrophic releasing hormone (CRH) have also 
been found in umbilical cord blood of human growth restricted pregnancies[88].  Higher 
levels of cortisol but reduced levels of ACTH were found in IUGR fetuses at cordocentesis 
between 18 and 38 weeks gestation: an inverse correlation of cortisol level with fetal 
hypoglycaemia was found in this study possibly indicating that in chronic hypoglycaemia in 
IUGR fetuses, the pituitary is under negative inhibition[89].  Other studies have reported 
reduced cortisol levels in small for gestational age fetuses, however, these fetuses were 
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categorised by birthweight alone and delivered at term so it is uncertain whether they were 
truly growth restricted[87].  However, these results in combination indicate that alterations in 
the HPA axis in IUGR fetuses occur. 
 
Thyroid hormones are also critical to growth and development of the fetus, particularly with 
regards to differentiation of the nervous system.  The maternal and fetal hypothalamus-
pituitary-thyroid axis work independently as the placenta is relatively impermeable to 
thyroxine (T3) and triiodothyronine (T4).  Thyroid Releasing Hormone (TRH) can transfer 
across the placenta resulting in a gradient from maternal to fetal plasma in terms of T4 and 
T3.  Studies on the growth restricted guinea pig have revealed decreased plasma thyroid 
concentrations in growth restricted fetuses[90]. 
 
In the human fetus, serum concentrations obtained by cordocentesis of free T4 and T3 are 
lower in fetuses with IUGR but TSH levels are unchanged.  An increase in thyroid receptor α 
and β were also noted in the IUGR placenta[91].  These findings indicated a deranged thyroid 
status in the growth restricted fetus. 
 
1.6.3 Haematological Adaptations in the IUGR Fetus 
A rat model has demonstrated increased numbers of nucleated red blood cells in the 
circulation of growth restricted fetuses which is associated with both acute and chronic 
hypoxia and acidemia[92].  The increase in nucleated red blood cells is not, however, a 
specific marker of chronic hypoxia alone but is also related to the inhibition of nitric oxide 
synthesis in relationship with erythropoietin levels.  Nitric oxide is an important regulator of 
erythropoietin production both in vivo and in vitro[92]. 
 
Erythropoesis is stimulated by relative hypoxemia in IUGR fetuses which is thought to be a 
compensatory mechanism.  Erythropoeitin is released in response to hypoxia which increases 
red blood cell mass through both medullary and extramedullary haematopoiesis[54, 93-94].  
Serum erythropoietin concentration is increased in proportion to the severity of fetal 
cardiovascular compromise in human fetuses[95].  The haematocrit of fetal blood is normal 
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or slightly increased and nucleated red blood cell counts are increased; the severity of 
hypoxia correlating with the extent of erythroblastosis[54]. 
 
Progressive hypoxemia results in entry of nucleated red blood cells into the peripheral 
circulation independent of erythropoietin levels[96].  Platelet aggregation and consumption 
also occurs which results in thrombocytopaenia[97].  The exact mechanism for this is 
unknown although the correlation between severity of placental pathology[98] and the extent 
of thrombocytopaenia indicates that a reduction in platelet and red blood cells counts may be 
secondary to consumption in placental thrombi[33].  White cell counts are also reduced in 
IUGR fetuses [99]. 
 
  
45 
 
1.6.4 Circulatory Changes in IUGR Fetuses 
Fetal adaptation to hypoxia consists of the humoral processes described above and 
cardiovascular changes.  Initial cardiovascular responses include redistribution of blood flow 
and, as the condition deteriorates, an increase in blood pressure, bradycardia and modification 
of the cardiac haemodynamics may occur[100].  Alterations in the cardiovascular system of 
growth restricted fetuses provide the basis for clinical monitoring of disease progression (see 
Chapter 2). 
 
1.6.4.1. Normal Physiology of the Cardiovascular System 
The heart begins to function during the fourth week of pregnancy and is completely formed 
by week six.  A large gradient of oxygen partial pressure (pO2) of 60mmHg occurs between 
maternal arterial blood and fetal umbilical venous blood which facilitates oxygen transfer 
from maternal to fetal circulations[100]. 
 
Variants of the fetal cardiovascular system compared to that of the neonate or adult occur due 
to the presence of the umbilical placental circulation, the absence of a significant pulmonary 
circulation and the presence of a number of shunting mechanisms in utero: the ductus 
arteriosus, ductus venosus and foramen ovale (see Figure 5).  Blood from the placenta travels 
via the umbilical vein through the ductus venosus into the inferior vena cava.  Blood then 
enters the right atrium from the inferior vena cava and is directed through the foramen ovale 
into the left atrium to supply the brain heart and lower extremities.  The foramen ovale causes 
atrial pressures to be almost identical resulting in the right and left ventricles experiencing the 
same filling pressure[100].  30% of left ventricular output passes the aortic arch to the 
descending aorta[100].   
 
Deoxygenated blood entering the right atrium from the superior vena cava is directed to the 
right ventricle, 90% of this blood then enters the systemic circulation via the ductus arteriosus 
and is diverted to the descending aorta.  The descending aorta represents about 65% of 
combined ventricular output[100].  High resistance in the pulmonary arteries maintains the 
right to left shunt through the ductus arteriosus[101].  The ductus arteriosus accounts for 
almost identical pressures in the pulmonary artery and the aorta[100]. 
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Consequently in the fetal circulation right and left cardiac ventricles perfuse the systemic 
circulation in parallel.  The left ventricle supplies the upper body and the right ventricle 
supplies the pulmonary circulation and lower body. 
 
As blood is transported through the fetal cardiovascular system alterations in oxygenation 
levels occur.  In the chronically catheterised sheep model the partial pressure of oxygen (pO2) 
in the umbilical vein is 32.8mmHg, 24mmHg in the ascending aorta and 21.7mmHg in the 
descending aorta[102].   
 
 
Figure 5 Diagram of the Fetal Circulation 
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1.6.4.2 Redistribution of Blood Flow and the Brain Sparing Effect in IUGR 
Traditionally it has been reported that the fetal circulation responds to hypoxemia by 
centralization of the circulation or ‘brain sparing’, whereby blood is diverted to preferentially 
supply essential organs such as the brain and heart often at the expense of organs such as the 
kidney, gastrointestinal tract and the lower limbs, where vasoconstriction is assumed to 
occur[100]. 
 
However, many of these animal models focused on the effects of acute hypoxemia (hypoxia 
being maintained for between 60 and 90 minutes)[103-104] but are still well cited in the 
literature[105-106] regarding the physiological changes in IUGR which is a more chronic 
condition.  Even in cases of acute hypoxia it has been reported that blood flow to the 
cerebrum, cerebellum, brain stem, heart and adrenals increases in an inverse relationship to 
arterial oxygen concentration and blood flow to the fetal lungs decreases progressively with 
hypoxia.  However, blood flow to the kidneys, digestive tract, pancreas and musculo-skeletal 
system remains constant or is actually increased in the transition from high to moderately low 
levels of arterial oxygen content before decreasing abruptly in severe hypoxia.  Umbilical 
blood flow was not found to change in relation to arterial oxygen content[107].   
 
Bocking et al specifically addressed the effects of prolonged hypoxia for 48 hours in an ovine 
model by restricting uterine blood flow.  They found that fetal cerebral, myocardial and 
adrenal blood flows were increased at 1, 24 and 48 hours of hypoxia.  However they 
demonstrated no change in the blood flow to nuchal muscle or renal blood flows with the 
same degree of hypoxia.  This demonstrated a maintenance of the normal protective 
circulatory adjustments with acute hypoxia for up to 48 hours in the absence of metabolic 
acidemia[108]. 
 
Rurak et al also assessed the circulatory effects of approximately 8 hours of hypoxia on 
sheep, finding an increase in blood flow to the cerebral hemispheres, myocardium, adrenal 
glands and brown adipose tissue, no alteration in flow to skeletal muscle and the gut but a 
reduction in flow to the spleen and kidney[109]. 
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In human fetuses Doppler velocimetry has been extensively used to study the fetal circulation 
and to monitor the progression of IUGR as catheterisation of the human fetus is not viable.  
Ultrasound and Doppler velocimetry will be discussed more extensively in Chapter 2,  
However, in brief Doppler velocimetry is only an indirect method of assessing blood flow, 
measuring flow impedance.  Commonly used indices are the pulsatility index (PI) which is 
the difference between the most positive and the most negative value during the cardiac cycle 
divided by the mean, the resistance index (RI) which is a ratio describing how much the end 
diastolic peak velocity declines in relation to the systolic peak and the peak systolic velocity 
(PSV).  Doppler indices have been extensively used to characterise the fetal circulation and 
the ‘brain sparing’ phenomenon.  A small number of studies are attempting to characterise 
the redistribution of blood flow by calculating volumetric flow measurements (see Chapter 
2). 
 
In IUGR fetuses, increased Doppler PI and RI in the umbilical, thoracic and descending 
aorta[10], peripheral pulmonary[110], mesenteric vessels[111], kidney[112], femoral and 
iliac arteries[113] have been interpreted as the hind limb reflex (vasoconstriction and a 
reduction in volume blood flow).  A reduction in the middle cerebral artery[10], spleen[114] 
and liver[115] have all been documented and these studies in combination have been cited in 
support of the ‘brain sparing’ phenomenon.  Progressive fetal demise has been found to be 
associated with abnormalities of blood flow in the venous system.  Forward flow in the 
venous system is determined by cardiac compliance, contractility and afterload.  When 
decompensation occurs there is decreased forward velocity during atrial systole.  Impaired 
preload handling is found in the precordial veins, hepatic veins and head and neck veins[10].   
 
Changes occurring in the umbilical, internal carotid, middle cerebral, femoral and renal 
arteries, the aorta and venous system will be discussed in more detail below. 
 
1.6.4.2.1 Umbilical Artery 
The umbilical artery was the first fetal vessel to be evaluated using Doppler velocimetry and 
is widely used in clinical practice.  It has been well reported that fetuses with IUGR have 
49 
 
raised resistance indices in the umbilical artery and as the disease progresses end diastolic 
flow becomes absent and then reversed[100].  There is a strong correlation between absent or 
reversed end diastolic flow and poor perinatal outcome[116].  Indeed SGA fetuses with 
normal Doppler velocimetry indices have significantly better neonatal outcomes[117].  
Abnormalities in the umbilical blood flow have been found to precede alterations in the fetal 
heart rate[118]. 
 
1.6.4.2.2 Cerebral Blood Flow and Brain Sparing 
The middle cerebral artery is the preferred vessel when studying cerebral blood flow due to 
its ease of accessibility, high reproducibility as well as providing information regarding the 
brain sparing effect[100].  Doppler indices of the middle cerebral artery are sensitive to 
vasoconstriction or dilatation and an increase in diastolic cerebral flow is interpreted as 
vasodilatation as a result of hypoxia[100].  Vasodilatation of the middle cerebral artery is 
thought to occur as part of the ‘brain sparing’ phenomenon, and is also reflected by a 
reduction in the PI of the middle cerebral artery[119].  Comparisons of the Doppler index and 
the pO2, partial pressure of carbon dioxide (pCO2) and O2 content by fetal blood sampling 
have shown a good correlation between the pO2 and the cerebral Doppler resistance indices in 
cases of severe hypoxia[120].   
 
A sudden increase in resistance of the middle cerebral artery on Doppler velocimetry where 
compensatory changes had previously been noted is associated with poor prognosis[121-
122].  A number of groups have assessed the loss of compensatory changes using volume 
blood flow assessment, finding that a reduction in volume blood flow occurs prior to an 
increase in the resistance indices of the middle cerebral artery [123] and that reversal of the 
adaptation is of sudden onset and associated with poor prognosis[124].  It is likely that in this 
scenario the vessel’s ability to vasodilate has been overwhelmed, hypoxia is decompensated 
and the fetus is acidaemic. 
 
Changes in regional fetal cerebral blood flow perfusion have also been studied in IUGR 
fetuses.  Fractional moving blood volume studies showed an initial and early increase in 
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blood to the frontal area.  Fetal deterioration was associated with a decrease in frontal 
perfusion with an increase towards the basal ganglia[125].   
 
A comparison of the cerebral and placental vascular resistance has also been proposed by 
means of the cerebral PI:umbilical artery PI ratio (C/U ratio).  This has been tested on 
hypertensive pregnancies with IUGR, showing a high sensitivity and specificity for the 
prediction of IUGR[100]. 
 
1.6.4.2.3 Carotid Arteries 
The PI of the internal carotid artery has been assessed by a number of groups in growth 
restricted fetuses.  Wladimiroff et al assessed third trimester pregnancies.  They found no 
alteration of the PI with gestation in appropriately grown fetuses but found a reduction in the 
internal carotid artery PI in growth restricted fetuses in comparison with control fetuses, 
which supports the brain sparing effect[126]. 
 
Arduini et al assessed the internal carotid artery as a predictor of growth restriction finding 
that the PI was lower in fetuses who developed growth retardation than in those with normal 
growth.  The ratio between the pulsatility indexes of the umbilical and internal carotid artery 
also proved an accurate predictor of growth restriction[127]. 
 
1.6.4.2.4 Cardiac Function and Coronary Blood Flow 
Compared with appropriately grown fetuses aortic PSV is reduced in growth restriction[128] 
and a decreased PI is observed in the ascending aorta[129].  In appropriately grown fetuses 
left and right ventricular ejection force values increase with gestation and the force from both 
ventricles is similar.  However, the ventricular ejection force is decreased in both ventricles in 
IUGR.  An ejection force of the left ventricle below the 5
th
 centile is associated with poor 
perinatal outcome[128].  Combined cardiac output is preserved in growth restricted fetuses 
however a reduced volume of blood is directed towards the placenta, both in absolute and 
relative terms[130]. 
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Diastolic function of the heart can be assessed by the ratio between blood flow velocity 
during passive ventricular filling (E) and the atrial contraction (A).  The E/A ratio increases 
linearly with gestation in healthy pregnancies.  In IUGR pregnancies the E/A ratio does not 
increase with gestation.  This may be due to delayed maturation of the ventricular 
myocardium[128]. 
  
Combined systolic and diastolic function can also be assessed by the Tei index:   
 
 
 
Where: 
ICT = isovolumic contraction time 
IRT = isovolumic relaxation time 
ET = ejection time measured from the Doppler 
wave form at the atrioventricular valve 
 
Equation 1 Tei Index 
 
Early in gestation IUGR fetuses have comparable Tei indices to appropriately grown fetuses.  
However after 27 weeks, Tei indices are increased[128]. 
 
Coronary blood flow is also altered in IUGR fetuses.  Under normal physiological conditions 
the coronary arteries are not visible using Doppler ultrasound.  However, increased coronary 
flow in IUGR fetuses results in visualisation of the vessels.  This coincides with deteriorating 
venous flows such as abnormal waveforms in the ductus venosus and pulsatility in the 
umbilical vein[131]. 
 
1.6.4.2.5 Descending Aorta 
Increasing vascular impedance in the placenta is reflected by alterations in the blood velocity 
waveform in the descending aorta.  With increasing severity of growth restriction, a reduction 
of diastolic velocities occurs, this may then progress to absent or even reversed end diastolic 
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flow[100, 132-133].  One study found that only placentas with evidence of infarction were 
associated with abnormal flow velocity in the descending aorta[134].  Absent or reversed end 
diastolic flow in the descending aorta is associated with adverse outcome and increased 
neonatal complications.  In cases of reversed flow this has been reported to be as high as 
100%[135]. 
 
Two studies have assessed volume flow in the descending aorta.  One study found no 
difference between growth restricted and control fetuses[132].  However, Gardiner et al 
found a reduction in volume flow in the descending aorta in a group of 11 growth restricted 
fetuses and 20 control fetuses between 20 weeks gestation and term.  This effect remained 
significant after standardisation for fetal weight[136].  Interestingly this paper found that 
despite a reduction in volume blood flow in the descending aorta the diameter of the thoracic 
descending aorta was actually increased in the growth restricted fetuses when standardised 
for fetal weight[136].   
 
1.6.4.2.6 Renal Artery 
Results of Doppler velocimetry in the renal artery of growth restricted fetuses have proved 
controversial.  Vyas et al found that in 114 appropriately grown fetuses, between 17 and 43 
weeks, gestation and 18 small for gestation fetuses, between 22 and 39 weeks, the PI was 
significantly higher in the growth restricted fetuses than in the appropriately grown controls.  
14 of the SGA fetuses had cordocentesis and umbilical venous pO2 was significantly lower 
than in appropriately grown fetuses.  No correlation in this study was made between renal 
artery parameters and the amniotic fluid index[112]. 
 
Arduini et al analysed blood flow velocity waveforms in 114 SGA fetuses (defined as an 
estimated fetal weight less than the 5
th
 centile) and correlated the findings with the amniotic 
fluid volume.  They found that growth restricted fetuses had an increased pulsatility index in 
comparison with appropriately grown fetuses and this finding was more pronounced in cases 
of oligohydramnios[137].  Other studies, however, have had conflicting findings.  Stigter 
assessed fetal renal artery in a group of severely growth restricted fetuses finding no 
correlation of the cord blood pH, birth weight or amniotic fluid index correlated for 
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gestational age.  Most of the PI values of the renal artery were in the normal range.  They did 
however find a significant decrease in the peak systolic velocity of the renal artery [138].  
Silver et al also found no difference in the renal artery PI between appropriately grown and 
growth restricted fetuses[139]. 
 
1.6.4.2.7 Femoral Arteries 
The femoral artery Doppler waveform has also been assessed.  Yoon et al assessed the 
femoral pulsatility index and biochemical parameters using cordocentesis of IUGR and 
appropriately grown fetuses at term finding that a reduction in pO2, raised pCO2 and a 
reduction in pH was found in IUGR fetuses associated with an increase in the femoral 
PI[140]. 
 
1.6.4.2.8 Venous System 
Evaluation of the venous system is an important assessment of fetal status.  When the fetal 
condition becomes critical due to increasing right ventricular afterload and heart failure, 
abnormal waveforms in the ductus venosus and inferior vena cava become apparent.  In 
severe fetal growth restriction with impaired myocardial function and cardiac output there is 
reversed flow in the inferior vena cava and the ductus venosus and pulsations in the umbilical 
vein may be evident.  Such findings are associated with very poor perinatal outcome[100].   
 
Volume blood flow has been assessed in a number of vessels in the venous system in growth 
restricted fetuses.  Rizzo et al[141], Bellotti et al[142] and Boito et al[143] all assed volume 
blood flow in the umbilical vein finding a reduction in volume blood flow in growth 
restricted fetuses.  They suggested that from the early stages of compromise the volume of 
fetal blood flow towards the placenta decreases as redistribution occurs. 
 
Volume blood flow has also been assessed in the ductus venosus.  Increased volume flow was 
noted in the ductus venosus when standardised for fetal weight in growth restricted fetuses.  
An increased proportion of umbilical blood was also noted to be shunted through the ductus 
venosus[142].  This group also simultaneously investigated hepatic venous flow.  Flow to the 
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liver was significantly reduced, attributable to increased shunting of blood through the ductus 
venosus[142]. 
 
1.6.4.2.9 Uterine Arteries 
A number of methods have been deployed to measure uteroplacental blood flow in humans 
including the nitrous oxide technique[144], clearance of radioactive 24N[145] and the flow 
probe technique[146].  These studies estimated term uterine blood flow to be 500-700ml/min 
with a two to threefold decrease in the presence of pre-eclampsia. 
 
Uterine Doppler velocimetry has superseded these earlier techniques in assessing the 
uteroplacental circulation.  The uterine artery has been extensively assessed to predict 
adverse pregnancy outcomes in high risk women.  In normal pregnancy a decrease in 
resistance indices occurs at 24-26 weeks gestation.  Between 22 and 24 weeks there is high 
sensitivity in identifying patients with increased risk of pre-eclampsia or IUGR with 
increased resistance indices or notching noted on the uterine artery waveform[147]. 
 
Longitudinal changes in uterine artery blood volume flow in IUGR pregnancies were 
assessed by Konje et al.  Volume blood flow and vessel diameter were significantly 
decreased in growth restricted pregnancies; these changes occurred early and became more 
pronounced as pregnancy advanced[148]. 
 
1.6.5 Adaptations in Individual Organ Systems in the Growth Restricted Fetus 
Alterations in individual organ systems have been reported in IUGR fetuses which may 
provide the basis for later disease manifestations (see page 61).   
 
1.6.5.1 Central Nervous System 
Increased blood flow to the brain was initially thought of as a neuroprotective mechanism.  
However changes in the pathophysiology of the brain have been found to occur in growth 
restricted fetuses.  Animal models have shown that IUGR can have a deleterious effect on 
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brain development.  However, some of the changes occurring in the growth restricted brain 
are thought to confer some degree of neuroprotection. 
 
A rat model of IUGR has demonstrated abnormal cerebral neuronal migration[149], a 
reduction in cerebral cortical thickness and neuronal density in the neocortex and 
hippocampus[150].  A reduction in cell number has also been found in the hippocampus and 
cerebellum in growth restricted animals in conjunction with retarded dendritic and axonal 
growth within these structures[151].  The rat model has also been used to demonstrate a 
reduction in the number of mature astrocytes within the brain [152]. 
 
A guinea-pig model demonstrated a delay in the initiation and the extent of myelination in the 
cerebral cortex.  This was proposed to be due to a reduction in the number of myelinating glia 
formed and the restricted capacity of those which do form to generate myelin[153].  In a 
sheep model of IUGR a reduction in growth and myelination of optic nerve axons observed at 
term did not persist at 2.3 years, suggesting delayed rather than compromised 
development[154].   
 
Severely growth restricted rat pups have been found to exhibit white matter damage 
persisting into adulthood.  Moderate growth restriction was associated with diffuse white 
matter lesions, microglial activation and astrogliosis.  Loss of pre-oligodendrocytes on 
postnatal day 7 was followed by a delay in myelination.  Following cortical excitotoxic insult 
on postnatal day 5 the size of the induced white matter lesion was smaller in pups with 
moderate growth restriction and larger in pups with severe growth restriction compared to 
normal pups.  The increased pre-oligodendrocyte proliferation in the white matter of pups 
with moderate growth restriction subjected to first growth restriction and then an additional 
insult may represent a neuroprotective mechanism of immature white matter[155]. 
 
Cerebral messenger ribonucleic acid (mRNA) levels of four mitochondrial proteins were 
found to be elevated in growth restricted animals and subsequently decreased in juvenile 
animals[156].  Cerebral mitochondrial/nuclear deoxyribonucleic acid (DNA) ratios and 
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mitochondrial marker protein levels were not altered in IUGR fetuses; however both were 
significantly decreased in IUGR juvenile pups.  These findings indicate that metabolic 
stresses associated with uteroplacental insufficiency in the rat alter both fetal and postnatal 
cerebral mitochondrial mRNA and DNA levels[157].  An increase in the number of 
mitochondrial profiles has also been noted in the visual cortex of growth retarded sheep 
fetuses which has been proposed to be a mechanism by which the cortical neurons 
compensate for reduced efficiency of aerobic metabolism in individual mitochondria[158]. 
 
The brain in IUGR rat pups has also been demonstrated to have increased glycolytic capacity 
compared to normal weight controls.  In the fetal brain energy is derived primarily from 
glucose metabolism via the Krebs cycle and oxidative phosphorylation in the mitochondria, 
and to a lesser extent glycolysis in the cytosol.  Enzymes involved in glycolysis are encoded 
by hypoxia responsive genes[159].  Induction of glycolytic enzymes in the brain in the rat 
model have been found to occur within 24 hours of maternal global hypoxia[160]. 
 
In a piglet model of IUGR it has also been demonstrated that animals with moderate IUGR 
exposed to mild hypoxia showed a significant elevation of brain lactate compared to normal 
weight piglets, which showed little or no increase in brain lactate[15].  Generation of lactate 
and the rate of glycolysis may also be influenced by brain glucose concentrations.  The 
glucose transporter (Glut) 1 transporter in endothelial and glial cells facilitates transport of 
glucose across the blood brain barrier.  This transporter has been found to be upregulated in 
IUGR fetal and neonatal rat brains[161].  Increased expression of the Glut 1 transporter in the 
brain may compensate for hypoglycaemia which is common in IUGR fetuses.  This suggests 
adaptive mechanisms exist to increase glycolytic capacity in the IUGR/neonatal brain which 
may in some circumstances be neuroprotective. 
 
Moxon-Lester et al analysed IUGR piglets during hypoxia using lactate/N-acetylaspartate 
(NAA) ratios.  The lactate response in IUGR piglets correlated inversely with apoptosis in the 
thalamus and frontal cortex of the brain measured 4 hours post hypoxia.  Apoptosis in IUGR 
piglets with high brain lactate was similar to that in the normal weight piglets, whereas IUGR 
piglets with low brain lactate had significantly higher apoptosis.  These findings indicate 
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increased susceptibility to hypoxic brain injury in IUGR neonates but suggest that increased 
glycolysis during hypoxia confers neuroprotection in some IUGR piglets[162]. 
 
Post-mortem studies of the brain of human IUGR fetuses have demonstrated although relative 
sparing in comparison with other organs occurs, brain weights are decreased between 15-25% 
in comparison with controls.  A more pronounced reduction in weight of the liver lungs and 
thymus are seen[163].  Autopsy studies have also revealed that total cell number in the frontal 
cortex is significantly decreased in growth restricted fetuses[164]. 
 
MRI volumetric analysis has indicated no reduction in brain volume in comparison with 
appropriately grown human fetuses.  However, an inverse correlation between brain volume 
and the severity of IUGR was found indicating the presence of subtle impairments in the fetal 
compensatory mechanism as the disease progresses[165].  MRI studies on neonates that were 
growth restricted in utero have found abnormalities in regional brain volumes, with a 
reduction in cortical gray matter[166] and a reduction in hippocampal volume[167] 
 
1.6.5.2 Cardiovascular system 
A sheep model has demonstrated that in chronic fetal hypoxia, there was no difference in 
relative heart weights between control and growth restricted fetuses; however there was an 
increased proportion of mononucleated cardiomyocytes in the growth restricted group.  The 
relative size of cardiomyocytes when expressed relative to heart weight was also larger in the 
growth restricted group compared with controls[168].  Alterations in vessel composition have 
also been reported.  A rat model of IUGR has demonstrated a lower elastin content in the 
fetal aorta[169].   
 
An MRI study has shown that cardiac volume was reduced in human growth restricted 
fetuses, however the relative cardiac volume of growth restricted fetuses was not reduced in 
accordance with animal models[165]. 
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Crispi et al analysed umbilical cord blood at delivery for biomarkers of myocardial cell 
damage, finding that B-type natiuretic peptide levels were higher in growth restricted fetuses.  
Heart fatty acid binding protein was also elevated in the cord blood of growth restricted 
fetuses indicating possible myocardial cell damage.  It is a marker for the early detection of 
cardiac injury in acute coronary syndromes and has been used to detect chronic minor 
myocardial injury in heart failure in adult patients[170].  These biomarkers are more sensitive 
than troponins which have been found to be unaltered between appropriately grown and 
growth restricted fetuses[170]. 
 
The structure of the aorta has also been shown to be altered in growth restricted neonates.  
Aortic wall thickness was assessed by ultrasonography in 25 newborn babies with IUGR and 
25 normal weight infants.  Maximum aortic thicknesses were higher in the growth restricted 
cohort, which became more pronounced after adjustment for birthweight.  IGF I is a known 
regulator of elastin synthesis (a component of vessel walls), and levels have been found to be 
lower in growth restricted infants in the umbilical cord at delivery[171]. 
 
1.6.5.3 Renal System 
In a piglet model of IUGR a reduction in renal size and nephron number in growth restricted 
newborn piglets has been noted.  This group also found that despite maintained renal blood 
flow resulting in hyperperfusion the filtration rate per nephron remained unaltered indicating 
a response to compensate for the deficit in nephron number does not exist[172]. 
 
Alterations have also been found to exist in the renin-angiotensin-aldosterone system 
(RAAS) in a rat model.  Increased renal renin expression has been found after IUGR[173].  
The rat model has also shown that the adrenal expression of the angiotensin 1b receptor is 
increased in growth restricted rats.  The promoter linked to the gene encoding the angiotensin 
1b receptor is hypomethylated which results in increased transcriptional activity[174].  It has 
been suggested that this may lead to upregulation of aldosterone synthesis that is present in 
low birth weight infants[175]. 
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Increased mineralocorticoid activity involving 11β-hydroxysteroid dehydrogenase (11βHSD) 
has been reported in growth restricted fetuses.  This enzyme, located in the distal renal 
tubular cells, converts active cortisol into inactive cortisone; which protects the 
mineralocorticoid receptor from stimulation by cortisol.  In the rat IUGR model, renal 
11βHSD expression is reduced which causes increased mineralocorticoid activity[176]. 
 
Human autopsy studies have confirmed that there is a reduction in glomerular number which 
corresponds to a decrease in birthweight[177].  MRI studies and ultrasound studies have 
shown a reduction in renal volume in IUGR fetuses[165].  The percentage of body volume 
occupied by the kidney is also reduced[165]. 
 
1.6.5.4 Gastrointestinal Tract 
Animal models demonstrate that growth restricted animals have a smaller weight of the 
stomach, small intestine and small intestinal mucosa.  The length of the small intestine and 
colon in IUGR pigs was also significantly reduced.  IGF I mRNA levels in intestinal mucosa 
of IUGR piglets was increased and the expression mRNA levels of insulin receptors and 
growth hormone receptors in the mucosa showed a tendency to be reduced[178].  The 
proximal small intestine has also been shown to demonstrate reductions in thickness of the 
wall, muscularis externa, mucosa, villus height and crypt depth and a reduction in villi and 
crypt density in a sheep model.  Wall thickness, and villus height were also reduced in the 
distal small intestine, although villi and crypt density did not alter between control and 
growth restricted animals[179].   
 
The pancreas was found to be reduced in weight attributable to both lowered cell numbers 
and smaller cell size and was disproportionately greater than the reduction in body weight as 
a whole.  The exocrine cells of the pancreas are also noted to be immature in comparison with 
normal weight piglets[179].  β-cell mitochondrial dysfunction has also been demonstrated in 
a rat IUGR model.  This leads to increased production of reactive oxygen species which in 
turn damages mitochondrial DNA.  This cycle of deterioration in mitochondrial function 
leads to a decline in β-cell function[180]. 
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The liver has impaired glucose transfer and hepatic storage in growth restriction[181]. A 
marked increase in the gluconeogenic pathway has also been demonstrated[182].  Impaired 
oxidative phosphorylation in hepatic mitochondria has been shown in a rat model[183]. 
 
A study of the pancreas at autopsy of 21 human fetuses with a birthweight less than the 10
th
 
centile demonstrated no difference in the percentage of β-cells between appropriately grown 
and SGA fetuses.  However, all fetuses were over 32 weeks gestation, with a mean 
gestational age of 36 weeks and it is not known whether these fetuses were truly growth 
restricted or simply small for gestational age[184]. 
 
1.6.5.5 Respiratory System 
Lipsett et al found that growth restriction did not alter the absolute lung weight or volume but 
resulted in an increased lung volume to body weight ratio by 19%, indicating sparing of lung 
growth with reduced somatic growth and a reduction in gaseous exchange surface 
density[185].  However, other groups have shown a reduction in lung weight with either no 
change in the lung weight to body weight ratio[186] or a reduction in the ratio[187].  These 
discrepancies may be due to the timing of onset of growth restriction.  Human studies have 
revealed a reduction in lung to total body ratio using MRI[165]. 
  
61 
 
1.7 Outcome of IUGR Fetuses 
 
Alterations in blood flow and adaptations in individual organ systems may form the basis for 
both short and long term complications associated with IUGR.   
 
1.7.1 Short Term Outcome and IUGR 
IUGR is associated with significant morbidity and mortality, the severity of which correlates 
to the degree of in utero compromise[188].  IUGR is also often associated with preterm birth 
which is, independent of IUGR, associated with significant morbidity and mortality.   
 
A meta-analysis has shown that IUGR fetuses are at a 15 fold increase risk of intra-uterine 
death[1].  The severity of IUGR is directly related to an increase risk of fetal demise; fetuses 
with absent or reversed end-diastolic flow on antenatal Doppler velocimetry having higher 
mortality rates[189].  This is independent of gestational age[190].   
 
If survival beyond the antenatal period occurs there is also a significantly increased risk of 
neonatal death.  The risk of neonatal mortality declines with increasing gestation in both 
appropriately grown and growth restricted preterm neonates, although this decline is more 
evident in appropriately grown preterm neonates[1].  Growth restricted fetuses are also 
subject to increased susceptibility to intrapartum asphyxia, particularly if vaginal delivery 
occurs due to transient interruptions to blood supply during labour which is poorly tolerated 
by the IUGR fetus with poor reserves[188]. 
 
Preterm (less than 37 weeks gestation) IUGR fetuses are associated with lower APGARs at 
birth, an increased risk of intracranial haemorrhage, sepsis, necrotising enterocolitis and 
respiratory distress syndrome compared with appropriately grown preterm neonates 
(p<0.01)[1].  Neonates are also at increased risk of hypoglycaemia and polycythaemia[188]. 
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The mechanism for the increased incidence of intraventricular haemorrhage in IUGR 
neonates is not fully understood, but perinatal hypoxia or hypotension may induce focal 
changes in the arterial end zone within the subependymal germinal matrix and with 
reperfusion or over perfusion following ischaemia, venous haemorrhage may occur in the 
subependymal germinal matrix[191].  Abnormal haematological parameters such as reduced 
platelet levels may compound the insult[192].   
 
IUGR neonates are at increased risk of sepsis due to a compromised immune system:  
Immunoglobulin G (IgG) concentration, phagocytic index, neutrophils and lysozymes have 
all been shown to be reduced in these infants[188, 193].  Increased pulmonary complications 
have been proposed to be attributable to intrauterine hypoxia resulting in: delayed metabolic 
adaptation, systemic inflammatory responses as well as reperfusion injury[188].  Increased 
oxygen-free radical generation is another proposed mechanism[194].  Increased incidence of 
necrotizing enterocolitis has been associated with fetuses with absent end diastolic flow in the 
umbilical artery on antenatal Doppler velocimetry.  This has been suggested to be attributable 
to diversion of blood flow away from the mesenteric circulation and polycythemia[188]. 
 
Metabolic adaptations to the adverse intrauterine environment such as decreased glycogen 
and adipose stores, increased insulin and altered gluconeogenesis may render the IUGR 
neonate more susceptible to hypoglycaemia[188].  Polycythemia in IUGR infants may be 
related to increased erythropoietin levels resulting from chronic hypoxia leading to increased 
red cell mass[193]. 
 
The risk of complications decreases with advancing gestation; however IUGR fetuses are still 
at considerable risk of perinatal complications even at later gestations. 
 
1.7.2 Long Term Outcome  
The intrauterine environment and reduced fetal growth are strongly associated with a number 
of chronic conditions in later life.  This phenomenon was first identified by Barker and Hale.  
The increased susceptibility is due to adaptations made in utero in response to limited nutrient 
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supply.  The malnourished fetus is programmed to exhibit a thrifty phenotype with increased 
fat deposition and possibly decreased energy output in later life.  When calories become 
ample postnatally altered homeostatic mechanisms lead to manifestations of adult disease 
such as the metabolic syndrome.  This phenomenon is also known as the Barker 
hypothesis[195]. 
  
1.7.2.1 Neurological Complications 
An increased incidence of cerebral palsy occurs in individuals that were growth restricted in 
utero.  Most of the existing literature regarding neurological outcomes of children that were 
growth restricted antenatally is retrospective due to the fact that adverse outcomes such as 
cerebral palsy occur infrequently and are not diagnosed until several years of age.  Perinatal 
data is usually poor in these retrospective studies.  Prospective evaluation of neurological 
outcomes requires large sample sizes and long term follow up which are prohibitive in terms 
of costs involved.   
 
Associations have, however, been documented between low birth weight and increased risk 
of cerebral palsy.  This risk is highest in preterm small for gestation delivered after 33 
weeks[196-197].  In growth restricted infants born prior to 33 weeks gestation, the 
association of SGA with cerebral palsy is less clear as the increasing risk of acquired brain 
injury (and consequently cerebral palsy) may confound any small increase in risk from 
growth restriction[3]. 
 
Low birthweight is also associated with poor developmental outcome.  In children who 
suffered antenatal IUGR with evidence of the brain sparing effect, accelerated visual 
maturation was found in the growth restricted cohort at 6 months of age, initially thought to 
be a beneficial adaptation[198].  No difference was noted in neurodevelopmental outcome at 
three years of age[199].  However, at five years of age a significant deficit in cognitive 
outcome was noted[200]. 
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Hawdon et al assessed 38 singleton male infants delivered between 36 and 42 weeks with a 
birthweight less than the 10
th
 centile comparing them with controls matched for social class 
and found that there was an increased incidence of behavioural problems, particularly 
attention-deficit hyperactivity in the SGA children.  However, this study has limited numbers 
and two of the SGA children were excluded due to profound handicap which prohibited 
testing[201]. 
 
IUGR has also been associated with an increased incidence of schizophrenia.  It has been 
suggested that protein or calorie malnutrition during the antenatal period may be responsible 
for this association[202]. 
 
1.7.2.2 Cardiovascular Complications 
IUGR predisposes to hypertension in later life by a number of mechanisms.  Reduction in 
kidney volume and nephron number, have been observed from both human and animal 
studies (see page 58).  Work from animal models has also indicated that altered expression of 
genes in pathways regulating nephrogenesis occurs in growth restricted animals[203].  
Alterations in the vascular endothelium may be another contributory factor.  Endothelial 
dependent and independent vasodilation is impaired and flow mediated dilatation is 
decreased in low birthweight individuals[203].  Blood pressure is also determined by arterial 
compliance which is related to the composition of the extracellular matrix which is known to 
be altered in IUGR[169].   
 
Increased incidence of coronary heart disease is also associated with IUGR.  This may in part 
be related to the alterations in vessel wall composition described above as well as abnormal 
lipid metabolism (see page 39) both of which predispose to atherosclerosis[204]. 
 
1.7.2.3 Metabolic Complications 
As adults, both leptin and insulin levels are correlated to birthweight independent of adult 
obesity[203].  Leptin has also been proposed to alter the development of hypothalamic 
neuronal projections, these alterations in brain anatomy may have a long lasting effect on 
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appetite centres within the brain[203].  Both of these mechanisms may contribute to the 
increased incidence of adulthood obesity in individuals who were growth restricted in utero. 
 
Low birthweight is also associated with an increased risk of type 2 diabetes from both 
epidemiological studies and animal models[203].  This may be attributable to impaired 
insulin secretion due to altered pancreatic structure (see page 59).  Altered hepatic 
gluconeogenesis and aberrant expression of glucose transporters may be additional 
contributory factors[114]. 
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1.8 AIMS OF THESIS 
 
Neurodevelopmental sequelae associated with IUGR often occur in the absence of overt 
structural lesions and although head growth is maintained, Doppler velocimetry studies in 
IUGR fetuses imply that blood flow to the brain is actually increased.  This in itself is a 
deviation from the normal physiological state.  Doppler velocimetry is, however, only an 
indirect assessment of blood flow.  This thesis therefore has three main aims: 
 
1) To assess changes in volume blood flow in IUGR fetuses compared with 
appropriately grown fetuses in the umbilical artery, middle cerebral artery and renal 
artery. 
2) To assess how the metabolic profile of the developing brain differs in growth 
restricted fetuses using proton magnetic resonance spectroscopy. 
3) To correlate volume blood flow in the middle cerebral artery with the metabolic 
profile of the developing brain in both appropriately grown and growth restricted 
fetuses. 
 
The thesis is organised into 6 further chapters as follows: 
 
Chapter 2 will discuss the ultrasound techniques which will be employed in this study: the 
use of Power Doppler and calculation of volume blood flow.  A brief overview of both the 
physics and safety of ultrasound and Doppler techniques will also be given. 
 
Chapter 3 will outline the ultrasound components of this study: the use of ultrasound and 
power Doppler to assess Doppler velocimetry, vessel diameters and volume blood flow in 
multiple vessels in IUGR and appropriately grown pregnancies.   
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Chapter 4 will discuss the Magnetic Resonance techniques which will be employed in this 
study: Magnetic Resonance Imaging as well as an introduction to Magnetic Resonance 
Spectroscopy.  An overview of the physics and safety of the techniques will also be given. 
 
Chapter 5 will explore the 
1
HMRS components of this study: assessment of the metabolic 
profile of fetal tissue in vivo comparing appropriately grown and growth restricted fetuses.   
 
Chapter 6 will correlate changes in volumetric blood flow detected using ultrasound 
techniques with metabolite ratios detected using 
1
HMRS in the developing brain. 
 
Chapter 7 will summarise the main findings of the thesis and will highlight areas for future 
research and their possible future clinical relevance. 
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Chapter 2 – Techniques to be Used in the Thesis: Ultrasound 
 
This chapter will illustrate the background physics and clinical applications of ultrasound, 
Doppler and Power Doppler, as well as providing an introduction to the calculation and 
applications of volumetric blood flow analysis.  These techniques will then be used to assess 
the redistribution of the fetal circulation in IUGR fetuses in Chapter 3. 
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2.1 Ultrasound 
 
Ultrasound has been used as a diagnostic tool in obstetrics since the 1950s.  It has numerous 
obstetric applications including: the diagnosis and confirmation of early pregnancy, 
determination of gestation, assessment of fetal size, diagnosis of fetal malformations, 
placental localisation, assessment of multiple pregnancies and the assessment of liquor 
volume. 
 
2.1.1 Physics 
Medical ultrasound works on the same principle as underwater SONAR (sound navigation 
and ranging) which is utilised in submarines.  Short bursts of sound are created and reflected 
echoes are detected.  Ultrasound utilises high frequency sound between 3 and 15 Mega hertz 
(MHz).   
 
Ultrasound waves are longitudinal compression waves.  When these travel through a medium, 
cyclical variations in pressure occur which are transmitted via molecular bonds within the 
medium. The speed of transmission of sound waves is dependent on the medium; stiffer 
mediums are associated with higher sound speeds and softer mediums with lower sound 
speeds.  Most soft tissues within the human body have a transmission speed similar to water 
(due to their high water content); this is of critical importance in medical ultrasound as it is 
assumed that the speed of sound in body tissues is 1540 ms 
-1
. 
 
Once a wave is generated at a given frequency in a particular material the wavelength can be 
calculated using the equation: 
 
Where: 
λ = wavelength 
c = speed of sound 
f = frequency 
Equation 2 Calculation of Wavelength 
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The wavelength becomes shorter as the frequency rises.  This is of vital importance to the 
quality of ultrasound images produced. 
 
2.1.1.1 Transducer 
The transducer is responsible for generating the ultrasound and detecting the returning 
echoes.  Transducers are made from materials that exhibit piezoelectricity.  This is the ability 
to generate electrical energy from mechanical energy.  The transducer contains over 300 
crystals (piezo electric devices) which are arranged in a row.  Each emits and receives an 
ultrasound beam in rapid succession. 
 
Vibration of the transducer is generated by connection to an electrical source.  The ultrasound 
pulse is generated and the vibrations are transmitted into the tissue as high and low pressure 
waves.  The reverse effect also occurs; mechanical energy produced from the returning echo 
causes the crystals to vibrate.  This mechanical energy is then converted into electrical 
energy.  By measuring the time between the generation of the sound and it being received, the 
amplitude and the pitch of the sound, computer software can generate images, calculate 
depths and speeds. 
 
 
2.1.1.2 A and B scans 
Each layer of tissue within the body produces a separate reflection of the ultrasound.  In early 
ultrasound scanners reflections from each layer resulted in a peak or amplitude which was 
displayed on the screen of a cathode ray oscilloscope.  This was known as an A-scan.  The 
amplitude was dependent on the difference in acoustic impedance between tissues each side 
of the boundary.  The A-scan only provided one-dimensional information and was 
consequently difficult to interpret anatomically without prior knowledge and assumptions, 
and had limited clinical value. 
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A 2-D scan can be produced by obtaining a series of A-scans in a closely packed regular 
format (from the multiple piezoelectric crystals within the transducer).  The amplitude of 
each echo is represented by the brightness of a spot at that position.  This is known as a B-
scan and is commonly used in current obstetric imaging. 
 
2.1.1.3 Obtaining a Picture 
Pulsed ultrasound is of high frequency and can be aimed in a particular direction.  It obeys 
the laws of geometric optics and when it encounters an interface of different echogenicity it 
may be reflected, refracted or absorbed.  It is the reflected waves that are detected by the 
transducer, in its capacity as a receiver, which can then be processed. 
 
When a wave is generated and encounters an obstacle that has dimensions similar to its 
wavelength diffraction occurs.  The transducer is such an obstacle and diffraction is a strong 
determining influence on the shape of the beam generated by the transducer.  Different sized 
transducers can consequently produce different beam shapes.  The shape of the beam can be 
separated into the near field (the region closest to the source which approximates to a parallel 
beam concept) and the far field (where the beam changes into a divergent shape, coming from 
a shape at the centre of the source). 
 
The point at which the near field becomes the far field is dependent on the source diameter.  
It can be represented by the formula: 
 
 
 
Where: 
d = distance at which transition takes place 
λ = wavelength 
a = radius of the source 
 
Equation 3 The Distance at which the Near Field Pattern Changes to the Far Field 
Pattern 
Focusing can reduce the width of the beam to a smaller dimension.  This can be achieved by 
lenses and mirrors. 
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A lens can narrow the beam at a selected depth.  However, it also causes additional 
divergence at other depths; hence beam width improvements at one point are at the expense 
of beam width degradation elsewhere.  A curved front face on the transducer can also create a 
comparable effect. 
 
The same factors that affect how the dimensions of the ultrasound beam are transmitted into 
the tissue also affect the shape of the region from which echoes can be received.  When the 
transducer acts as a detector there is a zone within which any echoes will be detected.  The 
shape of this area is determined in the same way.  Therefore, focusing applies to both 
transmission and detection of echoes. 
 
 
2.1.1.4 Additional factors 
The ultrasound wave is altered by a number of interactions as it passes through tissue.  These 
include reflection, scatter and absorption. 
 
2.1.1.5 Reflection 
When the ultrasound wave encounters an obstacle some of the energy is transmitted back in 
the direction from which it came.  The strength of this reflection depends on the nature of the 
obstacle and the background medium.  Characteristic acoustic impedance is important in this 
situation, denoted by the symbol Z.  This is specific to the material and depends on the 
density of the material and speed of sound in the medium: 
 
 
 
Where: 
Z = characteristic acoustic impedance 
ρ= density of the material 
c = speed of sound in the material. 
 
Equation 4 Characteristic Acoustic Impedance 
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The strength of the reflection can be described as a reflection coefficient R which is given by: 
 
 
Where: 
Z1 = acoustic impedance of material 1 
Z2 = acoustic impedance of material 2 
R = reflection co-efficient 
 
Equation 5 Reflection Co-efficient for the Interface between Two Materials 
 
Consequently the difference in the strength of reflection depends on the difference in acoustic 
impedance of the two materials at an interface. Most soft tissues have similar acoustic 
impedance; however, the interface between soft tissue and bone involves a considerable 
change in acoustic impedance and will create a strong echo. 
 
2.1.1.6 Scattering 
This occurs from tissue parenchyma where changes in acoustic impedance occur over a 
microscopic level.  Scattered ultrasound is low amplitude waves travelling in all directions; 
the waves, which return in the direction of the probe, are backscattered. 
 
2.1.1.7 Absorption 
This is the direct conversion of sound energy into heat and is inevitable.  Absorption follows 
an exponential law and the fraction of the beam energy lost due to absorption is the same for 
each centimetre travelled.  Higher frequencies are also absorbed at a greater rate than lower 
frequencies.   
 
Energy loss by all three mechanisms is referred to as attenuation.  This increases with depth 
and frequency. 
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2.1.2 Assessment of Fetal Biometry 
Ultrasound is widely used clinically in the evaluation of fetal growth.  This will be 
undertaken as part of this thesis.  Firstly, correct assessment of fetal age is imperative when 
assessing growth.  Ideally, this is assessed using ultrasound measurement of crown rump 
length between 7 and 12 weeks gestation.  Fetal growth is then assessed by measuring the 
biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and 
femur length (FL).  The anatomical landmarks of each of these sections will be briefly 
outlined below.  Measurements must be taken at least two weeks apart to give an accurate 
assessment of fetal growth.  Each measurement should also be taken in triplicate as this 
improves inter-observer variation[205]. 
 
2.1.2.1 Biparietal Diameter  
The BPD is the maximum diameter of a transverse section of the fetal skull at the level of the 
parietal eminences.  It is typically measured from a section which includes: a rounded occiput 
and pointed synciput; a long midline which is equidistant from proximal and distal skull 
echoes; the cavum septum pellucidum bissecting the midline one third of the distance from 
the synciput to the occiput; the two anterior horns of the lateral ventricles symmetrically 
placed about the midline and all or part of the posterior horns of the lateral ventricles again, 
symmetrically placed about the midline. 
 
The appropriate section is frozen and the callipers are placed from the outer aspect of the 
proximal skull surface to the inner aspect of the distal skull surface, at right angles to the 
midline and at the widest diameter. 
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2.1.2.2 Head Circumference 
The HC is measured in the same section as for the BPD (see page 74).  The HC can be 
measured by the ellipse method whereby the first onscreen cursor is placed on the outer edge 
of the skull at the occiput.  The second cursor is placed on the outer aspect of the skull at the 
synciput and a ready formed ellipse of dots is moved to fit the outline of the fetal skull.  The 
BPD and HC can be seen in Figure 6 below. 
 
 
Figure 6 Section Required for Measurement of the Biparietal Diameter and Head 
Circumference 
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2.1.2.3 Abdominal Circumference 
A section through the fetal abdomen is measured to include the following features: a circular 
section of the abdomen with an unbroken short rib echo of equal size visible on each side, a 
cross section of one vertebra visualised as a triangle of three white spots, a short length of the 
umbilical vein centrally placed between the lateral abdominal walls and present a third of the 
way along a line between the abdominal wall and the spine and the stomach.  The correct 
section can be seen in Figure 7 below. 
 
 
Figure 7 Section of the Abdomen Required for Measurement of the Abdominal 
Circumference 
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2.1.2.4 Femur Length 
The upper femur length is measured as this is less sensitive to acoustic shadowing from 
anteriorly placed fetal structures.  The full length of the femur is visualised with soft tissue 
visible at both ends (Figure 8 below).  It is optimally imaged when the bone lies at a slight 
angle to the horizontal.  The measurement is taken from the centre of the ‘U’ shape at each 
end of the bone. 
 
 
Figure 8 Section Required for Measurement of the Femur Length 
 
2.1.2.5 Estimated Fetal Weight (EFW) 
A variety of formulae exist for estimating the fetal weight.  The Hadlock formula is 
commonly used at Queen Charlotte’s and Chelsea Hospital which estimates fetal weight 
based on AC, BPD and FL measurements[206]. 
 
2.1.2.6 Centile Charts 
The BPD, HC, AC, FL and EFW are plotted onto centile charts which demarcate the centiles 
at a given gestational age.  An example of the charts used at Queen Charlotte’s and Chelsea 
Hospital can be seen in Figure 9 below.   
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Figure 9 Centile Charts for the Biparietal Diameter, Head Circumference, 
Abdominal Circumference, Femur Length and Estimated Fetal Weight 
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Customised growth charts have also been created which are individually generated 
corresponding to ethnic and maternal variations.  Ethnic background, maternal height and 
weight in pregnancy and fetal gender are used for individual adjustment of growth charts and 
expected weight.  Such charts improve the diagnosis of growth restriction, reducing the 
number of false positive cases[205]. 
 
IUGR pregnancies often show asymmetric growth restriction, whereby head growth is 
relatively conserved in comparison to femur and abdominal growth.  An example of a growth 
chart from an IUGR pregnancy can be seen in Figure 10 below. 
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Figure 10 Growth Pattern in IUGR 
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2.1.3 Liquor Volume 
Amniotic fluid increases to 1000mL at 34 weeks after which time it gradually decreases to 
800mL at term.  The amniotic fluid volume is a reflection of both the maternal and fetal 
condition and it can be clinically assessed by ultrasound. 
 
The Amniotic Fluid Index (AFI) is a semi quantitative technique for assessing amniotic fluid.  
The maternal abdomen is divided into four quadrants.  The ultrasound probe is held in the 
longitudinal axis, perpendicular to the floor and the largest vertical pool depth is recorded in 
each quadrant.  The sum of these measurements represents the AFI.  Although the AFI does 
alter with gestational age, an AFI of less than 5cm is defined as oligohydramnios and an AFI 
greater than 25cm is regarded as polyhydramnios.  Although this is considered the most 
effective clinical assessment of liquor volume considerable intra and inter-observer variation 
does exist[207]. 
 
IUGR fetuses often demonstrate a reduction in amniotic fluid which has been proposed to be 
attributable to reduced renal perfusion and consequently reduced fetal urine output[137].  
However, not all growth restricted fetuses show evidence of oligohydramnios.   
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2.2 Doppler  
 
Doppler ultrasound is a method with which the human circulation can be assessed, providing 
a reliable reproducible method of imaging and measuring normal and abnormal flow in 
arteries and veins. 
 
2.2.1 Background Physics 
The Doppler effect was first described by Christian Joahann Doppler (1803-1853).  The 
phenomenon occurs when there is a change in the frequency of a wave due to movement 
between the source generating it and the receiver.  It can be demonstrated for any type of 
wave including light, sound and ultrasound and is direction dependent.  The change in 
frequency or Doppler shift can be given by the formula: 
 
Where: 
 = shift frequency 
 = transmitted frequency 
 = received frequency 
 
Equation 6 Doppler Shift 
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This technology has been adapted to study blood flow.  Ultrasound scanners create a series of 
pulses which are transmitted to detect the flow of blood.  When tissues are stationary, echoes 
are unchanged from pulse to pulse.  However, when there is movement, differences occur in 
the time for the signal to be returned to the receiver.  These can be measured as a time 
difference or in terms of a phase shift from which the Doppler frequency is obtained.  It can 
be calculated using the formula: 
 
Where: 
 = the Doppler shift in the frequency 
f0 = frequency of transmitted sound 
 = velocity of the moving target 
θ = angle between the ultrasound beam        
and the direction of movement of the target 
 = speed of sound in tissue. 
 
Equation 7 Change in Doppler Shift 
 
These can then be processed to produce colour flow display or a Doppler sonogram. 
 
The motion must be in the direction of the beam for if it is perpendicular there is no relative 
motion between pulses.  The Doppler signal that is produced also depends on: the blood 
velocity, the higher the velocity the higher the Doppler frequency; ultrasound frequency, the 
higher frequencies give increased Doppler frequency; the angle of insonation is also 
important, the Doppler frequency increases as the ultrasound beam becomes more aligned to 
the flow direction. 
 
2.2.1.1 The Doppler frequency Spectrum 
A single blood cell is not sufficient to produce a signal which is detectable at the skin surface.  
Therefore, the signal used clinically is a result of multiple scattering from groups of cells, 
erythrocytes being the major component.  Cells within a vessel have a range of velocities.  
This can be compared to fluid flowing in a tube, i.e. parabolic or laminar flow.  The 
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maximum velocity occurs in the centre, and is twice the mean velocity.  An estimate of mean 
velocity is obtained by measuring peak velocity in a vessel’s centre and halving it.  This can 
be averaged over several cardiac cycles to account for variation throughout the cardiac cycle.   
An alternative model is plug flow which is seen close to the inlet of a vessel and it is the same 
at all radii reducing close to the vessel walls. Both these models of flow can be seen in Figure 
11 below. The umbilical artery shows parabolic flow throughout the cardiac cycle.  However, 
vessels often demonstrate a range of flow during the cardiac cycle, for example the 
descending aorta shows plug flow during systole and parabolic flow during diastole.   
 
 
Figure 11 Velocity Profile Associated with Laminar Flow (top) and Plug Flow (bottom) 
 
An ultrasound beam directed at a blood vessel will result in a range of Doppler shifts as 
opposed to one value as indicated by fd.  This range is denoted as a Doppler spectrum and can 
also be broadened by the scanner itself.  Also the frequency shift signal is stronger at some 
frequencies than others.  Therefore, the spectral display needs to be three dimensional to 
show time, frequency shift and Doppler signal strength. 
 
The vessel walls also give Doppler shifts which are low in frequency but high in intensity.  
Their amplitudes are higher than echoes from the erythrocytes as the acoustic mismatch 
between the vessel wall and blood is greater than that between the red-cell-plasma interface.  
Filters can therefore be used commonly at 200Hz. 
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2.2.2 Doppler Modes 
A number of different Doppler modes exist which have different clinical applications.  These 
include: continuous wave flow, colour mapping, pulsed Doppler and power Doppler.  These 
will be outlined below. 
 
2.2.2.1 Continuous Wave flow 
Continuous wave systems use continuous generation and reception of ultrasound, requiring 
two transducers.  Signals are obtained from all vessels in the path of the ultrasound beam.  
The transmitting transducer produces an ultrasonic beam which makes contacts with 
erythrocytes which then reflect and form echoes which are detected by the receiving 
transducer.  Signals are also generated from stationary targets which produce stronger echoes, 
although no Doppler shift.  All of these signals are mixed together and the Doppler 
demodulator identifies the echoes from moving targets and rejects stationary target echoes.  It 
also measures the size of the Doppler shift by comparing the incoming signal with a reference 
signal which is the original unshifted frequency 
 
Continuous wave flow meters are not limited by the maximum velocity that can be measured 
as they do not use real time imaging.  However, they are unable to discriminate in range; they 
cannot determine the specific location of velocities within the beam and are unable to 
produce colour flow images.  Consequently, continuous wave Doppler is used for non 
velocimetric applications such as fetal heart rate detection and external electronic fetal heart 
rate monitoring. 
 
2.2.2.2 Pulsed Wave Doppler and Colour Flow Imaging 
The requirements of colour flow imaging and pulsed wave Doppler are different.  Pulses and 
signal processing are optimised for each method and they are often used in conjunction with 
each other during obstetric ultrasound scanning. 
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2.2.2.2.1Colour Flow Imaging 
Colour flow Doppler can encompass large regions.  An ultrasound line is divided into blocks 
and the echo signals returning from each block are analysed for Doppler shift.  The detection 
is achieved by examining successive pulses along the scan line in pairs and evaluating for 
changes in phase.  This is in contrast to the Fourier spectral analysis used in pulsed Doppler.  
If a shift is detected then a colour is superimposed onto the B-mode ultrasound image.  This 
is repeated for several lines which build up the colour image.  It can, therefore, be used to 
identify the presence and direction of flow, to highlight circulation anomalies and to provide 
vessel angle correction for velocity measurements.  Pulsed wave Doppler can be used in 
conjunction to enable analysis of the flow at specific sites of a vessel.   
 
Assignment of colour to the frequency shifts is based on direction; although arbitrary, red 
usually denotes Doppler shifts towards the ultrasound beam and blue, those away from it.  
Magnitude can also be represented; different colour hues or lighter saturation for higher 
frequency shifts. 
 
The appearance of the colour flow image can be altered by the power and gain.  Colour flow 
uses higher intensity power than B-mode.  Safety indices (see page 93) should therefore be 
taken into consideration.  The gain should be set to allow good signal for flow and minimise 
interference from surrounding tissues.  Changes of frequency can be performed on the 
ultrasound machine.  High frequencies give better sensitivity to low flow and have better 
spatial resolution.  Low frequencies have better penetration and are less susceptible to 
aliasing at high velocities.  The pulse repetition frequency can also be altered.  Low pulse 
repetition frequencies should be used to examine low velocities but aliasing may occur with 
high velocities.  The frame rate can be improved by reducing the width and maximum depth 
of the colour flow, as more pulses are needed to analyse flow than for the generation of a B-
mode image. 
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2.2.2.2.2 Pulsed Wave Doppler 
In pulsed wave Doppler flow at one particular site is assessed and a sonogram obtained.  Due 
to the fact that the ultrasound is concentrated on one location this can be updated 
approximately 110 times per second and the range and distribution of velocities in the sample 
volume can be displayed as they change in real time.  Pulsed wave Doppler is also angle 
dependent and at angles approximating 90
o
 there is little flow signal.  Flow away from the 
transducer results in an inverted sonogram.  The resultant sonogram can be measured to 
assess flow characteristics.  The shape of the sonogram is often useful and flow velocities can 
be measured. 
 
Pulsed Doppler has two main limitations.  Firstly there is a maximum flow velocity that can 
be detected.  When pulses are transmitted at a given sampling frequency or repetition 
frequency the maximum fd that can be measured is half the pulse repetition frequency.  If the 
measured blood velocity and flow angle give an fd greater than half of the pulse repetition 
frequency ambiguity occurs which is termed aliasing.  The pulse repetition frequency is 
affected by the range of the sample volume.  The timing between sampling pulses must allow 
the pulse to return from the reflector to the transducer.  The receiver is unable to discriminate 
between the reflected signal from two pulses if they are generated too close together.  
Secondly, because Doppler information is only collected from one sample volume it requires 
the operator to identify the correct location to position it. 
 
The sonogram generated is reflective of pulsations arising from changes in the vascular 
system throughout the cardiac cycle.  A number of indices are used to describe these 
variations in the waveforms generated.  These are all dependent on the angle between the 
Doppler beam and the vessel: the PI, SD, RI and PSV (described in Chapter 1) 
 
2.2.2.3 Scale and Aliasing 
The appearance of the colour flow and pulse wave image can be altered with the scale.  If 
blood is moving slowly a low scale should be selected, so pulses are transmitted less 
frequently to detect the small amount of movement between pulses.  If blood is moving 
quickly the scale should be increased to transmit pulses at a higher pulse repetition frequency. 
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If a low pulse repetition frequency is used for high velocities aliasing occurs.  This is where 
high velocities are misrepresented as low or reversed velocities. 
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2.2.2.4 Power Doppler 
In power Doppler the Doppler signal is processed in an alternative way.  The magnitude of 
the colour flow output is shown as opposed to the Doppler frequency signal.  It does not 
display flow direction or velocity and can be used in conjunction with frame averaging to 
increase sensitivity to low flow.  There is no angle dependency as velocities are not being 
measured; instead the total signal level across all frequencies at each depth is displayed.  
Power Doppler has a better signal to noise ratio than colour Doppler which facilitates the 
accurate visualisation of small vessels and is more accurate for obtaining diameters of such 
vessels. 
 
When used in conjunction with pulsed Doppler, easy identification of vessels is facilitated 
and more effective insonation is possible without the effects of vessel wall movement on the 
Doppler signal acquired[148].   
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2.3 Volume Blood Flow 
 
Doppler ultrasonography has enabled the study of blood flow volume in a non invasive 
manner through calculation of the product of the cross sectional area of the vessel and time- 
averaged velocities.  Prior to this, assessment of flow volume was only possible by 
radiolabeled microspheres and other invasive techniques[208-209]. 
 
The maximum frequency of the waveform can be calculated which is imperative to calculate 
volume flow.  It can be given by the equation: 
 
Where: 
IWMF = the intensity weighted mean frequency 
 = amplitude 
 = frequency 
 
Equation 8 Intensity Weighted Mean Frequency 
 
If the angle between the Doppler and the blood vessel is known then the frequency can be 
converted into blood velocity. 
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In order to calculate volume flow estimation of the IWMF, angle of insonation and the vessel 
diameter are required.  It can be calculated using the formula: 
 
Where: 
 = peak velocity in cm/sec 
 = flow in cc/min 
d = diameter in cm 
 
Equation 9 Volume Blood Flow 
 
The measurement of peak velocity and vessel diameter can be measured simultaneously with 
real-time ultrasound phase locked systems.  However, this is dependent on the machine and 
software being used.  Studies have also shown that error from non simultaneous measurement 
of velocity and vessel diameter is less than 8% and therefore of unlikely practical 
importance[210]. 
 
Limitations of the technique include the fact that measurements can only be made to the 
nearest millimetre and the diameter has to be squared to calculate the cross sectional area of a 
vessel consequently squaring any error.  It also assumes that vessels are round and flow is 
parabolic; however the diameter of a vessel is not necessarily circular.  Concerns have also 
been raised regarding the timing of the measurements in relation to the cardiac cycle (i.e. if 
taken during systole or diastole) on the vessel diameter, a 10% difference in diameter may 
affect the estimated volume flow by as much as 25%[211].  However, Konje et al obtained 
values from normal pregnancies[212] from the uterine arteries and found these results to be 
similar to those obtained by electromagnetic flowmetry at hysterotomy[146].  Therefore, if 
measurements are consistently made during systole, the influence of the cardiac cycle on 
measurements obtained is likely to be minimal[148]. 
 
This method has also been validated in a sheep model by Acharya et al[51].  This group 
assessed volume blood flow in 5 pregnant sheep using a 6mm transit time ultrasonic 
perivascular probe flow to provide a direct assessment of volume blood flow.  They 
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simultaneously performed Doppler ultrasonography of the uterine artery, assessing vessel 
diameter with power Doppler and mean velocity which facilitated calculation of volume 
blood flow (see page 91).  They found a significant correlation between direct and ultrasound 
assessment of volume blood flow[51]. 
 
Another method of assessing quantification of blood flow volume is the calculation of 
fractional moving blood volume.  Using power Doppler the signal from blood vessels on a 
monochromatic intensity scale is assessed.  This technique compensates for the dependence 
of the power Doppler signal on machine settings and is therefore capable of measuring the 
volume of blood within a particular area of tissue as a fraction, where 100 represents 100% 
blood.  However, this technique does not provide absolute volume blood flow[213]. 
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2.4 Safety of Ultrasound and Doppler 
 
No adverse effects have been identified from fetal ultrasound.  However, modern ultrasound 
scanners operate at higher outputs and intensities for colour flow imaging and pulsed wave 
Doppler than for B-mode scanning and consequently precautions should be taken.  High 
levels of ultrasound can theoretically produce biological damage and this has been utilised in 
the clinical application of ultrasound in the selective killing of tumours.  There are three 
mechanisms by which ultrasound may cause biological effects.  These are cavitation, 
microstreaming and heating.  These will be discussed briefly below. 
 
2.4.1 Heating 
Energy lost from the ultrasonic wave is absorbed by the surrounding tissue.  Most of this 
deposited acoustic energy is transferred into heat.  This energy loss depends on the amplitude 
absorption coefficient of the tissue.  Heating effects are dependent on the volume being 
heated and consequently on beam width.  Other factors affecting the extent of the temperature 
rise include beam intensity, tissue-specific heat and thermal conductivity, time and blood 
supply. 
 
The World Federation of Ultrasound in Medicine and Biology (WFUMB) 1989 states that: 
‘based solely on a thermal criterion a diagnostic exposure that produces a temperature of 
1.5
o
C above normal physiological levels may be used without reservation in clinical 
examinations.’  They also state that ultrasound exposure causing temperature rises of greater 
than 4
o
C for over 5 minutes should be considered potentially hazardous[214]. 
 
Ultrasound machines, therefore, display the thermal index (TI) which gives the ultrasound 
operator an indication of the thermal implications and likely hazard of the examination. 
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TI is defined as: 
 
Where: 
TI = Thermal Index 
 = machine’s current output power 
 = power required to increase the 
temperature by 1 degree 
 
Equation 10 Thermal Index 
 
Wdeg is complex to calculate and is organ dependent.  Therefore three separate TI indices are 
used, one for soft tissue e.g. the upper abdomen, another for cranial bone in the adult setting 
and a third for bone.  The latter is most applicable to obstetric scanning. 
 
2.4.2 Cavitation 
This is the formation, oscillation and decay of small bubbles caused by the effect of an 
ultrasound wave.  Small bubbles are present in many tissues.  Ultrasound causes these to 
increase in size and vibrate at the ultrasound frequency.  Collapse of the bubble can generate 
local high temperatures and pressures.  Cells and tissues can be influenced by this effect 
however and the results are unpredictable.  There is no gas in fetuses which means that the 
threshold for cavitation is high.  The use of contrast agents lowers the threshold for cavitation 
but this is not current practice in obstetrics.  The effect is enhanced by low frequencies, long 
pulses, high negative pressures and the presence of bubble nuclei. 
 
2.4.3 Microstreaming 
This occurs where small local fluid circulations form either within or outside cells, due to the 
fact that ultrasound exerts a mechanical force on the medium through which it is travelling. 
 
Both microstreaming and cavitation have the potential to cause mechanical effects.  Similar 
safety precautions are used as for thermal effects and the mechanical index (MI) accounts for 
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these effects.  They are altered by large negative pressure values and low frequency.  It is 
defined by the equation: 
 
Where: 
 = the Mechanical Index 
 = maximum negative pressure in mega pascals 
 = frequency in MHz. 
 
 
Equation 11 Mechanical Index 
 
An MI of less than 1 is safe. 
 
2.4.4 Clinical Studies 
Stark et al performed B mode imaging on 425 children between 1968 and 1972 and recruited 
381 matched controls.  They found no biologically significant differences between exposed 
and unexposed children up to the age of 12[215]. 
 
Newnahm et al investigated the effects of frequent ultrasound during pregnancy.  They 
enrolled 2834 women between 16-20 weeks pregnant.  Patients were randomly allocated into 
receiving growth scans and continuous-wave Doppler flow studies at 18, 24, 28, 34 and 38 
weeks or one scan at 18 weeks.  They found that there was a higher incidence of birthweight 
less than 10
th
 and 3
rd
 centile in the intensive monitoring group[216].  However, the same 
group followed these patients up to 8 years of age.  They found that childhood growth and 
measurements of developmental outcome were similar to those who had received one single 
prenatal scan[217].  
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CHAPTER 3 – ULTRASOUND ASSESSMENT OF THE REDISTRIBUTION OF 
BLOOD FLOW IN IUGR FETUSES 
 
3.1 INTRODUCTION 
 
The ‘brain sparing phenomenon’ and associated circulatory changes in IUGR fetuses have 
been explored using Doppler velocimetry and have been extensively described in Chapter 1.  
Some of these changes are currently utilised in the clinical setting to monitor disease 
progression and facilitate management decisions regarding timing of delivery.  The vessels 
clinically assessed using Doppler velocimetry will be outlined briefly below. 
 
Uterine artery Doppler indices have been used to predict the risk of IUGR during pregnancy; 
raised resistance indices and/or waveform notching are findings that are often seen in cases of 
IUGR secondary to uteroplacental pathology.  They are commonly assessed between 22 and 
24 weeks gestation, at which time the sensitivity for identifying patients with IUGR is at its 
highest.  The negative predictive value is also high at this gestational age[147].  However, 
uterine artery Dopplers are only beneficial in assessment of a high risk population and 
changes are not always specific as abnormal Doppler waveforms may also be associated with 
and predictive for pre-eclampsia which may be found concomitantly or independent of 
IUGR[147].   
 
Umbilical artery Doppler flow velocity waveforms are routinely assessed throughout 
gestation in IUGR pregnancies and provide information on downstream peripheral vascular 
impedance of the placenta.  Abnormalities in diastolic blood flow are first apparent, reflected 
by an increased pulsatility index (PI) and resistance index (RI), followed by absent and then 
reversed end diastolic flow, although progression in severity may not always be sequential. 
 
The middle cerebral arteries are used to assess the extent of the redistribution phenomenon 
within the fetus.  When brain sparing occurs there is a reduction in cerebral flow resistance, 
reflected by a reduction in the PI and RI of this vessel.  In severe and terminal cases of IUGR 
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this adaptive mechanism is lost and normalisation of these parameters occurs.  MCA Doppler 
analysis has not been shown to be helpful in timing delivery because signs of brain sparing 
are a relatively early indicator of chronic hypoxemia[147].   
 
Although Doppler velocimetry is not routinely performed on the renal arteries, the amniotic 
fluid is assessed as a measure of fetal wellbeing.  A reduction in amniotic fluid has been 
proposed to be attributable to reduced renal perfusion and consequently reduced fetal urine 
output[137].  However, not all growth restricted fetuses show evidence of oligohydramnios.   
 
When the compensatory mechanisms of arterial blood flow redistribution have occurred, and 
it is no longer possible to maintain oxygen delivery to the myocardium, characteristic 
changes in the venous flow velocity waveforms occur, including loss of the a wave in the 
ductus venosus and pulsatility in the umbilical vein.  These indicate severe pathology[147]. 
 
3.1.1 Volumetric Blood Flow and IUGR fetuses 
Doppler velocimetry is, however, a measure of flow impedance and only provides an indirect 
assessment of blood flow.  Volumetric blood flow is a mechanism by which circulatory 
changes can be quantified in the IUGR fetus. 
 
As discussed in detail in Chapter 1 volumetric blood flow has already been utilised to 
investigate the redistribution phenomenon in IUGR fetuses in the uterine artery[148], 
umbilical vein[143], ductus venosus[142], hepatic vein[142], descending aorta[136] and 
middle cerebral artery[124].  Although normal data for volume blood flow calculation exists 
for multiple fetal vessels[218], no study has longitudinally assessed volume blood flow in the 
umbilical artery, renal artery and longitudinally in the middle cerebral artery.  These are 
vessels directly or indirectly assessed in the clinical setting, and calculation of their volume 
blood flow will enable the redistribution phenomenon and circulatory changes occurring in 
the IUGR fetus to be explored in more detail.   
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3.2 AIMS OF THE ULTRASOUND COMPONENT OF THE STUDY 
 
1) To assess Doppler Velocimetry of fetal vessels commonly imaged in clinical practice, 
utilising power Doppler in both appropriately grown and growth restricted fetuses.  
Vessels imaged will include: middle cerebral artery, umbilical artery and renal artery. 
2) To assess differences in vessel diameter between appropriately grown and growth 
restricted fetuses in the above vessels. 
3) To assess differences in volume blood flow between appropriately grown and growth 
restricted fetuses in the above vessels. 
Due to interim findings four additional vessels were also assessed: the ascending and 
descending aortas and the internal carotid and femoral arteries.  Additional aims included: 
1) Characterisation of vessel diameter, PI, PSV and volume blood flow in the descending 
and ascending aorta, internal carotid and femoral arteries. 
2) Investigation of differences between IUGR fetuses with early (prior to 34 weeks 
gestation) and late onset (post 34 weeks gestation) disease. 
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3.3 METHODS OF THE ULTRASOUND COMPONENT OF THE STUDY  
 
3.3.1 Ethics 
Full ethical approval for the ultrasound components of this study was obtained from the 
Hammersmith Hospital Research Ethics Committee (REC) number 07/Q0406/16.  Before 
agreeing to take part in the study patients were provided with an information leaflet. 
 
3.3.2 Power Calculation 
A power calculation was performed in order to establish a 5% statistical significance using 
known values in umbilical artery volume blood flow in normally grown fetuses[219].  The 
mean and the standard deviation of the normal population at 32 weeks (when many IUGR 
fetuses are electively delivered) were assumed: 256.46 +/- 58.9 ml/min.  A one sided t-test 
with 80% power at a 5% significance level was performed which showed that 72 IUGR and 
72 normally grown fetuses were required to detect a 10% difference in volumetric flow. 
 
3.3.3 Patient Recruitment 
All patients were recruited between June 2007 and January 2010 and only singleton 
pregnancies were included.  All fetuses underwent a dating scan between 11 and 14 weeks 
gestation.  Patients with normally grown fetuses were recruited from the main ultrasound 
department of Queen Charlotte’s and Chelsea Hospital following a normal anomaly scan 
between 20 and 23 weeks gestation.  Patients with fetal anomalies, multiple pregnancy, 
aneuploidy and infections were excluded. 
 
Fetuses with IUGR were recruited from the Centre for Fetal Care at Queen Charlotte’s and 
Chelsea Hospital.  This is a major tertiary referral unit.  Fetal growth restriction was defined 
as an estimated fetal weight <10
th
 centile plus abnormal Doppler velocimetry in the umbilical 
artery.  Where appropriate, karyotyping was offered to exclude aneuploidy.  An infection 
screen (encompassing toxoplasmosis, rubella and cytomegalovirus) and thrombophilia screen 
was performed on all patients. 
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All patients were provided with detailed information leaflets and full written consent was 
obtained.  Detailed patient demographics including maternal age, height, weight and 
ethnicity, parity and any existing medical conditions were recorded for each patient. 
 
3.3.4 Ultrasound Investigations 
Wherever possible, normal controls were imaged four times: 24, 28, 32 and 36 weeks 
gestation.  However, some women were not able to attend all appointments and not always on 
the dates specified.  IUGR fetuses were scanned at least as frequently as the control group, 
and sometimes more frequently depending on the clinical situation. 
 
All ultrasounds were performed on the Centre for Fetal Care, Queen Charlotte’s and Chelsea 
Hospital using a 6MHz curvilinear 6C2 transducer on a Siemens ultrasound system (Siemens 
Acuson Sequoia 512; Siemens, Germany). 
 
At each examination, all fetuses had full biometry assessed (see Chapter 2) which included, 
biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and 
femur length (FL).  These were used to estimate the weight for gestation in accordance with 
the formula by Hadlock[206].  The amniotic fluid index was also calculated (see Chapter 2).  
All fetuses had a full anatomy scan on at least one occasion in order to exclude fetuses with 
congenital abnormalities. 
 
Vessel diameter and Doppler velocimetery were assessed in the middle cerebral, renal and 
umbilical arteries.  For Doppler velocimetry measurements the high pass filter was set at 
75Hz in order to allow all velocities to be obtained.  The power setting was <94mW/cm
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spatial temporary average velocity and the sample volume was placed over the entire lumen 
of the vessel.  All Doppler measurements were taken in fetal apnoea (as fetal breathing 
movements are known to have effects on blood flow[211]).  Angles of insonation were kept 
as close to 0
o
 as possible and always less than 60
o
.  Pulse waved Doppler was then used to 
obtain velocimetry measurements, which included the PI and PSV.  This was assessed over a 
number of cardiac cycles; at least three waveforms were measured and an average value 
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taken.  All cycles had to demonstrate uniformity in both systolic and diastolic velocities.  
Vessel diameter measurements were obtained by utilising the cine loop function. The point of 
maximal vessel diameter within the cardiac cycle was frozen to obtain the measurement.  
This was repeated in triplicate for each vessel and an average taken.  The methods for each of 
these vessels will be outlined below: 
 
For the umbilical artery the vessel diameter was measured from a free loop of cord which was 
distant from both the cord insertion into the fetal abdomen and the insertion into the placenta.  
This was in accordance with techniques described in previous studies[219].  The chosen 
section of cord was enlarged and the diameter was measured without colour or power 
Doppler.  An inner-inner measurement was taken either longitudinally or in cross section.  
This was performed in the gray-scale mode as the vessel was easily defined in this manner.  
Following vessel diameter measurements Doppler velocimetry indices were obtained[219].   
 
For the middle cerebral artery, measurements were taken from a point defined at the level of 
the lesser wing of the sphenoid bone where the proximal portion was identified at its origin 
from the Circle of Willis and the selected image was magnified using the zoom function.  
Power Doppler was utilised to measure vessel diameter.  The vessel was then insonated and 
pulsed Doppler velocimetry measurements were obtained, in accordance with previous 
studies[124, 218].  The MCA in the near field was always used to obtain all the necessary 
measurements. 
 
For the renal artery a longitudinal view of the fetal kidneys was obtained and Power Doppler 
was utilised to visualise the artery.  The entire vessel was visualised from its origin as a 
lateral branch of the descending aorta to the hilum of the kidney.  The renal artery was then 
magnified utilizing the zoom function and diameters were measured shortly after the origin of 
the vessel from the descending aorta in the Power Doppler mode.  Following this, the vessel 
was then insonated in the power Doppler mode and pulsed Doppler velocimetry 
measurements obtained, again in accordance with previous studies[218].  The renal artery in 
the near field was always assessed. 
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Volume blood flow measurements were calculated using the formula described in Chapter 2 
which is in accordance with other studies[219].  For this calculation the mean maximum 
vessel diameter and the mean PSV again from at least 3 cardiac cycles were used.  As well as 
absolute measurements both volume blood flow and diameters were calculated standardised 
for fetal weight. 
 
From interim analysis of results of the renal, middle cerebral and umbilical arteries it became 
apparent that the diameters of these vessels were significantly greater in IUGR fetuses than 
appropriately grown control fetuses when standardised for fetal weight.  Due to this finding a 
number of other vessels were also assessed: ascending aorta, descending aorta, internal 
carotid artery and the femoral artery. 
 
A power calculation, using the Lenth Power Calculation website 
http://www.stat.uiowa.edu/~rlenth/Power/, was subsequently performed based on the mean 
and standard deviation of the diameter of the descending thoracic aorta standardised for fetal 
weight from a previously published paper of appropriately grown fetuses (6.07 and 0.14 
respectively).  At 80% power and 5% significance 25 appropriately grown and 25 growth 
restricted fetuses were required to detect a 10% difference between the two groups. 
 
The internal carotid artery was assessed on one side only as it was previously demonstrated 
that there were no significant differences in results from the left or right sides.  Power 
Doppler was used to visualise the carotid artery at its bifurcation into the internal and external 
carotid arteries.  This area was then magnified.  The internal carotid artery was measured 
shortly after its origin where the vessel was insonated and Doppler velocimetry obtained.  
The ascending aorta was measured in the three vessel view of the heart.  Power Doppler was 
not used to assess diameter as gray-scale provided sufficient visualisation.  Measurements of 
diameter were taken at their maximum in systole.  The descending aorta was visualised in the 
coronal plane.  Power Doppler was again not used to assess vessel diameter as gray scale 
provided sufficient visualisation.  Measurements were taken at the level of the fetal 
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diaphragm at their maximum in systole.  The femoral arteries were identified by obtaining a 
view of the femur and visualising the vessel using Power Doppler.  Measurements were taken 
at the midpoint of the vessel and attempts were made to keep the angle of insonation as low 
as possible.  Only one femoral artery, in the near field was assessed.  However, no significant 
difference in blood flow was found between the two sides. 
 
3.3.5 Ensuring Validity of Results 
Before analysing the datasets, a number of measures were taken to ensure validity of the 
techniques being used.  These were initially calculated in for the umbilical, middle cerebral 
and renal arteries, however, due to interim analysis four additional vessels (the ascending and 
descending aortas, internal carotid and femoral arteries) were also assessed.  Parameters 
assessed included: calculating inter and intra observer variability of measurements of vessel 
diameter and calculation of Doppler velocimetry measurements.  Reproducibility of data 
acquisition and comparison of left and right renal, internal carotid and femoral arteries was 
also undertaken.  These feasibility studies are outlined below: 
 
Measurements of the PI, PSV vessel diameter and calculation of volume blood flow in the 
renal, internal carotid and femoral arteries on the right and left side were taken for 15 patients 
as per the methods described above.  All datasets were stored and measurements performed at 
a later date by one assessor (LS).  Data was blinded to the assessor.  SPSS, version 17 
(Chicago IL) was used to generate an inter class correlation co-efficient and mean and 
standard deviation for percentage differences between the two vessels. 
 
In order to ensure reproducibility of results the measurement of vessel diameter and 
measurement of velocimetry was assessed by two observers (LS and MD).  Data for 15 
patients was obtained by one assessor, in accordance with the above methods, for the 
umbilical, renal, middle cerebral, ascending and descending aorta, internal carotid and 
femoral arteries.  This data was stored and interpreted at a later date by both assessors.  Each 
assessor also analysed the scan for the correct positioning of measurements.  Results of other 
assessments of these vessels were unknown to the assessors.  SPSS, version 17 (Chicago IL) 
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was used to generate an inter class correlation co-efficient and mean and standard deviation 
for percentage differences between the two assessments. 
 
Measurements of the PI, PSV vessel diameter and calculation of volume blood flow in the 
middle cerebral, umbilical, renal, ascending and descending aorta, internal carotid and 
femoral arteries were also assessed at the beginning and end of the ultrasound examination 
for 15 patients as per the methods described above.  All datasets were stored and 
measurements performed at a later date by one assessor (LS).  Data was blinded to the 
assessor.  SPSS, version 17 (Chicago IL) was used to generate an inter class correlation co-
efficient and mean and standard deviation for percentage differences between the two 
assessments. 
 
3.3.6 Pregnancy Outcome Data 
For all patients enrolled in the study any obstetric complications, such as pre-eclampsia, 
which developed during the pregnancy, were noted. 
 
Delivery parameters were recorded for each patient.  These included: intrauterine 
death/livebirth, gestation at delivery, sex of infant, mode of delivery, any intra-partum 
complications, one and five minute APGAR scores, lowest cord pH at delivery, need for 
resuscitation at delivery and admission to the neonatal unit.  Customised birthweight centiles 
were calculated based on delivery and maternal parameters using gestation network, United 
Kingdom edition (http://www.gestation.net/).   
 
Any neonatal complications to the time of discharge from hospital were also recorded.  These 
included: neonatal death, sepsis, respiratory distress syndrome, intraventricular haemorrhage, 
hypoglycaemia, jaundice and gastrointestinal complications. 
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3.3.7 Statistical Analysis 
Statistical analysis was performed using the SPSS software package version 17 (SPSS 
Chicago, IL, USA).  In association with the Public Health Department, Cardiff University, 
mixed effects analysis of covariance was used to assess the effects of volume blood flow, PI, 
PSV and vessel diameter in IUGR fetuses (when corrected for gestational age), as well as the 
influence of ethnicity, maternal age, sex of infant and maternal BMI.  Complex modelling 
which took into the account of repeated measures was used.  Each variable was assessed for 
normality prior to Mixed Effects ANCOVA analysis: where data was not normally 
distributed, original data sets were transformed by logging to base 10.  Demographic and 
delivery data, where continuous, was analysed using the t-test where data was normally 
distributed and Mann-Whitney where the criteria for normality were not satisfied.  Where 
data was categorical, the Chi-Squared test was used.  
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3.4 RESULTS OF THE ULTRASOUND COMPONENT OF THE STUDY 
 
228 patients were recruited in total for assessment of the umbilical, renal and middle cerebral 
arteries.  150 of these patients had appropriately grown fetuses and 78 had evidence of IUGR.  
Of the growth restricted fetuses, at the end of the pregnancy: 15 had a raised pulsatility index 
in the umbilical artery, 23 had a raised pulsatility index and evidence of cerebral 
redistribution, 32 had absent end diastolic flow, 5 had reversed end diastolic flow and 3 had 
evidence of venous changes in addition to reversed end diastolic flow in the umbilical artery. 
 
The number of scans obtained from IUGR and appropriately grown pregnancies can be seen 
in Figure 12. 
 
 
Figure 12 Number of Scans Obtained from IUGR and Appropriately Grown Fetuses 
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Due to preliminary findings of the study, in a subset of patients, additional vessels including 
the ascending and descending aorta, internal carotid and femoral arteries were also assessed.  
This subgroup included 96 appropriately grown control fetuses scanned between 16
+1
 and 
39
+6
 median 31
+6
 weeks gestation and 53 IUGR fetuses, scanned between 20
+0
 and 39
+2
 
weeks gestation median 28
+3
 weeks, 7 of which had a raised PI in the umbilical artery, 18 had 
a raised umbilical PI and cerebral redistribution, 20 had absent end diastolic flow in the 
umbilical artery, 5 had reversed flow and 3 had additional evidence of venous abnormalities.   
 
3.4.1 Maternal Demographics 
Maternal characteristics of women with both appropriately grown and IUGR fetuses that had 
the umbilical, middle cerebral and renal arteries assessed can be seen in Table 2 below. 
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Maternal Characteristic IUGR Appropriately Grown Significance 
Age 
Median (Range) 
 
32 (21-58) 
 
32 (17-45) 
 
p=0.425  
BMI 
Median (Range) 
 
24.8 (18-51) 
 
23 (17-38) 
 
p= 0.001 
Parity 
0 
1 
2 
3 
>3 
 
54.7% 
22.7% 
13.3% 
8% 
1.3% 
 
66.4% 
23.1% 
9% 
1.5% 
0% 
 
p=0.166  
Ethnicity 
Caucasian 
Asian 
South East Asian 
Afro carribean 
Middle Eastern 
Other 
 
47.4% 
23.1% 
2.6% 
21.3% 
2.8% 
2.8% 
 
73.8% 
8.2% 
4.5% 
9% 
1.5% 
3% 
 
p=0.017 
Smoking 
Smokers 
Non Smokers 
 
10.7% 
89.3% 
 
4% 
96% 
 
p=0.98  
 
Table 2 Maternal Demographics of Patients with Appropriately Grown and IUGR 
Pregnancies 
Maternal demographics of women with both appropriately grown and growth restricted 
fetuses with additional vessels of the descending and ascending aorta, internal carotid and 
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femoral arteries are shown in Table 3. 
Maternal Characteristic IUGR Appropriately Grown Significance 
Age 
Median (Range) 
 
32 (21-58) 
 
31 (17-42) 
 
0.63 (ns) 
BMI 
Median (Range) 
 
25 (18-36) 
 
22 (17-38) 
 
p=0.011 
Parity 
0 
1 
2 
3 
>3 
 
51% 
25% 
14% 
7% 
2% 
 
68% 
20% 
10% 
2% 
0% 
 
 
p=0.357  
Ethnicity 
Caucasian 
Asian 
South East Asian 
Afro carribean 
Middle Eastern 
Other 
 
47% 
18% 
4% 
25% 
4% 
2% 
 
67% 
10% 
7% 
10% 
2% 
4% 
 
 
p=0.017 
Smoking 
Smokers 
Non Smokers 
 
10% 
90% 
 
8% 
92% 
 
p=0.928 
 
Table 3 Maternal Demographics of Fetuses with Additional Vessels Assessed 
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3.4.2 Ensuring Validity of Results 
3.4.2.1 Intra and Inter-observer Variability of Umbilical, Middle Cerebral, Renal, Femoral 
and Internal Carotid Arteries and the Descending and Ascending Aortas 
 
Vessel Intra-Observer 
Variability 
Correlation       
Co-efficient 
Intra-Observer 
Mean Percentage 
Difference and 
Standard Deviation 
Inter-Observer 
Variability 
Correlation       
Co-efficient 
Inter-Observer 
Mean Percentage 
Difference and 
Standard Deviation 
Umbilical artery  
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.98 (p=<0.001) 
0.98 (p=<0.001) 
0.98 (p=<0.001) 
0.99 (p=<0.001) 
 
5.6 (3.2) 
2.9 (2.7) 
2.3 (2.9) 
5.6 (4.8) 
 
0.92( p=<0.001) 
0.98 (p=<0.001) 
0.94 (p=<0.001) 
0.97 (p=<0.001) 
 
5.3 (4.2) 
4 (4.1) 
8.3 (17.7) 
8.8 (8.1) 
Renal artery  
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.94 (p=<0.001) 
0.95 (p=<0.001) 
0.96 (p=<0.001) 
0.97 (p=<0.001) 
 
4.1 (3.5) 
4.1 (3.8) 
5 (3.4) 
8.5 (4.8) 
 
0.8 (p=0.01) 
0.96 (p=<0.001) 
0.96 (p=<0.001) 
0.97 (p=<0.001) 
 
7 (6.3) 
6.6 (4.7) 
4.1 (5.4) 
8.6 (5.5) 
Middle cerebral artery  
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.98 (p=<0.001) 
0.99 (p=<0.001) 
0.95 (p=<0.001) 
0.97( p=<0.001) 
 
4 (2) 
3.5 (3.7) 
3.4 (2.6) 
5 (3.5) 
 
0.89 (p=<0.001) 
0.97 (p=<0.001) 
0.98 (p=<0.001) 
0.98 (p=<0.001) 
 
6.7 (3.3) 
5.3 (3) 
4.1 (2.8) 
5.7 (4.7) 
Internal Carotid 
PI 
PSV 
Vessel Diameter 
 
0.94 (p=<0.001) 
0.99 (p=<0.001) 
0.85 (p=<0.001) 
 
5.1 (4) 
2.3 (2.3) 
4.5 (3.8) 
 
0.73 (p=0.005) 
0.94 (p=<0.001) 
0.68 (p=0.01) 
 
9 (8.7) 
10.7 (15.9) 
23.1 (14.2) 
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Volume Blood Flow 0.94 (p=<0.001) 8.6 (7.2) 0.811 (p=0.01) 44.6 (27.9) 
Ascending Aorta 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.94 (p=<0.001) 
0.99 (p=<0.001) 
0.99 (p=<0.001) 
0.99 (p=<0.001) 
 
5.7 (3.1) 
1.9 (2) 
3.5 (2.1) 
6 (4) 
 
0.84 (p=<0.001) 
0.99 (p=<0.001) 
0.94 (p=<0.001) 
0.95 (p=<0.001) 
 
5.4 (2.9) 
5.7 (3.3) 
6.6 (4.8) 
12.6 (6.6) 
Descending Aorta 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.88 (p=<0.001) 
0.99 (p=<0.001) 
0.98 (p=<0.001) 
0.98 (p=<0.001) 
 
5 (3.8) 
1.6 (1.8) 
3 (1.5) 
6.4 (2.8) 
 
0.821( p=0.009) 
0.96 (p=<0.001) 
0.95 (p=<0.001) 
0.98 (p=<0.001) 
 
7.4 (7.1) 
5.4 (5) 
4.6 (4.6) 
8.7 (4.4) 
Femoral Artery 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.87 (p=<0.001) 
0.99 (p=<0.001) 
0.87 (p=<0.001) 
0.95 (p=<0.001) 
 
7.1 (4.9) 
5 (5.1) 
7.5 (4.2) 
14.6 (10.5) 
 
0.76 (p=0.02) 
0.96 (p=<0.001) 
0.533 (p=ns) 
0.772 (p=0.03) 
 
10.8 (12.9) 
15.6 (10.4) 
10.8 (8) 
32.4 (22.3) 
 
Table 4 Intra and Inter observer Variability of Assessment of Multiple Vessel 
Parameters 
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3.4.2.2 Variability Analysis of Measurements Taken at the Beginning and End of a Scan 
on the Same Patient for the Umbilical, Middle Cerebral, Renal, Femoral and Internal 
Carotid Arteries and the Ascending and Descending Aorta 
 
Vessel 
Intra-Scan Variability 
Correlation Co-efficient 
Intra-Scan Mean             
Percentage Difference and 
Standard Deviation 
Umbilical artery  
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.865 (p<0.001) 
0.642 (p=0.045) 
0.849 (p<0.001) 
0.92 (p<0.001) 
 
11 (7.5) 
17 (13) 
5.8 (3.2) 
18.7 (12) 
Renal artery  
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.915 (p<0.001) 
0.848 (p<0.001) 
0.911 (p<0.001) 
0.944 (p<0.001) 
 
6 (7) 
15 (10) 
6 (3) 
20 (12) 
Middle cerebral artery  
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.824 (p<0.001) 
0.882 (p<0.001) 
0.956 (p<0.001) 
0.912 (p<0.001) 
 
12 (35) 
11 (18) 
4.6 (3.35) 
10 (10.9) 
Internal Carotid 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.636 (p=0.34) 
0.836 (p<0.001) 
0.946 (p<0.001) 
0.938 (p<0.001) 
 
14 (12) 
15.6 (12) 
3.6 (3.6) 
14 (12) 
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Ascending Aorta 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.612 (p=0.044) 
0.921 (p<0.001) 
0.914 (p<0.001) 
0.971 (p<0.001) 
 
15 (12) 
11 (7.6) 
7.4 (4.1) 
18 (14) 
Descending Aorta 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.884 (p<0.001) 
0.64 (p=0.04) 
0.934 (p<0.001) 
0.969 (p<0.001) 
 
 
9.3 (4.7) 
15 (11) 
5 (2.8) 
15 (9.6) 
Femoral Artery 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.652 (p=0.03) 
0.564 (p=ns) 
0.7( p=0.01) 
0.62 (p= ns) 
 
12 (7) 
20 (12) 
8.8 (5.8) 
17.5 (17.2) 
 
Table 5 Inter-scan Variability Measurements 
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3.4.2.3 Comparison of Measurements from Right and Left Renal, Internal Carotid and 
Femoral Arteries 
 
Vessel Correlation Co-efficient 
Mean Percentage Difference   
and                                    
Standard Deviation 
Renal Arteries 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.936 (p<0.001) 
0.639 (p=0.01) 
0.97 (p<0.001) 
0.965 (p<0.001) 
 
5.7 (3.6) 
4.6 (8.6) 
2.5 (2.6) 
16.7 (12.8) 
Internal Carotid Arteries 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.864 (p<0.001) 
0.955 (p<0.001) 
0.944 (p<0.001) 
0.99 (p<0.001) 
 
9.5 (5.8) 
4.2 (6.6) 
2.2 (2.9) 
4.6 (6.2) 
Femoral Arteries 
PI 
PSV 
Vessel Diameter 
Volume Blood Flow 
 
0.842 (p<0.001) 
0.969 (p<0.001) 
0.843 (p<0.001) 
0.984 (p<0.001) 
 
8 (6.5) 
4.2 (4.9) 
2.9 (2.8) 
6 (7.1) 
 
Table 6 Intra and Inter Observer Variability Measurements of Additional Vessels 
Assessed 
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3.4.3 Umbilical Artery 
362 ultrasound scans of the umbilical artery were obtained from appropriately grown fetuses 
between 16
+1
 and 39
+6
 weeks gestation, median gestational age 31
+5
 weeks gestation.  182 
successful scans of the umbilical artery were obtained in IUGR fetuses between 20
+0
 and 39
+2
 
weeks gestation, median gestational age 29
+0
 weeks gestation.  The angle of insonation of the 
umbilical artery was 0 degrees in all cases. 
 
3.4.3.1 Umbilical Artery Pulsatility Index 
 
Figure 13 Umbilical Artery Pulsatility Index in Appropriately Grown and Growth 
Restricted Fetuses 
 
In appropriately grown fetuses, the umbilical artery PI decreased as gestation progressed 
(p<0.001).  The pulsatility index was significantly increased in IUGR fetuses (p=<0.001). 
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Figure 14 Umbilical Artery Pulsatility Index in Appropriately Grown Fetuses and 
IUGR Fetuses Categorised by Disease Severity 
 
The finding of raised umbilical PI in IUGR fetuses was confirmed for all subgroups (p<0.01 
in all cases).  No effect was seen from maternal characteristics: BMI, ethnicity or age. 
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3.4.3.2 Umbilical Artery PSV 
 
Figure 15 Umbilical Artery Peak systolic Velocity in Appropriately Grown and Growth 
Restricted Fetuses 
 
In appropriately grown fetuses, the PSV increased with increasing gestational age (p<0.001).  
The peak systolic velocity was significantly lower in IUGR fetuses than appropriately grown 
fetuses (p=0.01). 
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Figure 16 Umbilical Artery Peak Systolic Velocity in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Severity 
 
However, on subgroup analysis only IUGR fetuses with absent end diastolic flow had 
significantly lower PSV than appropriately grown fetuses (p<0.001).  No effect was seen 
from maternal characteristics: BMI, ethnicity or age. 
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Figure 17 Umbilical Artery Peak Systolic Velocity in Appropriately Grown Fetuses and 
Growth Restricted Fetuses Classified by Onset of Disease 
 
Fetuses with late onset IUGR had a significantly lower PSV than appropriately grown control 
fetuses (p<0.001); however there was no difference between fetuses with early onset IUGR 
and the control group (p=0.375). 
 
 
 
 
120 
 
3.4.3.3 Umbilical Artery Diameter 
 
Figure 18 Umbilical Artery Diameter in Appropriately Grown and Growth Restricted 
Fetuses 
 
Umbilical artery diameter increased significantly as gestation progressed in appropriately 
grown fetuses (p<0.001).  There was no difference between the umbilical artery diameter 
between appropriately grown and growth restricted fetuses (p=0.477). 
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Figure 19 Umbilical Artery Diameter in Appropriately Grown and Growth Restricted 
Fetuses Categorised by Disease Severity 
 
When subgroup analysis was performed there was no statistical difference between 
appropriately grown fetuses and IUGR fetuses with a raised pulsatility index, raised 
pulsatility index and cerebral redistribution and those with reversed end diastolic flow 
(p=0.122, 0.06 and 0.142 respectively).  However, fetuses with absent end diastolic flow had 
significantly increased umbilical artery diameter (p=0.016).  Only 3 fetuses had both reversed 
end diastolic flow and venous changes, consequently this subgroup analysis was not 
performed.  No effect was seen from maternal characteristics: BMI, ethnicity or age. 
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Figure 20 Umbilical Artery Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses 
 
When standardised for fetal weight, appropriately grown fetuses’ umbilical artery diameter 
per kg decreased with increasing gestation (p<0.001) and IUGR fetuses had a significantly 
increased diameter of the umbilical artery in comparison with the control population 
(p=<0.001). 
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Figure 21 Umbilical Artery Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Severity 
 
On subgroup analysis all subgroups of IUGR had a statistically significant increase in 
umbilical artery diameter (p=<0.001 in all cases).  Subgroup analysis was again not 
performed for fetuses with venous changes as only three fetuses were in this group.  No effect 
was seen from maternal characteristics: BMI, ethnicity or age.  
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Figure 22 Umbilical Artery Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Onset of Disease 
 
The umbilical artery diameter per kg was significantly increased in both early and late onset 
IUGR fetuses in comparison with appropriately grown controls (p<0.001 in both cases).  
There was no significant difference in the umbilical artery diameter per kg of IUGR fetuses 
with and without pre-eclampsia (p=0.076). 
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3.4.3.4 Umbilical Artery Volume Blood Flow 
For the calculation of volume blood flow, fetuses with reversed end diastolic flow were 
excluded from the analysis. 
 
Figure 23 Umbilical Artery Volume Blood Flow in Appropriately Grown and Growth 
Restricted Fetuses 
 
In appropriately grown fetuses volume blood flow in the umbilical artery increased with 
increasing gestation (p<0.001).  There was no statistical difference between all IUGR fetuses 
and appropriately grown fetuses in volume blood flow in the umbilical artery (p=0.549). 
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Figure 24 Umbilical Artery Volume Blood Flow in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Severity 
 
When subgroup analysis was performed there was no significant difference in absolute blood 
flow between appropriately grown fetuses and those with high pulsatility index in the 
umbilical artery, or high pulsatility index in the umbilical artery and cerebral redistribution 
(p=0.061 and 0.97 respectively).  However, there was a significant decrease in absolute 
volume blood flow in IUGR fetuses with absent end diastolic flow in comparison with 
appropriately grown controls (p=<0.001).  No effect was seen from maternal characteristics: 
BMI, ethnicity or age. 
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Figure 25 Umbilical Artery Volume Blood Flow per Kilogram in Appropriately Grown 
and Growth Restricted Fetuses 
 
In appropriately grown fetuses, volume blood flow per kilogram decreased with increasing 
gestational age (p<0.001).  Overall volume blood flow per kilogram was statistically higher 
in growth restricted fetuses (p=0.003) 
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Figure 26 Umbilical Artery Volume Blood Flow per Kilogram in Appropriately Grown 
and Growth Restricted Fetuses Categorised by Disease Severity 
 
When standardised for fetal weight, volume blood flow/kg was significantly higher in IUGR 
fetuses, for increased pulsatility index in the umbilical artery, raised pulsatility index in the 
umbilical artery and cerebral redistribution and absent end diastolic flow ( p=0.0034, p=0.05 
and p=0.006 respectively).  No effect was seen from maternal characteristics: BMI, ethnicity 
or age. 
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Figure 27 Umbilical Artery Volume Blood Flow per Kilogram in Appropriately Grown 
and Growth Restricted Fetuses Categorised by Disease Onset 
 
When standardised for fetal weight the umbilical artery volume blood flow per kilogram was 
significantly higher in early onset IUGR fetuses (p=<0.001); however, fetuses with late onset 
IUGR showed no difference in umbilical artery blood flow when standardised for fetal 
weight compared with normal controls.  IUGR fetuses with pre-eclampsia had no significant 
difference in volume blood flow per kg in the umbilical artery in comparison with 
appropriately grown control fetuses (p=0.094). 
 
  
130 
 
3.4.4 Middle Cerebral Artery 
362 ultrasound scans of the middle cerebral artery were obtained from appropriately grown 
fetuses between 16
+1
 and 39
+6
 weeks gestation, median gestational age 31
+5
 weeks gestation. 
182 ultrasound scans of the middle cerebral artery were successfully obtained in IUGR 
fetuses between 20
+0
 and 39
+6
 weeks gestation, median gestation 29
+0
 weeks gestation. The 
angle of insonation for the middle cerebral artery ranged from 0 to 30 degrees, with a median 
angle of insonation of 0 degrees. 
 
3.4.4.1 Middle Cerebral Artery Pulsatility Index 
 
Figure 28 Middle Cerebral Artery Pulsatility Index in Appropriately Grown and 
Growth Restricted Fetuses 
 
131 
 
In appropriately grown fetuses, the middle cerebral artery PI increased between 24 and 32 
weeks then decreased again.  The middle cerebral artery pulsatility index of IUGR fetuses 
was significantly lower than appropriately grown fetuses (p<0.001). 
 
 
Figure 29 Middle Cerebral Artery Pulsatility Index in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Severity 
 
Subgroup analysis confirmed that IUGR fetuses with cerebral redistribution, AEDF and 
REDF all had significantly lower MCA PI (p = 0.036, <0.001 and <0.001 respectively).  No 
effect was seen from maternal: BMI, ethnicity or age.  Only one IUGR fetus in this study had 
evidence of a low MCA PI which then returned to the normal range (loss of the brain sparing 
effect).  This fetus subsequently died in the neonatal period. 
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3.4.4.2 Middle Cerebral Artery Peak Systolic Velocity 
 
Figure 30 Middle Cerebral Artery Peak Systolic Velocity in Appropriately Grown and 
Growth Restricted Fetuses 
 
In appropriately grown fetuses the middle cerebral artery PSV increased with increasing 
gestational age (p<0.001).  The middle cerebral artery PSV was significantly increased in 
IUGR fetuses in comparison with appropriately grown control fetuses (p<0.001). 
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Figure 31 Middle Cerebral Artery Peak Systolic Velocity in Appropriately Grown 
Fetuses and Growth Restricted Fetuses Categorised by Disease Severity 
 
When subgroup analysis was performed the PSV was unchanged from the control population 
in IUGR fetuses with an increased pulsatility index in the umbilical artery; however, all other 
subgroups of IUGR (raised pulsatility index in the umbilical artery and cerebral 
redistribution, AEDF and REDF) had a strongly significant increase in the PSV (p<0.001 in 
all cases).  No effect was seen from maternal characteristics: BMI, ethnicity or age. 
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Figure 32 Middle Cerebral Artery Peak Systolic Velocity in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Onset of Disease 
 
Fetuses with early onset disease had a significantly higher PSV in the middle cerebral artery 
than control fetuses (p=0.009).  However there was no difference between the PSV in fetuses 
with late onset IUGR and control fetuses (p=0.9173) 
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3.4.4.4 Middle Cerebral Artery Diameter 
 
 
Figure 33 Middle Cerebral Artery Diameter in Appropriately Grown and Growth 
Restricted Fetuses 
 
In the appropriately grown fetuses the middle cerebral artery diameter increased with 
increasing gestation (p<0.001).  Overall, IUGR fetuses had a significantly increased middle 
cerebral artery diameter (p<0.001). 
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Figure 34 Middle Cerebral Artery Diameter in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Severity 
 
Subgroup analysis revealed a significant increase in diameter for all cases of IUGR across 
gestation except fetuses with only a raised pulsatility index in the middle cerebral artery: 
raised PI in the umbilical artery p=0.516, all other subgroups p<0.001.  No effect was seen 
from maternal characteristics: BMI, ethnicity or age. 
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Figure 35 Middle Cerebral Artery Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses 
 
Middle cerebral artery diameter per kg decreased with increasing gestational age (p<0.001).  
When standardised for fetal weight the middle cerebral artery diameter per kg was 
significantly increased in IUGR fetuses in comparison with appropriately grown control 
fetuses (p<0.001). 
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Figure 36 Middle Cerebral Artery Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Severity 
 
On subgroup analysis the middle cerebral artery diameter per kg was significantly greater in 
all groups of IUGR: raised PI in the umbilical artery p=0.034, p<0.001 for all other 
subgroups.  No effect was seen from maternal characteristics: BMI, ethnicity or age. 
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Figure 37 Middle Cerebral Artery Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Onset of Disease 
 
When classified into early and late onset IUGR, fetuses with early onset IUGR had a 
statistically significant increase in the middle cerebral artery diameter per kg than 
appropriately grown control fetuses.  However, there was no statistical difference between 
IUGR fetuses with late onset disease and appropriately grown control fetuses p=0.072.  There 
was no significant difference in middle cerebral artery diameter per kg in IUGR fetuses with 
and without PET (p=0.999). 
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3.4.4.5 Middle Cerebral Artery Volume Blood Flow  
 
 
Figure 38 Middle Cerebral Artery Volume Blood Flow in Appropriately Grown and 
Growth Restricted Fetuses 
 
In the appropriately grown fetuses, middle cerebral artery volume blood flow increased with 
increasing gestational age (p<0.001).  Overall middle cerebral artery volume blood flow was 
significantly higher in IUGR fetuses than appropriately grown fetuses (p<0.001).  Ethnicity, 
maternal age and BMI had no affect on this relationship. 
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Figure 39 Middle Cerebral Artery Volume Blood Flow in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Severity 
 
On subgroup analysis an increase in volume blood flow was strongly significant for all 
subgroups (p<0.001) apart from a raised pulsatility index in the umbilical artery (p=0.075).  
Ethnicity, maternal age and BMI had no affect on this relationship. 
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Figure 40 Middle Cerebral Artery Volume Blood Flow per Kilogram in Appropriately 
Grown and Growth Restricted Fetuses 
 
In appropriately grown control fetuses there was no alteration in volume blood flow per kg 
with gestation (p=0.088).  Volume blood flow per kg was significantly higher in IUGR 
fetuses than in appropriately grown control fetuses (p<0.001). 
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Figure 41 Middle Cerebral Artery Volume Blood Flow per Kilogram in Appropriately 
Grown and Growth Restricted Fetuses Categorised by Disease Severity 
 
On subgroup analysis volume blood flow/kg in the middle cerebral artery was significantly 
higher in all subgroups of IUGR: raised PI in umbilical artery p=0.009, p<0.001 for all other 
subgroups.  No effect was seen from maternal characteristics: BMI, ethnicity or age. 
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Figure 42 Middle Cerebral Artery Volume Blood Flow per Kilogram in Appropriately 
Grown and Growth Restricted Fetuses Categorised by Disease Onset 
 
When IUGR fetuses were categorised into early and late onset disease a significant increase 
in volume blood flow per kg in the middle cerebral artery was evident in early onset IUGR 
fetuses in comparison with appropriately grown fetuses (p<0.001).  However, there was no 
difference between volume blood flow in the middle cerebral artery in appropriately grown 
fetuses and fetuses with late onset IUGR (p=0.372).  There was no significant difference in 
middle cerebral artery volume blood flow per kg between IUGR fetuses with and without 
PET (p=0.282). 
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3.4.5 Renal Artery 
In appropriately grown control fetuses, 341 ultrasound scans of the renal artery were 
successfully obtained between 16
+1
 and 39
+6
 weeks gestation with a median gestational age of 
31
+4
 weeks gestation.  In the IUGR fetuses, 153 ultrasound scans of the renal artery were 
successfully obtained between 20
+0
 and 39
+2
 weeks gestation with a median gestational age of 
29
+4
 weeks gestation.  The angle of insonation of the renal artery ranged from 0 degrees to 45 
degrees with a median of 0 degrees. 
 
3.4.5.1 Renal Artery Pulsatility Index 
 
 
Figure 43 Renal Artery Pulsatility Index in Appropriately Grown and Growth 
Restricted Fetuses 
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There was no significant difference in the renal artery pulsatility index between appropriately 
grown and growth restricted fetuses p=0.707. 
 
 
Figure 44 Renal Artery Pulsatility Index in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Severity 
 
On subgroup analysis there was still no difference between the renal artery PI in 
appropriately grown and any subgroup of IUGR fetuses. 
 
Only 7 scans from IUGR fetuses had an AFI less than 5 therefore the correlation between 
AFI and renal artery PI in IUGR fetuses with oligohydramnios was not statistically assessed. 
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3.4.5.2 Renal Artery Peak Systolic Velocity 
 
 
Figure 45 Renal Artery Peak Systolic Velocity in Appropriately Grown and Growth 
Restricted Fetuses 
 
In appropriately grown control fetuses the PSV increased with increasing gestation 
(p<0.001).  Overall there was no significant reduction of the PSV of the renal artery in IUGR 
fetuses, in comparison with appropriately grown control fetuses (p=0.025). 
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Figure 46 Renal Artery Peak Systolic Velocity in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Severity 
 
The renal PSV was not significantly different from control fetuses in IUGR fetuses with a 
high pulsatility index in the umbilical artery or those with a raised pulsatility in the umbilical 
artery and cerebral redistribution (p=0.265 and 0.197 respectively).  However fetuses with 
absent end diastolic flow had a significantly reduced renal artery PSV compared with 
appropriately grown control fetuses (p<0.001).  Only six scans in total were obtained from 
IUGR fetuses with either REDF in the umbilical artery or venous changes; therefore these 
subgroups had insufficient numbers for analysis.  No effect was seen from maternal 
characteristics: BMI, ethnicity or age. 
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There were insufficient numbers to analyse differences between IUGR fetuses with an AFI 
less than 5 and appropriately grown fetuses. 
 
3.4.5.3 Renal Artery Diameter 
 
Figure 47 Renal Artery Diameter in Appropriately Grown and Growth Restricted 
Fetuses 
 
In appropriately grown control fetuses the renal artery diameter increased with increasing 
gestational age (p<0.001).  IUGR fetuses had a significantly higher renal artery diameter in 
comparison with appropriately grown control fetuses (p<0.001). 
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Figure 48 Renal Artery Diameter in Appropriately Grown and Growth Restricted 
Fetuses Categorised by disease Severity 
 
On subgroup analysis, all categories of IUGR had a significant increase in the renal artery 
diameter: raised umbilical artery PI p=0.045, raised umbilical artery PI and cerebral 
redistribution p<0.001 and AEDF p<0.001.  No effect was seen from maternal characteristics: 
BMI, ethnicity or age.  There were insufficient numbers to statistically assess differences in 
renal artery diameter in IUGR fetuses with oligohydramnios. 
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Figure 49 Renal Artery Diameter per Kilogram in Appropriately Grown and Growth 
Restricted Fetuses 
 
Renal artery diameter per kg decreased with increasing gestation in appropriately grown 
control fetuses (p<0.001).  When standardised for fetal weight, the renal artery diameter per 
kg was significantly increased in IUGR fetuses in comparison with appropriately grown 
control fetuses p<0.001. 
152 
 
 
Figure 50 Renal Artery Diameter per Kilogram in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Severity 
 
The renal artery diameter per kg was significantly increased in all subgroups of IUGR: 
p=0.023 for IUGR fetuses with raised PI in the umbilical artery and p<0.001 for all other 
subgroups.  No effect was seen from maternal characteristics: BMI, ethnicity or age. 
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Figure 51 Renal Artery Diameter per Kilogram in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Onset 
 
In both cases of early and late onset IUGR there was a significant increase in renal artery 
diameter per kg than in the appropriately grown control fetuses.  There was no statistical 
difference between IUGR fetuses with and without PET with regards to renal artery diameter 
per kg (p=0.329). 
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3.4.5.4 Renal Artery Volume Blood Flow 
 
Figure 52 Renal Artery Volume Blood Flow in Appropriately Grown and Growth 
Restricted Fetuses 
 
In appropriately grown control fetuses renal artery volume blood flow increased with 
increasing gestation (p<0.001).  Renal artery volume blood flow was significantly increased 
in IUGR fetuses in comparison with appropriately grown control fetuses (p=0.002). 
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Figure 53 Renal Artery Volume Blood Flow in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Severity 
 
On subgroup analysis a significant increase in volume blood flow was observed for all 
subgroups of IUGR: raised PI in the umbilical artery p=0.011, raised PI in the umbilical 
artery and cerebral redistribution p=0.018, AEDF p=0.046.  No effect was seen from 
maternal characteristics: BMI, ethnicity or age. 
 
Numbers were insufficient to assess a statistical difference between renal artery volume blood 
flow between IUGR fetuses with oligohydramnios and the control population. 
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Figure 54 Renal Artery Volume Blood Flow per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses 
 
In appropriately grown control fetuses, renal artery volume flow per kg decreased with 
increasing gestational age (p<0.001).  IUGR fetuses had significantly increased renal artery 
volume blood flow per kg in comparison with appropriately grown control fetuses (p<0.001). 
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Figure 55 Renal Artery Volume Blood Flow per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Severity 
 
Renal artery volume blood flow per kg was significantly increased for all subgroups of IUGR 
(p<0.001 in all cases).  No effect was seen from maternal characteristics: BMI, ethnicity or 
age. 
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Figure 56 Renal Artery Volume Blood Flow per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Onset 
 
The renal artery volume blood flow per kg was significantly increased in both late and early 
onset IUGR fetuses in comparison with appropriately grown fetuses (p=0.001 and p=0.003 
respectively). 
 
There was no statistical difference in the renal artery volume blood flow per kg between 
IUGR fetuses with pre-eclampsia and those without (p=0.809). 
 
Renal artery volume blood flow per kg was not statistically assessed in IUGR fetuses with 
oligohydramnios as numbers were too small.  
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Figure 57 Correlation of the Amniotic Fluid Index with Renal Artery Volume Blood 
Flow 
 
There was no correlation between renal artery volume blood and AFI. 
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3.4.6 Results of PI, PSV Diameter and Volume Blood Flow in Additional Fetal Vessels 
Assessed: the Descending and Ascending Aorta, Internal Carotid and Femoral Arteries 
The results of the descending aorta, ascending aorta, internal carotid and femoral arteries are 
summarised in Table 7 below.  Graphs indicating these results in further detail are located in 
Appendix 1. 
Vessel and Parameter 
Control  
Fetus range 
IUGR     
Fetus range 
Control 
Fetus 
Median 
IUGR 
Fetus 
Median 
P value 
Descending Aorta 
Gestation (weeks) 
Angle Correction (degrees) 
PI 
PSV 
Diameter (cm) 
Diameter/kg (cm/kg) 
Volume Blood Flow (cc/min) 
Volume Blood Flow/kg (cc/min/kg) 
 
22
+6
-39
+6
 
20-60 
0.93-2.5 
36-281 
0.23-0.75 
0.12-0.9 
128-2010 
88-1301 
 
20-39
+2
 
11-60 
1-3.8 
30-178 
0.25-0.78 
0.01-1.84 
68-1323 
17-1350 
 
31
+3
 
52 
1.5 
105 
0.49 
0.28 
609 
349 
 
28
+6
 
51 
1.92 
89 
0.44 
0.47 
431 
393 
 
 
0.881 
<0.001 
<0.001 
0.507 
<0.001 
<0.001 
0.147 
Ascending Aorta  
Gestation (weeks) 
Angle Correction (degrees) 
PI 
PSV 
Diameter (cm) 
Diameter/kg (cm/kg) 
Volume Blood Flow (cc/min) 
Volume Blood Flow/kg (cc/min/kg) 
 
16
+1
-39
+6
 
0-60 
0.7-3.26 
48-351 
0.27-1.01 
0.14-1.58 
85-3322 
165-1966 
 
20-39
+2
 
11-60 
1-2.98 
35-268 
0.27-0.82 
0.16-2.08 
104-2581 
113-2510 
 
31
+6
 
49 
2.01 
112 
0.56 
0.32 
860 
513 
 
28
+3
 
51 
1.64 
121 
0.55 
0.57 
833 
885 
 
 
0.73 
<0.001 
0.427 
0.003 
<0.001 
0.043 
<0.001 
Internal Carotid 
Gestation (weeks) 
Angle Correction (degrees) 
PI 
PSV 
Diameter (cm) 
Diameter/kg (cm/kg) 
Volume Blood Flow (cc/min) 
Volume Blood Flow/kg (cc/min/kg) 
16
+1
-39
+6
 
10-60 
0.76-2.65 
20-194 
0.12-0.32 
0.049-0.82 
11-234 
10-116 
 
20
+0
-39
+2
 
0-60 
0.9-2.26 
26.9-169 
0.14-0.39 
0.006-0.94 
26-169 
2-354 
 
31
+5
 
53 
1.46 
72 
0.18 
0.11 
57.4 
34.8 
 
28
+3
 
50 
1.22 
78.5 
0.23 
0.25 
96 
97 
 
 
0.780 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Femoral 
Gestation (weeks) 
 
16
+1
-38
+2
 
 
21-39
+2
 
 
31
+1
 
 
29
+0
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Angle Correction (degrees) 
PI 
PSV 
Diameter (cm) 
Diameter/kg (cm/kg) 
Volume Blood Flow (cc/min) 
Volume Blood Flow/kg (cc/min/kg) 
10-60 
0.75-1.9 
10-123 
0.12-0.25 
0.002-0.69 
5-108 
0.31-96 
0-60 
0.48-1.6 
13-108 
0.14-0.24 
0.005-0.79 
11.8-80.5 
0.4-143 
51 
1.18 
51 
0.18 
0.11 
37.6 
24.3 
50 
1.13 
36.6 
0.2 
0.21 
33 
33.1 
0.855 
0.009 
<0.001 
<0.001 
<0.001 
0.065 
0.001 
 
Table 7 Results of PI, PSV, Vessel Diameter and Volume Blood Flow in Additional 
Vessels Assessed 
 
3.4.7 Volume Blood Flow per kg in Early and Late onset IUGR Fetuses for Additional 
Vessels Assessed 
Due to some differences identified between early and late onset IUGR fetuses from the 
middle cerebral umbilical and renal arteries, the relationship between vessel diameter and 
volume blood flow when standardised for fetal weight was explored in more detail for the 
descending and ascending aorta, internal carotid and femoral arteries. 
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Figure 58 Descending Aorta Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Onset 
 
Both early and late onset IUGR had significantly increased descending aorta diameter per kg 
in comparison with appropriately grown control fetuses (p<0.001 and p=0.01 respectively). 
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Figure 59 Descending Aorta Volume Blood Flow per Kilogram in Appropriately Grown 
and Growth Restricted Fetuses Categorised by Disease Onset 
 
Fetuses with either early or late onset IUGR had no significant difference between volume 
blood flow per kg in the descending aorta and the control group. 
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Figure 60 Ascending Aorta Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Onset 
 
Fetuses with early onset IUGR had a significantly increased ascending aorta diameter per 
kilogram than appropriately grown fetuses (p<0.001).  However there was no difference 
between fetuses with late onset IUGR and appropriately grown fetuses (p=0.115) 
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Figure 61 Ascending Aorta Volume Blood Flow per Kilogram in Appropriately Grown 
and Growth Restricted Fetuses Categorised by Disease Onset 
 
Fetuses with early onset IUGR had significantly increased volume blood flow per kilogram in 
the ascending aorta in comparison with appropriately grown control fetuses (p=0.011).  
Fetuses with late onset IUGR had no significant difference in volume blood flow in 
comparison with appropriately grown control fetuses (p=0.729) 
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Figure 62 Internal Carotid Diameter per Kilogram in Appropriately Grown and 
Growth Restricted Fetuses Categorised by Disease Onset 
 
Carotid artery diameter per kg was significantly higher in both early and late onset IUGR 
fetuses in comparison with appropriately grown controls (p<0.001 in both cases). 
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Figure 63 Internal Carotid Artery Volume Blood Flow per Kilogram in Appropriately 
Grown and Growth Restricted Fetuses by Disease Onset 
 
Volume blood flow per kg was significantly higher in the carotid artery in both early and late 
onset IUGR fetuses in comparison with the control group (p<0.001 in both cases). 
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Figure 64 Femoral Artery Diameter per Kilogram in Appropriately Grown and Growth 
Restricted Fetuses Categorised by Disease Onset 
 
Femoral artery diameter per kg was significantly increased in both early and late onset IUGR 
fetuses in comparison with controls (p<0.001). 
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Figure 65 Femoral Artery Volume Blood Flow per Kilogram in Appropriately Grown 
and Growth Restricted Fetuses Categorised by Disease Onset 
 
Femoral artery volume blood flow per kg was significantly higher in early onset IUGR 
fetuses (p<0.001); however there was no difference in volume blood flow per kg between late 
onset IUGR fetuses and control fetuses (p=0.69) 
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3.4.8 Outcome Parameters of Fetuses that Underwent Ultrasound Assessment 
 
Parameter IUGR Appropriately Grown Significance 
Number of Patients 75 124  
Gestation at Delivery 
Range 
Median 
 
21
+2
-40
+2
 
32
+1
 
 
29
+2
-43
+0
 
40
+0
 
 
p<0.001 
Sex of Infant 
Girls 
Boys 
Undetermined 
 
55% 
27% 
18% 
 
54% 
46% 
0% 
 
p=0.253 (ns) 
Birthweight Centile 
Range 
Median 
 
0-9 
2 
 
1-99 
39 
 
p<0.001 
Mode of Delivery 
Spontaneous Vaginal 
Ventouse 
Forceps 
In Labour Caesarean Section 
Non Labour Caesarean Section 
 
26 
1 
1 
5 
41 
 
68 
8 
6 
16 
26 
 
 
 
p<0.001 
Complications in Perinatal Period 
Livebirth 
Intrauterine Death 
Neonatal Death 
Admissions to Neonatal Unit 
 
66 
9 
5 
38 
 
124 
0 
0 
4 
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Intraventricular Haemorrhage 
Sepsis 
Respiratory Distress 
Necrotising Enterocolitis 
Uncomplicated Neonatal Course 
7 
8 
26 
3 
26 
0 
0 
4 
0 
120 
 
p<0.001 
 
Table 8 Outcome Parameters of Appropriately Grown and Growth Restricted Fetuses 
 
Complication Control Pregnancy IUGR Pregnancy 
Pre-eclampsia 8 44 
Gestational Diabetes 4 2 
Placenta Praevia 3 1 
Placental Abruption 1 0 
Uncomplicated 114 30 
 
Table 9 Complications of Appropriately Grown and Growth Restricted Pregnancies 
 
Numbers were too small to statistically assess the outcome of IUGR fetuses with various 
blood flow parameters. 
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3.5 DISCUSSION OF THE ULTRASOUND COMPONENT OF THE STUDY 
 
The initial aims of this study were to investigate, Doppler velocimetry, vessel diameter and 
consequently calculate volume blood flow in three fetal vessels which are commonly 
assessed in clinical practice: the umbilical artery, middle cerebral artery and renal artery (due 
to its association with liquor volume).  This study has demonstrated that the utilisation of 
power Doppler is a feasible reproducible method for acquisition of the PI, PSV, vessel 
diameter and calculation of volume blood flow in these vessels.  Maternal demographics did 
vary between IUGR and appropriately grown pregnancies; however maternal age, BMI or 
ethnicity had no effect on results from any vessel.  The presence of pre-eclampsia also had no 
effect on measurements of vessel diameters or volume blood flow when standardised for fetal 
weight. 
 
3.5.1 Umbilical Artery 
Fetuses with reversed flow in the umbilical artery were excluded from this analysis due to the 
fact that the PI and mean velocity would not be possible to calculate accurately. 
 
A decrease in the umbilical artery PI in the control group was observed as gestation 
progressed which is consistent with previous published data.  IUGR fetuses had a 
significantly increased pulsatility index in comparison with appropriately grown fetuses.  
This is unsurprising as IUGR in this study was defined as an estimated fetal weight below the 
10
th
 centile accompanied by abnormal Doppler velocimetry in the umbilical artery.   
 
In appropriately grown control fetuses the PSV increased with increasing gestational age.  
This is accordance with previously published data[219].  The PSV was significantly reduced 
in IUGR fetuses overall.  However, on subgroup analysis, based on disease severity, this was 
only significant for IUGR fetuses with absent end diastolic flow in the umbilical artery.  
When analysed according to late or early onset IUGR, fetuses with late onset IUGR had a 
significantly reduced PSV; however, those with early onset disease did not. 
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These findings in Doppler velocimetry are likely to be reflective of the fact that in normal 
pregnancies the fetoplacental vasculature expands throughout pregnancy and the appearance 
of sinusoidal dilatation in terminal villous capillaries towards term, resulting in more than 
50% of the stromal volume being vascularised.  However, these vascular changes may be 
compromised in IUGR resulting in higher resistance in the umbilical artery (see Chapter 1). 
 
Umbilical artery diameter increased with increasing gestational age between 16
+1
 and 39
+6
 
weeks gestation, in accordance with a previously published study assessing fetuses between 
18 and 40 weeks gestation[219].  When standardised for fetal weight, the umbilical diameter 
per kg decreased with increasing gestational age.  The absolute diameter of the umbilical 
artery was unchanged between IUGR and appropriately grown control fetuses.  However, on 
subgroup analysis IUGR fetuses with absent end diastolic flow had a significantly increased 
umbilical artery diameter in comparison with the control group.  When standardised for fetal 
weight all severity subgroups of IUGR (increased pulsatility index in the umbilical artery, 
increased PI in the umbilical artery and cerebral redistribution and absent end diastolic flow 
in the umbilical artery) had an increased vessel diameter per kg in comparison with 
appropriately grown control fetuses.  When classified into late and early onset IUGR, all 
IUGR fetuses also had a significantly increased umbilical diameter per kg.  There did not 
appear to be any correlation between umbilical diameter per kg and outcome in IUGR 
fetuses, although numbers in each outcome group were are too small at present to analyse 
statistically. 
 
In appropriately grown fetuses umbilical artery volume blood flow increased with increasing 
gestational age between 16
+1
 and 39
+6
 weeks gestation.  This finding and the absolute volume 
blood flow measurements are in agreement with the normative data previously published by 
Goldkrand et al from a group of 252 appropriately grown fetuses between 18 and 40 weeks 
gestation[219].  When standardised for fetal weight, umbilical artery volume blood flow 
decreased with increasing gestation, a finding again supported by previous published 
data[219].  Overall there was no difference in volume blood flow between appropriately 
grown and growth restricted fetuses in all subgroups apart from those with AEDF which had 
a significant reduction in volume blood flow.  When standardised for fetal weight, volume 
blood flow was significantly increased in IUGR fetuses.  On subgroup analysis this was the 
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case for all subgroups of IUGR.  However, when IUGR fetuses were categorised according to 
late or early onset disease, late onset IUGR fetuses did not have significantly altered blood 
flow/kg compared with the control population whereas early onset IUGR fetuses had 
increased volume flow/kg.  Numbers at present were too small for statistical analysis 
however there did not appear to be any correlation between umbilical volume blood flow per 
kg and outcome in IUGR fetuses. 
 
Due to the fact that the peak systolic velocity was either unchanged or reduced in IUGR 
fetuses, the increase in systolic volume blood flow observed in growth restricted fetuses was 
predominantly mediated by the increase in vessel diameter.  This may be due to altered vessel 
composition.  Previous studies have demonstrated that the umbilical artery in IUGR is thinner 
and stiffer than in appropriately grown control fetuses with fewer elastic fibres[220] and 
increased mRNA of collagen I and III[221].  Alternatively an increase in vasodilatory 
substances or a reduction in circulating vasoconstricting factors may be responsible (this is 
discussed in more detail below).  
 
Differences in findings between early and late onset disease may be due to the fact that the 
pathophysiology of late and early onset IUGR are different; none of the late onset IUGR 
fetuses had absent or reversed end diastolic flow in the umbilical artery.  Early onset IUGR is 
associated with abnormal development of the villous tree which can result from a severe 
reduction in uterine blood flow.  A reduction in non branching angiogenesis and decreased 
placental vascularisation results in a reduction in villi number with poor capillary formation.  
Peripheral villi which contain slender unbranched and uncoiled capillary loops have also been 
reported.  This results in a reduction in surface area available for maternal-fetal nutrient 
transport[17].  Late onset IUGR demonstrates increased branching angiogenesis secondary to 
deficient remodelling of the spiral arteries.  Uteroplacental hypoxia is thought to be due to 
increased expression of factors which stimulate branching angiogenesis[17].  IUGR in late 
pregnancy is also associated with increased maturation of the placenta (Grannum grade 2 or 
3) and a 40% increase in capillary fraction volume[31].   
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However differences in volume flow between early and late onset IUGR may also be due to 
inconsistencies in flow velocity waveforms between appropriately grown and late onset 
IUGR fetuses, where end diastolic flow is always present and early onset IUGR, where end 
diastolic flow is often absent.  In this study volume blood flow was calculated using systolic 
flow only; the formula derives mean flow by halving peak systolic velocity.  However, 
diastolic velocities differ significantly between IUGR and control fetuses and IUGR fetuses 
with late and early onset disease.  76 of the 178 scans obtained from IUGR fetuses had absent 
flow in diastole.  In fetuses with positive end diastolic flow the PI was significantly higher in 
IUGR fetuses than in appropriately grown controls indicating a larger difference between 
systolic and diastolic flow velocities.  Although this was also the case for the late onset IUGR 
fetuses, it may be attributable to the fact that there were no fetuses with absent end diastolic 
flow in this subgroup to significantly produce a difference between late onset IUGR fetuses 
and appropriately grown controls.  Therefore, it is still possible that IUGR fetuses have lower 
blood flow than the control group. 
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3.5.2 Middle Cerebral Artery 
In this study, results from the PI in the middle cerebral artery in appropriately grown control 
fetuses were consistent with those from previously published studies[100, 222].  Konje et al 
also utilised power Doppler in order to insonate the vessel accurately to obtain the MCA 
waveform[222].  The PI increased between 24 and 32 weeks then decreased again.  
Subsequent to 32 weeks a low PI was physiologically present in appropriately grown fetuses.  
This is again in accordance with previously published data[17].  Only one fetus in this study 
showed evidence of the loss of the brain sparing effect (a previously documented low MCA 
PI which then returned to the normal range).  This fetus was delivered but subsequently died 
in the neonatal period. 
 
The MCA PSV measurements from appropriately grown control fetuses were comparable 
with those from previously published studies[100].  The MCA PSV increased between 16
+1
 
and 39
+6
 weeks gestation.  The MCA PSV was significantly increased in IUGR fetuses with 
evidence of cerebral redistribution absent or reversed end diastolic flow in the umbilical 
artery or venous changes.  This is in accordance with previously published studies and is 
likely to represent elevated left cardiac output and increased placental vascular 
resistance[223].  When IUGR fetuses were categorised into late onset and early onset disease, 
early onset IUGR fetuses had a significantly higher middle cerebral artery PSV than the 
control group; however, late onset IUGR fetuses did not.  This may reflect that brain sparing 
is not occurring in these fetuses, and the brain is not receiving an increased proportion of 
cardiac output.   
 
The middle cerebral artery diameter increased with gestation in appropriately grown fetuses 
between 16
+1
 and 39
+6
 weeks gestation and remained constant when standardised for fetal 
weight.  Konje et al who assessed 81 appropriately grown fetuses between 24 and 38 weeks 
gestation found that the middle cerebral artery diameter ranged from 2.7+/-0.7mm at 24 
weeks gestation to 4.6 +/-1.0mm at 38 weeks gestation[218], findings consistent with this 
study.  Overall IUGR fetuses had a significantly increased diameter in the middle cerebral 
artery.  When subgroup analysis, based on disease severity in IUGR fetuses, was performed 
all subgroups other than a raised pulsatility index in the umbilical artery had a significantly 
increased diameter compared with appropriately grown fetuses.  However, when standardised 
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for fetal weight, all subgroups of IUGR fetuses based on disease severity had an increased 
middle cerebral artery diameter per kg.  When classified into early and late onset disease 
there was no difference in the middle cerebral artery diameter per kg between late onset 
IUGR fetuses and control fetuses.  There was, in contrast, an increased diameter per kg 
between early onset IUGR fetuses and the control group.  Numbers at present were too small 
for statistical analysis, although there did not appear to be any correlation between middle 
cerebral artery diameter per kg and outcome in IUGR fetuses. 
 
In appropriately grown control fetuses the middle cerebral artery volume blood flow 
increased with increasing gestation between 16
+1
 and 39
+6
 weeks gestation.  These findings 
are again consistent with results published by Konje et al who reported that at 24 weeks the 
mean flow volume in the middle cerebral artery was 39+/-19 cc/min and at 38 weeks was 
140+/-63.9 cc/min.  When standardised for fetal weight there was no alteration in volume 
blood flow per kilogram with increasing gestation.  Overall IUGR fetuses had significantly 
increased blood flow in the middle cerebral artery in comparison with appropriately grown 
control fetuses.  On subgroup analysis this proved to be significant for all subgroups of IUGR 
fetuses based on disease severity, even those with a normal MCA PI.  This was also the case 
when the middle cerebral artery blood flow was standardised per kilogram.  When IUGR 
fetuses were classified based on early or late onset disease only late onset fetuses had 
increased volume blood flow per kg in comparison with appropriately grown control fetuses.  
Numbers at present were too small for statistical analysis although there did not appear to be 
any correlation between middle cerebral artery volume blood flow per kg and outcome in 
IUGR fetuses. 
 
This study has therefore demonstrated that in accordance with the ‘brain sparing’ theory 
cerebral blood flow is increased in IUGR fetuses.  As in the case of the umbilical artery some 
differences did occur in the middle cerebral artery waveform between IUGR and 
appropriately grown fetuses: IUGR fetuses often had a higher end diastolic flow than control 
fetuses (reflected by a reduced PI).  Volume blood flow in this study has been calculated 
using the mean systolic velocity only.  However, if anything this error would under-estimate 
total volume blood flow in IUGR fetuses. 
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This increase in cerebral blood flow is mediated by both an increase in PSV and increased 
vessel diameter.  Increased vessel diameter is likely to precede a fall in the PSV due to the 
fact that fetuses in this study with a normal MCA PI did not have a significantly reduced 
PSV, but vessel diameter was significantly increased.  IUGR fetuses that would not 
traditionally be classified as having ‘brain sparing’ i.e. those with only an increased PI in the 
umbilical artery did still have increased cerebral blood flow in comparison with appropriately 
grown control fetuses.  Fetuses with late onset IUGR did not have a significantly increased 
MCA diameter per kg, and the PSV was not different from control fetuses.  Consequently, 
fetuses with late onset IUGR did not appear to experience increased cerebral blood flow.  It 
must be noted that only 23 scans were obtained from fetuses with late onset IUGR, in 
comparison with 124 from fetuses with early onset IUGR.   
 
It has previously been reported that IUGR fetuses delivered after 33 weeks gestation have an 
increased risk of cerebral palsy [196-197].  The association between IUGR and cerebral palsy 
is less clear in IUGR fetuses delivered before 33 weeks[3].  This finding may be attributable 
to the fact that there seems to be a lack of brain sparing in late onset IUGR fetuses.  These 
findings may indicate that the pathophysiology of early onset IUGR is different from that of 
late onset IUGR.  For example, vessel wall composition may be altered in early onset but not 
late onset IUGR fetuses or an alteration in the balance of vasoactive factors may occur 
between early and late onset disease.  These are discussed in further detail below. 
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3.5.3 Renal Artery 
From this study it has been demonstrated that the renal artery PI, when the vessel is identified 
and insonated using power Doppler, did not alter significantly during gestation in 
appropriately grown control fetuses between 16
+1
 and 39
+6
 weeks gestation.  The renal artery 
PI ranged from 0.98 to 2.7 with a median of 1.93 and a mean of 1.93.  These findings are 
comparable to those obtained by Konje et al in a previous study establishing normal ranges of 
the PI in multiple fetal vessels using power Doppler, where the renal PI ranged from 1 to 3.8 
with a mean of 2.0[222].  Silver et al identified and insonated the renal artery using colour 
Doppler but also found that the mean PI was 1.99 with a range of 1.57-2.11.  No statistical 
difference was found between the PI in the renal artery in appropriately grown fetuses in 
comparison with IUGR fetuses.  Although results of previous studies have been conflicting 
with regards to changes in the renal artery PI in IUGR fetuses; this finding is in accordance 
with papers published by other groups[138-139].  Vyas et al did find a significant increase in 
the renal artery PI in IUGR fetuses between 17 and 43 weeks from assessment of 18 
examinations from IUGR fetuses[112].  However, this study included 154 scans from IUGR 
fetuses.  Other studies have found an association between an increased renal artery PI only in 
growth restricted fetuses with oligohydramnios[224].  In this study only 7 IUGR fetal scans 
showed evidence of oligohydramnios.  Therefore, numbers were too small at the time to see 
if any relationship between AFI and renal artery PI occurred.   
 
It has been demonstrated that the peak systolic velocity increases with increasing gestation in 
appropriately grown control fetuses p<0.001.  Little change in the PSV with increasing 
gestation was found by Joern et al in fetuses between 28 and 42 weeks gestation[225].  This 
study analysed fetuses between 16
+1
 and 39
+6, 
and, this discrepancy in gestational age of 
fetuses assessed may be responsible for the differing results.  No other studies have reported 
how the PSV alters with gestation in appropriately grown fetuses.  The increase in PSV found 
in this study may be indicative of an increase in the percentage of cardiac output directed 
towards the kidney.  IUGR fetuses with absent end diastolic flow in the umbilical artery had 
significantly lower PSV than appropriately grown control fetuses.  This was not the case for 
IUGR fetuses with increased pulsatility index in the umbilical artery or increased pulsatility 
index in the umbilical artery and evidence of cerebral redistribution.  This finding is in 
accordance with that of Stigter et al who reported that in 16 severely growth restricted fetuses 
that the PSV decreased with time and this correlated with venous cord pH at delivery[138].   
180 
 
 
In the appropriately grown control fetuses the renal artery diameter increased with increasing 
gestational age.  When standardised for fetal weight, the renal artery diameter per kg 
decreased with increasing gestation.  Konje et al assessed the renal artery diameter 
longitudinally in 81 appropriately grown fetuses finding that it ranged from 2.4mm +/-0.7 at 
24 weeks gestation to 4.1mm+/-1.4 at 38 weeks gestation.  These findings are comparable to 
results from this study.  IUGR fetuses had a significant increase in both the renal artery 
diameter and renal artery diameter per kg in comparison with appropriately grown control 
fetuses; this remained the case for all severity subgroups of IUGR.  Both early and late onset 
IUGR also had significantly increased renal artery diameter per kg in comparison with 
appropriately grown fetuses.  No previous studies have compared vessel diameter in the renal 
artery of appropriately grown control fetuses in comparison with IUGR fetuses.  Numbers at 
the time were too small for statistical analysis, although, there did not appear to be any 
correlation between renal artery diameter per kg and outcome in IUGR fetuses. 
 
Renal artery volume blood flow increased with increasing gestational age in appropriately 
grown control fetuses.  This finding is comparable with results from Konje et al who 
longitudinally assessed 81 appropriately grown fetuses, finding the renal artery volume blood 
flow ranged from 27.5 +/-16.8 cc/min at 24 weeks gestation to 76.5 +/-46.8 cc/min at 38 
weeks gestation[218].  Konje et al also reported that when flow was adjusted to estimated 
fetal weight there was an initial fall in renal blood flow to 30 weeks, after which point 
volume flow per kg increased[218].  Renal artery volume blood flow was significantly higher 
in IUGR fetuses in comparison with control fetuses.  This remained significant for all 
severity subgroups of IUGR and when the volume blood flow was standardised per kg of 
fetal weight.  When categorised into early and late onset IUGR, both late and early onset 
growth restricted fetus had significantly increased renal artery volume blood flow per kg in 
comparison with appropriately grown fetuses.  Only 7 scans were obtained from IUGR 
fetuses with reduced liquor volume so it was not possible to assess how this impacted on 
volume blood flow.  In all fetuses with normal liquor there did not appear to be any 
correlation between renal artery volume flow and the AFI.  Numbers at the time were too 
small for statistical analysis, although, there did not appear to be any correlation between 
renal artery volume blood flow per kg and outcome in IUGR fetuses. 
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The ‘brain sparing’ phenomenon has often been reported to be associated with a reduction in 
blood flow to ‘non essential’ organs: such as, the gut, kidneys and the lower extremities in 
IUGR fetuses.  However, much of these hypotheses were based on animal models of acute 
hypoxaemia (see Chapter 1).  However, when analysed in detail some of these studies have 
even indicated that in acute hypoxia renal flow may actually be preserved or transiently 
increased during the transition between high to moderately low levels of arterial oxygen 
content[107-108]. 
 
Previous studies comparing renal blood flow in human IUGR fetuses have not calculated 
absolute volume blood flow but instead assessed Doppler velocimetry which is only an 
indirect assessment of flow impedance.  Some of these studies have indicated no difference in 
renal artery PI between growth restricted and appropriately grown fetuses, or, an increase in 
renal PI only in cases of oligohydramnios[137, 139].  The results of this study actually 
indicated an increase in renal volume blood flow in IUGR fetuses.  This is most likely to be 
mediated by an increase in vessel diameter as the PSV is reduced with increased severity of 
IUGR. 
 
In a piglet model of IUGR, in neonatal piglets, reduction in renal blood flow during 
normocapnic hypoxemia is less pronounced than in controls which may indicate a capacity to 
withstand periods of disturbed oxygenation[226] and it is possible that compensatory 
mechanisms are also active in utero in IUGR fetuses.  Structural changes in the kidney are 
well reported in IUGR with a reduction in renal volume and nephron number[227].  These 
alterations have also been implicated in the link between being growth restricted in utero and 
cardiovascular disease in later life.  The renin angiotensin system is known to undergo 
abnormal maturation in the fetal kidney.  Renin is a vasoconstrictor secreted by the kidney 
which also activates the renin-angiotensin aldosterone system, resulting in further 
vasoconstriction.  Low plasma renin activity [228] and reduced levels of renal renin protein 
and mRNA have been reported in newborn IUGR rats[229].  Studies in human fetuses have 
reported an increase in plasma renin levels in umbilical cord blood, although, these studies 
are limited in number of IUGR fetuses assessed (between 3 and 15) and definitions of IUGR 
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are primarily statistical: an estimated fetal weight less than the 10
th
 centile [230-232].  
However, human studies have reported a reduction in umbilical artery levels of Angiotensin 
II, a potent vasoconstrictor, at delivery.  Angiotensin II is formed following angiotensinogen 
cleavage by renin, generating angiotensin I which is then converted to angiotensin II[232].  
The fact that the same study reported an increase in renin yet a decrease in angiotensin II 
indicates that the RAS is abnormal in IUGR fetuses.  Alterations may also occur in receptors 
at a tissue level for these substances.   
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3.5.4 Additional Vessels Assessed 
Due to interim analysis of the data from the umbilical, renal and middle cerebral arteries, it 
became apparent the vessel diameter of the umbilical and renal arteries was significantly 
higher when standardised for fetal weight in the IUGR fetuses than in the appropriately 
grown control group.  It was also found that distinct differences were noted in IUGR fetuses 
with early and late onset disease.  Due to these findings, further vessels were analysed to 
explore the redistribution phenomenon and vessel diameter in more detail, as well as to assess 
differences between early and late onset IUGR.  Additional vessels assessed included: the 
ascending and descending aortas, the internal carotid and femoral arteries. 
 
In accordance with previously reported velocimetry studies and in accordance with ‘brain 
sparing phenomenon’ the PI of the descending aorta in IUGR fetuses was significantly higher 
than the control group and the PI of the internal carotid artery was lower in IUGR fetuses 
than in appropriately grown fetuses[126].  This study also demonstrated a reduction in the PI 
of the ascending aorta, in accordance with increased flow.  The femoral artery appeared to 
have a lower PI in the IUGR fetuses than in the control group which is in contrast to a 
previous study by Yoon et al which reported an increase in the femoral PI of growth 
restricted fetuses[140].  This difference may be due to the fact that the femoral arteries are 
small and consequently hard to consistently identify and insonate and it proved hard to keep 
the angle below 60 degrees. 
 
Findings of an increased volume blood flow in the ascending aorta and internal carotid artery 
when standardised for fetal weight again support the ‘brain sparing’ hypothesis whereby 
blood is preferentially diverted from ‘non essential’ organs in order to supply the developing 
brain.  Although absolute blood flow was decreased in the descending aorta in IUGR fetuses, 
in contrast to previous assumptions of the ‘brain sparing effect; no significant difference 
between blood flow in the descending aorta was noted between appropriately grown fetuses 
and growth restricted fetuses when standardised for fetal weight.  This was the case for all 
severity subgroups and there was also no significant difference between IUGR fetuses with 
early or late onset disease and the control group (although the numbers of fetuses with late 
onset IUGR were small n = 11).  These findings are in contrast to those of Gardiner et al who 
reported a significant decrease in volume blood flow in 11 IUGR fetuses in comparison with 
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20 controls.  These differences may be due to the fact that a smaller number of IUGR fetuses 
were assessed in the Gardiner study.  However, they did assess blood flow velocity and 
vessel diameter simultaneously using a phase locked echo-tracking system and their angle of 
insonation was kept lower than in this study thereby improving accuracy of flow velocity 
measurements (see limitations section page 187). 
 
In this study the femoral artery appeared to have significantly increased blood flow when 
standardised for fetal weight in IUGR fetuses in comparison with the control group.  This 
increased flow was only significant for fetuses with early onset disease and there was no 
significant difference between late onset IUGR fetuses and control fetuses (although there 
were fewer numbers of late onset IUGR fetuses).  Although it is possible that the femoral 
artery vasodilates in IUGR fetuses, in an attempt to maintain tissue perfusion by the 
mechanisms described above, it is also possible that technical errors may have accounted for 
these unexpected results, the inter-observer correlation co-efficient showed that there was 
poor agreement between two assessors (although the intra-observer correlation was 
acceptable and all measurements were taken by one assessor).  The femoral artery is very 
small in diameter and consequently hard to identify and measure and is very dependent on 
fetal position.  The results of this study were not in accordance with previously published 
data regarding the velocimetry of the femoral artery and it is, therefore, possible that 
identification/measurement errors occurred[126].  The formula for calculation of volume 
blood flow squares the diameter, thereby compounding any measurement errors.  These 
changes in volume blood flow are most likely to be mediated by an increase in vessel 
diameter.  It was also demonstrated that the femoral artery appeared to have significantly 
different volume blood during a single examination which may again affect the significance 
of the results obtained. 
 
The descending aorta, ascending aorta, internal carotid and femoral arteries all had a 
significantly higher vessel diameter when standardised for fetal weight in IUGR fetuses than 
in the control group.  No other study has comprehensively assessed vessel diameters in 
multiple sections of the vascular tree.  However, Mori et al assessed fetal haemodynamic 
changes in fetuses during development using arterial pressure pulse and blood flow velocity 
waveforms.  As part of this study they found that there was an increase in the diastolic 
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diameter of the descending aorta when standardised for weight in 25 fetuses with IUGR[233].  
Gardiner et al also found that growth restricted fetuses had an increased maximum, minimum 
and mean diameter in comparison to appropriately grown fetuses in the descending aorta 
when standardised for fetal weight[136]. 
 
This increased vessel diameter may be secondary to defective elastin deposition.  It has 
already been proposed that IUGR is associated with long term abnormal vascular morphology 
and function.  There is significant evidence to suggest that adults who were IUGR in utero 
have higher blood pressure in later life[227].   The aorta and carotid arteries have elastin as a 
major component: elastin accounting for 50% of the dry weight of the thoracic aorta.  Aortic 
elastin is arranged in concentric lamellae, interspersed with smooth muscle and collagen.  Its 
synthesis begins in early fetal life and continues into the perinatal period.  Fetal arterial 
structure has been shown to adapt to abnormal pressures and flow.  In pregnancies where 
there is only one umbilical artery, the entire placental blood flow passes through the common 
iliac on one side only.  In a post-mortem study of 8 children with a single umbilical artery in 
utero, the iliac vessel on the side of the umbilical artery was found  to be rich in elastin 
whereas the contralateral artery was small in diameter and thin walled[234].  Renal artery 
structure has also been found to be aberrant in IUGR fetuses both in terms of elastin 
composition and collagen. 
 
Serum levels of Insulin Like Growth Factor (IGF) 1 have been found to be lower in IUGR in 
comparison with AGA infants when assayed in umbilical cord blood at delivery.  
Mechanisms leading to impaired elastogenesis in IUGR are unclear, although, experiments in 
chicks and rats have shown a relationship between IGF-1 and aortic elastogenesis [235], 
[236].  Administration of IGF-1 also increases aortic elastin synthesis in animal models[237].  
It is, therefore, possible that the increase in vessel diameter of IUGR fetuses may be 
secondary to aberrant vessel wall development and diameters are larger as elastin is not 
present in sufficient quantities to provide recoil of the vessel wall. 
 
The balance of circulating vasoactive factors in the feto-placental unit may also affect vessel 
diameter in IUGR fetuses.  A number of vasodilatory factors including vasoactive intestinal 
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polypeptide (VIP)[238] adrenomedullin[239] and nitric oxide breakdown products[240] have 
all been shown to be increased in the umbilical cord blood of IUGR pregnancies.  A 
reduction in some vasoconstrictor substances, such as angiotensin II, has been demonstrated 
in IUGR cord blood [232] and although other vasoconstrictor substances have been reported 
to be increased in the umbilical artery of IUGR fetuses, such as endothelin I[241], reduced 
contractile effects on tissue have been reported.  Bodelsson et al assessed sections of the 
umbilical cord in IUGR and appropriately grown fetuses to noradrenaline and endothelin I 
finding a reduction in contractile effects[241].  This may be reflective of altered receptor 
expression which may also be occurring in other tissue types within the fetus. 
 
Although central catecholaminergic pathways are unchanged in the brains of IUGR sheep 
fetuses, peripheral pathways are thought to be affected: norepinephrine levels in brown fat, a 
normally densely innervated peripheral tissue, are reduced despite no alteration in either 
alpha1 or beta adrenergic receptor numbers or affinity states[242].  It is, therefore, possible 
that a decrease in adrenergic innervations of blood vessel walls may reduce vasoconstriction. 
 
Consequently vessel diameter, and in association volume blood flow abnormalities, may be 
mediated by a combination of altered vessel wall composition and innervation and an 
alteration in the balance between vasodilatory and vasoconstrictor substances. 
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3.6 Limitations of Ultrasound Component of the Study 
 
As mentioned above this study does have a number of limitations.  Although attempts were 
made to eliminate observer variability, as all scans were analysed by one assessor, intra-
observer variability did occur.  This was more pronounced for smaller vessels such as the 
carotid artery and femoral artery.  These vessels were more difficult to identify and to 
accurately measure vessel diameters.  These results indicate that there is sufficient 
consistency in results for all vessels when measurements are taken at different time points, 
with the exception of the femoral artery.  The femoral artery is a small vessel which is hard to 
identify, as well as the fact that the angle of insonation may alter considerably depending on 
the position of the leg which may also add to this error.  However, even where the correlation 
co-efficient is acceptable, volume blood flow in the umbilical artery and renal arteries varies 
with a mean of 18.7% and 20% respectively which is a large error. 
 
Previous studies when assessing found comparable correlation co-efficients for intra observer 
variability to those found in this study.  Konje et all found 5-6% error when assessing 
diameters of the MCA, 4-7% when assessing the ascending and descending aorta and 7-12% 
when assessing the renal artery[222].  Goldrand also found at 6.2% error when assessing the 
intraobserver variability of the umbilical artery[219]. 
 
Although power Doppler was used to assess vessel diameter measurement are squared when 
volume blood flow is calculated which would also square any measurement error.  Mean 
volume blood flow is also calculated by halving peak systolic velocity and does not take into 
account varying diastolic flow that may occur both during gestation and between IUGR and 
appropriately grown fetuses.  An error of 4mm in calculation of vessel diameter has 
previously been reported to result in a 25% difference in volume blood flow[136].  The cross 
section of the vessel is also assumed to be round although vessels such as the descending fetal 
aorta tend to be flattened in an antero-posterior direction which may also affect accuracy of 
volume flow calculation. 
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Concerns have also been raised regarding the timing of the measurements in relation to the 
cardiac cycle (i.e. if taken during systole or diastole) on the vessel diameter, a 10% difference 
in diameter may affect the estimated volume flow by as much as 25%[211].  However, Konje 
et al obtained values from normal pregnancies[212] from the uterine arteries and found these 
results to be similar to those obtained by electromagnetic flowmetry at hysterotomy[146].  
Therefore, if measurements are consistently made during systole, the influence of the cardiac 
cycle on measurements obtained is likely to be minimal[148].  Attempts were also taken to 
minimise error by taking the average of a number of cardiac cycles. 
 
A number of groups used mean velocity for the calculation of volume blood flow[136].  
Although unquestionably more accurate, the availability of this measurement is limited by the 
ultrasound equipment used.  This study half of the PSV to calculate volume blood flow.  
However this technique has previously been utilised by other groups previously[219].  The 
PSV (and consequently volume blood flow) is sensitive to angle correction and although 
power Doppler attempted to improve insonation, errors still occur due to limited resolution of 
the image and possible inaccuracies in alignment of curved vessels such as the umbilical 
artery.  The angle of insonation was kept as low as possible and this was easily achievable for 
the umbilical, MCA and renal arteries, although, the ascending and descending aorta, carotid 
and femoral arteries proved harder to insonate and at an angle of 60 degrees: the percentage 
velocity error for a 5 degree angle error is 15%[243].  No literature to date has examined the 
effects of insonation of vessels with regards to the timing within the cardiac cycle. 
 
Vessel insonation may also theoretically be affected by standing wave formation.  This is 
formed when two waves with the same frequency travelling in opposite directions collide 
resulting in oscillation witout transmission of energy.  Theoretically this could alter vessel 
insonation, however, the probability of a reflected and a projected wave having identifical 
frequencies is low and therefore this is unlikely to be of pratical importance. 
 
The measurement of peak velocity and vessel diameter can be measured simultaneously with 
real-time ultrasound phase locked systems.  However, this is dependent on the machine and 
software being used.  Studies have also shown that error from non simultaneous measurement 
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of velocity and vessel diameter is less than 8% and therefore of unlikely practical 
significance[210]. 
 
The method of volume blood flow calculation used in this study has also been validated in a 
sheep model by Acharya et al[51].  This group assessed volume blood flow in 5 pregnant 
sheep using a 6mm transit time ultrasonic perivascular probe flow to provide a direct 
assessment of volume blood flow.  They simultaneously performed Doppler ultrasonography 
of the uterine artery, assessing vessel diameter with power Doppler and mean velocity which 
facilitated calculation of volume blood flow (see page 91).  They found a significant 
correlation between direct and ultrasound assessment of volume blood flow[51]. 
 
It must also be taken into account that power calculations were conducted for overall 
diagnosis of IUGR.  Certain subgroups of IUGR may behave differently, i.e. late or early 
onset disease or fetuses with absent end diastolic flow and where results are not significant 
for subgroup analysis it may have been reflective of insufficient sample size. 
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Chapter 4: Techniques Used in the Thesis: Magnetic Resonance Imaging and 
Spectroscopy  
 
4.1 Magnetic Resonance Imaging 
 
Magnetic Resonance Imaging (MRI) is a non-invasive imaging technique which has been 
increasingly utilised for assessing the fetus over the last 15 years, partly due to its excellent 
safety profile[23, 244-245], good soft tissue contrast and anatomical delineation, and its 
ability to provide additional information to obstetric ultrasound[246].  MRI is particularly 
useful in assessing the fetal brain and provides more accurate cerebral biometry, superior 
visualisation of the posterior fossa, assessment of sulcal formation[247-248] and white matter 
detail associated with cell migration.   
 
4.1.1 Physics of Magnetic Resonance Imaging 
4.1.1.1 Atomic Structure 
All substances are composed of atoms, including body tissue.  Atoms comprise of a central 
nucleus, containing neutrons and protons, which is surrounded by orbiting electrons.  Protons 
have a positive electrical charge, neutrons have no charge and electrons are negatively 
charged. 
 
4.1.1.1.1 Spin 
In most nuclei, the number of protons is equal to the number of neutrons (the mass number).  
In this situation, half the protons and neutrons spin in one direction, half in the other and 
overall the nucleus has no net spin.   
 
Nuclei that have an odd mass number are known as isotopes.  Spin directions are not 
distributed equally and the nucleus therefore has a net spin, known as angular momentum and 
these nuclei are MRI active.  Examples of MR active nuclei include hydrogen 1, carbon 13, 
oxygen 17 and phosphorous 31.  The hydrogen nucleus is used in clinical MRI due to its 
abundance in human tissue and the fact that it has a relatively large magnetic moment. 
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MR active nuclei possess an electrical charge and spin which enables them to behave like 
small magnets.  This is in accordance with the laws of electromagnetic induction which state 
that if two of the three forces, motion, magnetism and charge, are present then the third is 
automatically induced.   Consequently nuclei acquire a magnetic moment and can align with 
an external magnetic field. 
 
4.1.1.1.2 Precession 
Each nucleus is spinning on a given axis.  By adding an external constant magnetic field (B0), 
an additional spin/wobble is generated about the access of B0, similar to that of a gyroscope 
in the earth’s gravitational field.  This is termed precession and the frequency of precession is 
directly proportional to the strength of the magnetic field.  It is defined by the Larmor 
equation: 
 
Where: 
 = magnetogyric ratio (42.56 MHz/Tesla for 
hydrogen) 
B0 = magnetic field strength 
 
Equation 12 Larmor Frequency 
 
B0 is the magnetic field applied from the magnet to the patient.  When this external magnetic 
field is applied the nuclei interact with the magnetic field and distribute themselves to 
different energy levels.  
 
4.1.1.2 The Zeeman Effect 
When there is no external magnetic field the magnetic moments of the nuclei are randomly 
orientated.  However, when an external magnetic field B0 is present alignment occurs with 
the magnetic field.  Some of the nuclei align with the field and some align against it 
cancelling each other out.  Nuclei which align their magnetic moments parallel to the external 
field are in a low energy state and are termed spin up nuclei whereas those that are in anti-
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parallel alignment are in a higher energy state and are termed spin down.  This is known as 
the Zeeman effect. 
 
 
Figure 66 Energy Transfer of Nuclei during Excitation 
 
Nuclei are constantly oscillating between these two states but at any given time there is a net 
alignment with the external magnetic field as this is the lower energy state.  This excess in 
alignment with the field is known as the net magnetization vector or M0.  The larger the 
external magnetic field, the more nuclei are in alignment at any given time. 
 
4.1.1.3 Excitation with a Radio Frequency Field 
If an electromagnetic radio frequency pulse is applied at an oscillating perturbation (Larmor 
frequency) close to its own natural frequency of oscillation, the nucleus is able to absorb the 
energy and resonate.  If the external pulse is at a different frequency to the Larmor frequency 
of the nucleus this phenomenon does not occur.  The addition of this radio frequency which 
causes resonance is termed excitation.   
 
Excitation facilitates an increase in the number of nuclei in the high energy state.  The 
difference between the two energy states is the energy required to produce resonance via 
excitation. 
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The result of resonance is that the net magnetization vector moves out of alignment from B0 
due to the fact that excitation facilitates an increase in the number of nuclei in the high energy 
state.  The angle to which this occurs is known as the flip angle and its amplitude is 
dependent on the amplitude of the radio frequency pulse - it is normally 90
o
.  Resonance also 
causes the magnetic moments of the nuclei to move into phase with each other. 
 
4.1.1.4 Signal Detection 
Due to resonance, in phase magnetization precesses at the Larmor frequency in the transverse 
plane.  The magnetic resonance signal is a result of this in phase magnetisation inducing a 
voltage in a closely located receiver coil. 
 
When the radiofrequency pulse ceases, the hydrogen nuclei lose their energy from the 
radiofrequency pulse, i.e. relax.  The net magnetization vector again realigns with B0 as some 
of the high energy nuclei return to their lower energy state, with magnetic moments aligned 
in the spin up direction. 
 
The amount of magnetization in the longitudinal plane gradually increases; this is called 
recovery.  Simultaneously the amount of magnetization in the transverse plane decreases 
which is known as decay.  As the magnitude of transverse magnetization decreases so does 
the magnitude of the voltage induced in the coil.  The induction of reduced signal is known as 
the free induction decay (FID) signal.  
 
The recovery of longitudinal magnetization is known as T1 recovery and is attributable to 
nuclei giving their energy to the surrounding environment (spin lattice relaxation).  The time 
course over which this happens is described by an exponential curve.  T2 decay is due to 
nuclei exchanging energy with neighbouring nuclei and is due to the interaction of their 
magnetic fields.  It is known as spin-spin relaxation.  This signal decay due to transverse 
relaxation is denoted by an exponential curve. 
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4.1.1.5 Pulse Timing Parameters 
Pulse sequences can be used to describe the radiofrequency pulses: indicating frequency and 
repetition.  The time between each pulse is known as the repetition time (TR), and determines 
the amount of T1 relaxation that is able to occur.  The echo time (TE) is the time from the 
application of the pulse to the peak of the signal induced in the coil.  It is a measure of how 
much decay of transverse magnetization is allowed to occur.  It consequently controls the 
amount of T2 relaxation. 
 
4.1.2 MRI Sequences Used During this Study 
During the course of this study, the fetal brain was assessed for any structural abnormalities 
and the location of the region of interest to be examined using 
1
HMRS (see page 195) was 
determined using T2 weighted single shot fast spin echo (ssFSE) sequences in the axial, 
coronal and sagital planes obtained on a 1.5 Tesla (T) MRI scanning system.  Single shot 
sequences were used due to the fact that each acquisition was obtained in less than one 
second enabling optimal images in the presence of fetal motion. 
 
T2 weighted images are produced as the T2 time of fat is shorter than that of water so the 
transverse component of magnetization of fat decays faster.  The magnitude of transverse 
magnetization in water is large.  Water, therefore, has a high signal and appears bright on a 
T2 contrast image.  The magnitude of transverse magnetization in fat is small; fat therefore 
has a low signal and appears dark on a T2 weighted image. 
 
ssFSE uses a single 90
o
 Radiofrequency (RF) pulse applied to the spin system which after it’s 
turned off results in the realignment of longitudinal magnetization and a de-phasing of 
transverse magnetization.  This is followed by several 180
o
 pulses which causes a partial 
rephasing of the transverse magnetization and produces several spin echoes.  This increases 
the k-space signal (temporary image space in which data from digitized MR signals are stored 
during data acquisition) and reduces the time required for image acquisition.  
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4.2 Magnetic Resonance Spectroscopy 
 
Although conventional MR imaging provides information regarding the structure of the 
developing fetus, it is unable to provide functional information.  Advanced MR techniques 
such as functional MRI (fMRI), diffusion weighted imaging (DWI) and Proton Magnetic 
Resonance Spectroscopy (
1
HMRS) have been used to assess the immature brain postnatally, 
but reports of in utero applications are limited.   
 
4.2.1 Physics of Magnetic Resonance Spectroscopy 
1
HMRS is based on the same physical principles as MRI but provides data in the form of a 
chemical spectrum of metabolites.  It is this technique which was primarily used for the MR 
component of this study, assessing the development of the fetal brain in utero using 
1
HMRS, 
both in normal and growth restricted pregnancies (see Chapter 5). 
 
4.2.1.1 Chemical Shift 
Magnetic Resonance Spectroscopy is based on the principle that nuclei incorporated into 
different molecules or located in various chemical groups within the same molecule 
experience slightly different magnetic field strengths.  This is attributable to the fact that the 
molecular electronic structure adjacent to the nucleus results in a local magnetic field, which 
adds to the applied field.  A radio frequency pulse that varies in frequency over a sufficiently 
wide range perturbs all nuclei.  The relative resonant frequency of the nucleus is known as 
the chemical shift and is due to the magnetic screening produced by electrons close to the 
nucleus.  Chemical shifts are expressed in terms of parts per million (ppm) as this makes 
chemical shift independent of magnetic field strength. 
 
Chemical shift is measured relative to a reference signal in proton magnetic resonance 
spectroscopy.  This may be internal or external: internal references are preferable on 
theoretical grounds as they are located in the same magnetic environment.  Suitable internal 
reference standards should have resonant frequencies independent of changes in their local 
chemical and physical environment (such as alterations in pH and metal ion concentration) 
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and they must be present in the tissue at a concentration which enables an adequate signal to 
noise ratio to be obtained from them in the study time.  Commonly used internal references 
are N-acetyl-aspartate or water. 
 
4.2.1.2 Signal Acquisition 
Radiofrequency pulses are used to perturb the magnetization, which is known as ‘pulse 
Fourier transform spectroscopy’ in a single pulse sequence.  Pulses are usually generated 
such that the net magnetization is perturbed to produce significant components or transverse 
magnetization perpendicular to the main applied field.  The vectors continue precessing at 
frequencies proportional to the sum of the applied and local fields.  This precession induces a 
current in an adjacent antenna.  The signal is recorded as a function of voltage against time, 
which, for a single radiofrequency pulse is denoted as the free induction decay (FID).  The 
FID can be analysed mathematically (a process known as Fourier transformation) for all its 
constituent frequencies which results in a spectrum. 
 
4.2.1.3 Shapes and Widths of Spectral Peaks 
The resultant spectrum gives information not only about molecular structure but also about 
metabolite concentrations.  The amplitude of the resonant peak depends on the number of 
nuclei precessing at the same frequency hence MRS gives information regarding metabolite 
concentration.  The strength and widths of peaks are also affected by the spin lattice and spin-
spin relaxation (T1 and T2 see page 193) and their characteristic exponential decay times.  
Highly mobile molecules produce narrow resonances in the spectrum in comparison with 
broad, low level resonances from immobile nuclei.  This is due to the fact that mobile nuclei 
experience an average field which is more homogeneous than immobile species and, 
consequently, resonate over a narrower frequency band.  Consequently MRS is more useful 
for investigating mobile metabolites. 
 
4.2.1.4 Spin-spin coupling and multiplet structure 
A phemonemon called spin-spin coulpling can occur where the spins of adjacent nuclei 
interact with each other which affects resonance energy levels splitting the peaks into 
multiplet structures.  Most resonances exhibit this splitting but the chemical shift differences 
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between components vary in magnitude and are consequently not always observable.  The 
coupling is mediated by electrons in chemical bonds between the nuclei.  Lactate is an 
example of a metabolite which undergoes spin-spin coupling.  It consists of two multiplets, a 
doublet and a quartet due to –CH3 and –CH protons.  The –CH proton may be parallel or 
antiparallel to the applied magnetic field and is constantly changing from one spin state to the 
other.  At any given time half of the lactate –CH3 protons will sense the –CH proton in the 
parallel state; the other half will be in the antiparallel state.  The spin state of the –CH proton 
causes a slight change in the local magnetic field experienced by the three equivalent –CH3 
protons splitting the resonance into a doublet with components of equal amplitude.  For the –
CH multiplet there are eight possible spin combinations for the –CH3 protons.  The separation 
of multiplet components is known as the coupling constant J. 
 
An additional consequence of spin-spin coupling is called amplitude and phase modulation 
which affects the amplitudes and phases of spectra obtained by spin-echo techniques.  
Multiplets of varying complexity are produced, each component of which resonates at a 
different frequency.  During the delay between pulses of a spin echo sequence, the 
components precess.  For certain delays their phases are inverted and their amplitudes 
reduced.  This is the case for lactate –CH3 doublet structure.  At other spin-echo delays the 
phase is normal.  A doublet will be completely reversed by the second pulse in the spin echo 
sequence when the spin echo delay is: 
 
Where: 
 = spin echo delay 
J = coupling constant 
 
Equation 13 Invertion of Spin-Spin Coupling 
 
4.2.1.5 Echo Techniques 
Many spectra comprise a multitude of overlapping peaks which renders interpretation 
difficult.  The spin echo technique simplifies the spectra by editing resonances according to 
their spin-spin relaxation rates and can be a way of measuring T2s.  The magnetization is 
initially flipped through an angle θ and then the magnetic vector fans out in the x,y plane 
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during a dephasing period due to spin-spin relaxation and magnetic field in-homogeneity.  
Another rephrasing pulse is applied after which spins rephrase during the second half of spin 
echo due to the same field inhomogenities and frequency effects.  This results in a detectable 
echo.  By increasing the delay between successive pulses the amplitudes of resonances with 
shorter T2s are successively reduced, which simplifies spectra and allows more accurate 
measurement of the areas and positions of the remaining peaks. 
 
For localised MRS, commonly used sequences include Stimulated Echo Acquisition Mode 
(STEAM) and Point Resolved Spectroscopy (PRESS).  Localization is achieved by 
applications of orthogonal gradients with a frequency selective pulse.  Both STEAM and 
PRESS consist of three orthogonal slice selective radiofrequency pulses: PRESS uses spin 
echo and STEAM stimulated echo sequence.  PRESS  comprises a double spin echo sequence 
90
o
 – 180o – 180o and has been most extensively used in fetal imaging as it provides twice as 
much signal as compared to STEAM.   However, STEAM which comprises 3 slice selective 
90
o
 pulses, facilitates shorter echo times than PRESS (less than 19ms at 1.5T) and 
consequently some groups have used STEAM sequences at short echo times in the fetus and 
PRESS sequences for longer echo times[249].  
 
4.2.2 Spectral Acquisition  
Prior to spectral acquisition, conventional MRI as described on page 194, should be obtained 
to establish fetal position and identify the anatomy of the region to be investigated.  Each 
spectrum may be acquired in just over 3 minutes. 
 
Good quality fetal data requires that an optimal receiver coil with several elements is placed 
as near as possible to the fetal brain. Heerschap et al tested various radio frequency coil 
configurations suitable for use in fetal MRI, measuring the signal to noise ratio (SNR) and the 
practicalities in positioning the receive coil near the fetal head.  They assessed the system 
body coil, Helmholtz receive coil, phased array body receive coil and linear and circular 
polarized surface coils, finding a flexible linear coil to be most suitable[250].  Other groups 
have used a combination of anterior body or cardiac phased array coils[251] and posterior 
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spinal coils. This study utilises a five channel cardiac coil, optimally positioned over the fetal 
head as identified by palpation and subsequent imaging. 
Spectra may be acquired from multiple regions within the brain using a technique called 
multivoxel acquisition. To date with many issues about fetal size, position and motion only 
data using a single voxel technique has been published from fetal studies.  The region of 
interest or voxel is identified following the anatomical scan and can be adjusted but is 
typically around 20 x 20 x 20 mm
3
 for fetal studies. The voxel consequently encompasses a 
relatively larger amount of brain tissue in second trimester fetuses compared with third 
trimester fetuses.  Signal to noise increases with the size of the voxel however the region of 
interest becomes more heterogeneous.  It is not currently realistic to collect data specifically 
from only grey or only white matter in the small immature fetal brain.  Commonly used 
single voxel techniques include STEAM and PRESS which are described in detail above 
(page 197). 
 
Water suppression is needed to avoid metabolite signals being swamped by the very large 
water peak.  In addition, the presence of water can distort the baseline of the spectrum, 
making it difficult to measure individual peaks. However, tissue water can be used as an 
internal concentration reference to quantify absolute tissue concentrations of metabolites.  
Then a scan without water suppression is required to obtain a reference signal from the same 
voxel.  Metabolite relaxation times should be used for calculation of absolute concentrations 
but these values vary depending on magnetic field strength, tissue type and water content.   
 
The repetition time (TR) and echo time (TE), are important acquisition parameters as they 
affect the spectra and information available.  In general, in MR experiments, there is a 
requirement of an adequate signal relative to the noise present. It is often necessary to repeat 
the experiment and average the result to improve the signal to noise ratio.  
 
The TR effects the duration of the scan.  A long TR increases the acquisition time and 
therefore the likelihood of patient movement whereas a short TR does not allow for full 
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relaxation of the peaks. In fetal MR spectroscopy a compromise has to be reached - a TR of 
1500 – 2500 ms maximises metabolite recovery and decreases the chance of motion artefact. 
 
The TE is the delay between the centre of the first radiofrequency (RF) pulse and the centre 
of the echo formed or how long the magnetization stays in the transverse plane before being 
refocused to form the echo. Relaxation effects lead to decay of the magnetization and the 
amount of this decay depends on the TE. Apart from signal amplitude, in spin echo 
experiments, the phase of the signal may depend on the TE (as already mentioned), leading 
for example, to positive or inverted peaks at different echo times. This may facilitate the 
identification of specific metabolites.  At short echo times acquisitions have better signal to 
noise ratios and the ability to detect metabolites such as Myo-ins.   
 
Different echo times may also alter the predictive ability of metabolite ratios.  Neonatal 
studies have demonstrated that high Lac:NAA ratios and low NAA:Cho ratios correlate with 
a poorer outcome in neonates who have sustained hypoxic brain injury.  Longer echo times of 
136ms and 272ms have better predictive value than a shorter echo time of 31ms[252],  
attributable to the fact that T2 related signal decay alters for NAA, Cho and Cr at differing 
echo times[253-254].  Longer echo times present a clearer baseline and allow easier 
quantification however some metabolites are visible more clearly at shorter echo times (e.g. 
Myo-ins). 
 
After spectral acquisition, repeat conventional imaging using ssFSE helps confirm that no 
significant movement of the fetus has occurred and that the region of interest remains in the 
original location within the brain. 
 
4.2.3 Spectral Post Processing 
The scanner software should perform some immediate automatic processing of the data, 
allowing immediate display of the spectrum for a quick assessment of quality.  For 
quantitative analysis spectra can be processed offline.  There are two approaches to spectral 
analysis: the time domain and the frequency domain.  The aim of the analysis is to estimate 
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signal intensities (in the time domain) or areas under the peaks (in the frequency domain) 
corresponding to the metabolites.  This can be achieved by curve fitting with assumed 
theoretical line shapes.  Analysis in the frequency domain requires pre-processing steps 
including Fourier Transformation, phasing, baseline correction and often line broadening (to 
reduce noise in the spectrum).  Analysis in the time domain is less operator-dependent as it 
does not require phasing and baseline correction.  Curve fitting in the frequency domain is 
often done using in house developed software.    
 
Another approach is to use a linear combination of model spectra. Model spectra are acquired 
or simulated for all metabolites expected to be present in the spectrum (s-provencher.com).  
JMRUI is a widely used software package providing analysis in the time domain and 
available for free for the academic community from (www.mrui.uab.es).  This was the 
software package that was used during the course of this study.  Datasets are acquired in 
blocks which results in the production of 32 individual spectra for each echo time.  Aberrant 
spectra which may be indicative of fetal motion can be eliminated at this stage and the 
remaining spectra summed.  Post processing steps can be applied to improve the quality of 
spectra produced.  For jmrui pre-rpocessing steps aid spectra display and help define the 
starting values.  Post processing steps that were utilised during this study will be discussed 
below. 
 
4.2.3.1 Noise reduction 
Various techniques can be deployed to reduce noise in the spectrum.  The signal can be 
multiplied by an exponentially decaying function.  This preserves useful information while 
reducing noise.  However there is a trade off as the duration of the FID is reduced which 
causes broadening of peaks.  This technique is known as Line Broadening.  Processing data 
in the time domain can also eliminate broad components from the spectra by truncating the 
initial points of the signal. 
 
Zero filling is another method by which baseline smoothing can be achieved.  The number of 
points in the spectrum can be increased by adding an equal number of zero points at the end 
of the FID, before performing Fourier transformation.  This brings out detail in the spectrum 
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which may otherwise be lost.  It also facilitates more precise determination of the positions 
and heights of resonances as more points are available to define peaks. 
 
 
4.2.3.2 Phasing the Spectrum 
The outputs from Fourier transformation of the real and imaginary FID inputs consist of two 
spectra commonly known as u and v.  Due to the delay between the end of the transmitter 
pulse and the beginning of data acquisition spectra have phases which depend on frequency.  
In order to obtain spectra where each point has the same phase and are superimposed on flat 
baselines the frequency dependence must be corrected.  Most phase effects can be resolved 
by manual phase adjustment. 
 
4.2.3.3 Quantification of Metabolites 
In principle, the area of the peak produced is proportional to the number of protons 
contributing to the signal.  However absolute concentrations can only be established if all 
factors affecting the MR signal properties are accurately accounted for (e.g. relaxation times, 
number of equivalent protons and acquisition methods) and the signal does not overlap with 
additional peaks in the spectrum.  Consequently the relative concentrations are often used, 
expressed as ratios to a peak whose concentration is known i.e. a standard or as ratios to 
another stable compound in the spectrum.   
 
Ratios can be calculated through the JMRUI software package using AMARES which 
enables signal fitting in the time domain.  Each peak and midpoint of each individual peak 
within the spectrum is identified and the programme fits a curve for each metabolite peak.  
Prior knowledge is important as certain peaks are known to be inverted at certain echo times, 
for example lactate at 136ms; therefore the phase is set to 180
o
 for such molecules.  Once 
curves have been fitted ratios between metabolites can be calculated. 
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4.2.4 Metabolites Visible using Proton Magnetic Resonance Spectroscopy 
Metabolites which have been successfully identified in the fetus using 
1
HMRS include N-
acetylaspartate (NAA), creatine (Cr), choline (Cho), myo-inositol (Myo-ins) and lactate (Lac) 
(see Table 10 below).  As discussed above metabolites which are mobile and are not 
incorporated into structures such as cell membranes and myelin are optimally visible using 
MRS[251]. An example of a fetal spectra can be seen in Figure 67.   
 
 
Metabolite Peak Abbreviation 
Resonance                          
Parts Per Million (ppm) 
Choline 
(This peak also comprises of phosophocholine 
and other related metabolic products) 
Cho 3.2 
Creatine 
(This peak also comprises of 
phosphorylcreatine.) 
Cr 3.0 
Lactate Lac 1.3 
Myo-inositol Myo-ins 3.5 
N-acetylaspartate  
(This peak also has contributions from N-
acetyleaspartateglutamate.) 
NAA 2.0 
 
Table 10 Metabolites Detectable in the Fetus Using Proton Magnetic Resonance 
Spectroscopy 
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Figure 67 Example of a Fetal Spectra Illustrating the Presence of Myo-inositol (3.5 
ppm), Choline (3.2 ppm), Creatine (3.0ppm), N-acetylaspartate (2.0ppm) and Lactate 
(inverted bifid peak at 1.3ppm) at an Echo Time of 136ms. 
 
The role of each of these metabolites will be outlined below. 
 
4.2.4.1 Choline 
The signal derived from choline at 3.2ppm is a composite comprising of contributions from 
the trimethyl amine –N(CH3)3 groups of glycerophosphocholine, phosphocholine and free 
choline.  The Cho peak is reflective of only a small part of the tissue level of Cho containing 
compounds as 90% is not visible on MRS as it is incorporated into substances such as myelin 
and only mobile metabolites result in a detectable signal.  Myelination begins in midgestation 
when phospholipids are first detected, followed by sphingomyelin which contains choline, 
galactocerebrosides and glycoproteins.  Simultaneously phospholipid concentration 
decreases.[255]  This process requires high levels of choline as substrate for cell membrane 
formation[251]. 
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Choline is a water soluble essential nutrient found in high levels in glial cells[256] but it is 
also an intermediate in the synthesis of the neurotransmitter acetylcholine and consequently 
neurons are involved in its uptake[257].  Choline uptake is an important regulatory process in 
the brain and high affinity choline uptake has been shown to be the rate determining step in 
the synthesis of the neurotransmitter acetylcholine. 
 
Choline is present in all cells, and is generally considered a marker of membrane turnover, 
higher levels being reported in acute and chronic multiple sclerosis lesions[258]. 
 
4.2.4.2 Creatine 
The creatine signal detectable at 3.0ppm comprises of both creatine and phosphocreatine.  
Creatine is synthesised in the liver from amino acids L-arginine, glycine and L-methionine 
and transported to the brain.  Creatine is present in all cell types, but cell culture experiments 
have demonstrated higher concentrations in astrocytes and oligodendrocytes than in 
neurons[259].  Regional variations within the brain have also been noted with higher levels in 
grey matter than white matter and in the cerebellum as opposed to supratentorial 
regions[260]. 
 
Creatine and phosphocreatine, compounds are both involved in energy metabolism through 
the creatine kinase reaction, generating phosphocreatine and in turn adenosine triphospate 
(ATP). Creatine concentrations have been measured by high-performance liquid 
chromatography in different regions of the developing brain from preterm and term babies at 
autopsy, finding an age dependent increase, similar for the precentral area and frontal lobe 
and more pronounced in the basal ganglia and thalamus[261].  It has been suggested that this 
is due to higher metabolic rates in these areas, where myelination occurs earlier than in 
cortical regions, which is an energy demanding process[262].  Chugani et al demonstrated 
higher metabolic rates using positron emission tomography in these areas[263]. 
 
Due to the fact that Cr and phosphocreatine constitute the high energy reserves of a cell an 
increase in levels of Cr may indicate increased demand from gliosis and/or 
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remyelination[264], levels have been shown to increase in cases of white matter gliosis[258]. 
Levels of creatine are decreased in acute hypoxic encepahlopathy[265]. 
 
4.2.4.3 NAA 
The peak at 2.0ppm is reflective of both NAA and NAAG.  NAA is thought to be synthesized 
in neuronal mitochondria[266] from acetyl-CoA and aspartate by N Acetyltransferase (Asp-
NAT) ; a process which is dependent on the mitochondrial energy state[267].  NAA is then 
transported to the neuronal cytoplasm and is transferred to oligodendrocytes[268].  At this 
point the acetate portion is used for myelin synthesis and the aspartate portion is used for 
energy production or protein synthesis.  Aspartoacyclase, the enzyme that catalyzes NAA de-
acetylation is only detectable in oligodendrocytes[269].  A developmental increase of 
aspartoacyclase in oligodendrocytes has been found to parallel CNS myelination in animal 
studies[270]. 
  
NAA was traditionally thought to be a neuronal marker, due to its localization within the 
nervous system and within neurons[271-272] and the finding that brain tumours of glial 
origin did not contain NAA whereas those of neuronal origin did[273]. However, more 
recently NAA has also been identified in both immature and mature oligodendrocytes[274].   
 
The exact function of NAA is uncertain.  It has been implicated as a modulator of 
inflammation[275], an organic osmolyte in neurons, a precursor for the neuronal dipeptide 
NAAG, a source of acetate for myelin lipid synthesis in oligodendrocytes and a role in energy 
metabolism in neuronal mitochondria[268].  Within the brain, NAA is thought to be 
uniformly distributed within the cerebellum, pons, mid brain, insular cortex and parieto-
occipital lobe[260]. 
 
Reduced levels are often interpreted as a reduction in the number of neurons or altered 
mitochondrial function[276].  
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4.2.4.4 Myo-inositol 
Myo-inositol is detectable at 3.5ppm and is a pentose sugar synthesized from glucose-6-
phosphate (G-6-P) in two steps. First, G-6-P is isomerised to  
Myo-inositol 1-phosphate, which is then de-phosphorylated to give free Myo-inositol.  In 
humans most inositol is synthesized in the kidneys but it is also produced in the brain and 
liver[277].   
 
It is a crucial constituent of living cells participating in several physiological functions.  
These include an osmolyte maintaining osmotic homeostasis within cells via the sodium/-
myo-inositol transporter (SMIT)[262], a precursor for inositol-derived lipid synthesis and 
part of the inositol triphosphate intraceullar second messenger system[262].  This pathway 
operates throughout the life of a cell and is hypothesised to play a role in neuronal plasticity, 
the regulation of cell growth and long term depression relevant to memory and learning.  
High concentrations of myo-inositol are found within the central nervous system[262]. 
Inositol serves an important role in the process of neurulation[278].  Inositol and glucose are 
competitive for cellular uptake in the rat embryo, the supplementation of inositol has the 
potential to block embryopathic effects of hyperglycemia[279]. 
 
It was initially thought that ionsitol was primarily localised to the glia and consequently was 
believed to be an astrocyte marker[280].  In the human fetal brain astrocytes appear to 
multiply and differentiate independently and prior to myelinogenesis in many locations[251].  
However, it has subsequently been found that inositol concentrations in some neuronal 
populations exceed those in glia[281].   
 
Intra cellular concentrations are maintained by transport across the plasma membrane, via 
carrier molecules, de novo synthesis from glucose 6 phosphate and efflux which is mediated 
via a volume sensitive organic osmolyte channel. 
 
Concentrations of inositol in neural cells exceed those in plasma due to a sodium dependent 
uptake mechanism with high affinity for inositol; it is mediated by a specific SMIT molecule.  
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SMIT is widely distributed throughout the CNS in both neural and non neural cells.  SMIT 
activity and expression can be regulated by osmotic stress, increasing in hyperosmolar 
conditions.  SMIT expression is also regulated by inositol, but this is thought to be 
differential in different areas of the brain indicating different isoforms.  Protein kinase C has 
also been reported to inhibit SMIT[277]. 
 
Myo-inositol is increased after acute perinatal brain injury possibly indicating upregulation of 
osmolytes after hypoxia-ischaemia and acidosis.  Myo-inositol levels also increase in chronic 
stage perinatal white matter injury in preterm infants which has been suggested to represent 
changes in ceullar composition with an increase of astroglia[282].   
 
4.2.4.5 Lactate 
Under normal conditions lactate, present at 1.33ppm, is below the limits of detectability of 
spectroscopy in the adult brain. 
 
Lactate is the end product of anaerobic glycolysis.  Animal models have demonstrated that 
lactate accumulates in the fetal brain in cases of acute hypoxia[283].  Human neonates are 
also known to produce lactate in response to hypoxic insults, the level of which correlates 
with poorer neurological outcome[252].  The neonatal brain is however thought to have an 
enhanced capacity to metabolise lactate in comparison with the adult brain, possibly due to an 
adaptation to the relatively hypoxaemic and hyperlacticacidemic state of the perinatal 
period[284].  Consequently further research is required to elucidate the exact significance of 
lactate as a marker of hypoxic-ischemic damage during the perinatal period as the developing 
brain has a greater metabolic tolerance to hypoxia[262]. 
 
However, it has also been suggested that lactate can act as a fuel source in the immature brain 
[285-286].  Lactate has been detected in small amounts in the apparently normal preterm 
neonatal brain, levels decreasing with advancing gestation[287].   
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Lactate has also been implicated in the synthesis of myelin.  Sanchez-Abarca et al found that 
neurons, astrocytes and oligodendrocyte were able to use lactate.  Oligodendrocytes were also 
found to actively use lactate by oxidation and lipogenesis and lactate utilization by 
oligodendrocytes was three times higher than that in astrocytes and neurons.  This high rate 
lactate utilization was mainly accounted for by the rate of lipogenesis:  oligodendrocytes 
synthesise myelin which requires active lipogenesis.  Therefore, it is possible that lactate is 
implicated in the synthesis of myelin[288]. 
 
However it is unclear how lactate is produced in the fetal brain and what its biological 
significance is, if detected. 
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4.2.5 Limitations of 
1
HMRS 
1
HMRS has been successfully used in the neonatal population to investigate alterations in 
brain metabolism in hypoxic encephalopathy and certain metabolic diseases[289-291]. 
However, fetal studies to date have been limited because acquisition is hampered by small 
fetal size, distance from the coil and fetal motion. Some groups have tried to minimise the 
effect of motion by sedating the mother with benzodiazepines[251] or by only scanning 
women who were of advanced gestation with  engagement of the fetal head in the maternal 
pelvis[250, 292].  As maternal respiration causes fetal motion  obtaining the spectra during 
maternal breath holding may improve the spectral quality [293].  Fetal imaging and 
spectroscopy are also hampered by a low signal to noise ratio because the coil is positioned 
on the maternal abdomen, some distance from the fetus.  
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4.3 Safety of MRI/ 
1
HMRS 
 
Most studies reported in the literature indicate that fetal MRI is a safe imaging modality.  
Assessment of the exact risk is complex as there are a wide variety of field strengths, gradient 
strengths and radiofrequency pulses in use.  These generate varying amounts of radio 
frequency energy and acoustic noise.  However, potential harmful effects for the fetus may 
arise from one of a number of sources: the static magnetic field, the radiofrequency field or 
time-varying magnetic gradients. 
 
4.3.1 Static Magnetic Fields 
The main priority prior to any Magnetic Resonance Imaging Investigation is to ensure all 
patients and staff are metal free when approaching the magnetic.  Consequently a full metal 
checklist is completed with the patient to ensure that they have had no operations or injuries 
which may involve the embedding of metal in their body or jewellery or metal on their 
clothing which may prove hazardous. 
 
A survey of pregnant MRI workers exposed to the static field fringe fields showed no 
significant adverse outcomes[244].Experiments on human cultured cells showed no effect on 
their growth[294-295].  Some animal model studies have indicated that pre-implantation 
embryos may have a reduced survival rate and cell migration may be adversely effected at 
high field strengths[245].  However human MRI scans are not performed in the first trimester 
and field strengths are currently limited to 1.5 T in clinical imaging. 
 
4.3.2 Radiofrequency Fields 
The hazard associated with radiofrequency fields is thermal heating.  Elevation of fetal 
temperature is potentially hazardous.  The fetus is particular sensitive to elevations in 
temperature during periods of organogenesis, the central nervous system being particularly 
vulnerable[245]. 
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In humans a 2
o
C rise over 24 hours can result in a range of neural tube and cranio-facial 
defects[245].  A human study by Li et al suggested an association of risk of miscarriage with 
the use of hot tubs[296]. 
 
Animal studies have shown that a rise in temperature of 2-2.5
o
C for one hour results an 
increased incidence of microcephaly[245].  However assessing the exact temperature of the 
fetus in human studies is more problematic.  This issue has been addressed in pigs using a 
1.5T MRI scanner with HASTE sequences and no significant rise was noted although this is 
only one of many sequences used in fetal scanning[297]. 
 
To ensure patient safety any pulse sequence developed must not result in a rise in body 
temperature above 0.5
o
C for the normal mode, 1
o
C for controlled mode and 1
o
C in 
experimental mode.  Specific absorption rates (SAR) limits are therefore set.  The 
manufacturer establishes SAR levels for each pulse sequence[245]. 
 
It has been suggested that adverse fetal effects may be avoided if the temperature of the fetus 
is kept below 38
o
C and that the body temperature of the woman does not rise more than 
0.5
o
C[298].  Due to the fact that the fetal temperature is 0.5
o
C higher than that of the mother 
this also needs to be taken into account when ensuring safety of the imaging. 
 
4.3.3 Time-varying Magnetic Fields 
The risks associated with pulsed electromagnetic gradient fields are biological effects, 
acoustic noise damage, peripheral nerve and muscle stimulation, cardiac fibrillation and 
magnetophosphenes.  However, the most important of these for the fetus are biological 
effects and acoustic noise. 
 
The biological effects of time varying electromagnetic field have been reviewed and no 
measurable effects from anxiety, spatial memory, long term memory, intelligence quotient, 
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visual acuity, reaction time or long term stress, nerve and muscle stimulation or teratogenic 
effects have been reported[245]. 
 
MRI is associated with large amounts of noise generated due to rapid switching of currents 
within the gradient coils.  When this is combined with the presence of strong magnetic fields 
Lorentz forces result which make the coils vibrate and produce a loud banging noise.  High 
frequency hearing loss, shortened gestation and decreased birth weight has been reported 
from excessive noise, greater than 99 dB during pregnancy[299].  Clinical MRI systems can 
produces noises between 80 and 120dB.  The mother is protected with headphones however 
the fetus is not.  It is difficult to assess how much the noise is attenuated by maternal tissues 
and amniotic fluid.  A 30dB attenuation in MRI acoustic noise has been reported using a 
hydrophone in a male volunteer’s stomach[300].  However this is not truly reflective of the 
intrauterine environment. 
 
4.3.4 Clinical Studies of MRI Safety 
The acute effects of fetal MRI have been assessed by monitoring the fetal heart during 
imaging.  No alterations in the CTG have been reported[245].  Fetal MRI has been shown not 
have a detrimental effect on fetal growth in utero[301].  Baker et al followed up children who 
were underwent fetal MRI to the age of three years and no increased incidence of disease or 
disability (including hearing deficits) were reported when compared to a control group[23]. 
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CHAPTER 5 – 
1
HMRS ASSESSMENT OF THE METABOLIC PROFILE OF THE 
BRAIN IN IUGR 
 
5.1 INTRODUCTION 1HMRS COMPONENT OF THE STUDY 
 
Proton Magnetic Resonance Spectroscopy (
1
HMRS) has only recently been applied to 
investigate the fetus and fetal studies to date are, therefore limited, partly due to the technical 
restrictions described in Chapter 4.  Development of the fetal brain is known to involve 
changes of biochemistry as well as morphology and 
1
HMRS is a safe technique for studying 
in vivo metabolism.  Due to the fact that fetal data is limited it is important to understand the 
metabolic changes occurring in the normally developing brain with increasing gestation using 
Magnetic Resonance Spectroscopy (MRS), before investigating the effects of pathology.  
This section will briefly outline the current understanding of spectroscopy changes in healthy 
fetuses in the brain and other non neural tissue. 
 
5.1.1 Assessment of Normal Fetal Development using 
1
HMRS 
5.1.1.1 Brain 
The development of the normal fetal brain has been studied by a number of groups using 
MRS.  Choline (Cho), creatine (Cr), Myo-inositol (Myo-ins) and N-acetylaspartate (NAA) 
have all been detected in the normally developing fetal brain between 22 and 41 weeks 
gestational age (GA) [249-250, 302].  By 34 weeks GA the fetal spectrum is comparable to 
that of a term born neonate with dominant resonances for Cho, Cr and NAA at a long echo 
time e.g. 135ms and Myo-ins, Cho, Cr and NAA dominant resonances at a short echo time 
e.g. 30ms[302]. 
 
The physiological role of NAA, Cho, Cr, NAA and Lac has been discussed in Chapter 4.  
However, a summary of their functions is given in Table 11 below. 
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Metabolite Peak Abbreviation 
Resonance  
Parts Per 
Million (ppm) 
Roles 
Choline 
(This peak is also comprised of 
phosphocholine and other 
related metabolic products) 
Cho 3.2 
Myelination                
Metabolism of membrane lipids 
Creatine 
(This peak also comprises of 
phosphorylcreatine.) 
Cr 3.0 Cellular energy metabolism. 
Lactate 
Lac 1.3 
End product of anaerobic 
glycolysis.                        
Possible fuel in the developing 
brain. 
Myo-inositol 
Myo-ins 3.5 
Osmoregulation                 
cellular nutrition and 
detoxification[254] 
N-acetylaspartate  
(This peak also has 
contributions from N-
acetyleaspartateglutamate.) 
NAA 2.0 
Neuronal marker                   
Also identified in both immature 
and mature 
oligodendrocytes[274]. 
Synthesized in mitochondria 
 
Table 11 Metabolites Detected in the Fetal Brain Using 
1
HMRS 
 
Absolute metabolite concentrations have been reported in some fetal papers, however, these 
can only be established if all factors affecting the MR signal properties are accurately 
accounted for (e.g. relaxation times, number of equivalent protons and acquisition methods) 
and the signal does not overlap with additional peaks in the spectrum.  Consequently, the 
relative concentrations are often used, expressed as ratios to a peak whose concentration is 
known, i.e. a standard or as ratios to another stable compound in the spectrum.   
216 
 
 
Kok et al found no change in the absolute level of Cr using an echo time of 135ms with 
gestation in 35 fetuses between 30 and 41 weeks (calculated based on assumptions of spin 
relaxation times and brain tissue water content), suggesting that the apparently stable Cr 
could be suitable for quantification of other metabolites in the form of ratios over Cr[249]. 
Girard et al studied  58 fetuses with a gestational age range between 22 -39 weeks and 
showed that Cr levels increased in the fetal brain with increasing gestation; however, this was 
only found at a short echo time of 30ms and not a longer echo time of 135ms[251].    
 
NAA is detectable as early as 22 weeks and absolute levels (again calculated using the above 
assumptions of spin relaxation times and brain tissue water content) and the ratios of NAA:Cr 
and NAA:Cho increase with increasing gestational age[249, 302].  These changes in 
metabolite ratios are, therefore, likely to reflect the development of dendrites and synapses as 
well as oligodendrocyte proliferation and differentiation [274].  
 
Fetal studies have shown that levels of Cho[302] and the ratio of Cho:Cr[249] in central brain 
tissue are highest between 22 and 28 weeks and then decrease with increasing gestation. 
These observed spectral changes with gestation have been attributed to the high levels of Cho 
required for cell membrane formation[251], or increased pre-myelination in late 
pregnancy[249].  
 
Myo-ins has been shown to be the predominant resonance in the brain spectrum at a short 
echo time e.g. before 28 weeks.  Levels of Myo-ins in the fetal brain have been found to 
decrease with increasing gestation by Girard et al[251].  However, Kok et al found no 
significant change in Myo-ins levels with increasing gestation[249]; although their sample 
covered a narrower gestational range, only including 3
rd
 trimester fetuses.  High levels of 
Myo-ins early in gestation may be attributable in part to the high density of glial cells 
between 22 and 28 weeks gestation[302]. 
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The role of Lac in the developing brain is uncertain and it has not been reported in the normal 
fetal brain.  It is however a recognised marker of tissue injury in the neonatal brain after acute 
birth asphyxia[252] and has also been found in much smaller amounts in the apparently 
normal developing neonatal brain.  Leth et al performed MRS on 13 appropriate for 
gestational age and 10 small for gestational age neonates between 28 and 41 weeks gestation.  
Lac was detected in all 10 small for gestational age but also 10 of 13 appropriate for 
gestational age infants[303].   
 
5.1.1.2 Non neural studies  
Fenton et al attempted to assess the fetal heart and liver in three healthy pregnant volunteers 
at term using a PRESS sequence.  In the fetal liver they were able to demonstrate a lipid peak 
at the same range as that found in the adult liver.  Lipids were also found in the fetal heart 
spectra with a short echo time, but longer echo times did not yield information possibly due 
to the motion of the fetal heart[293]. 
 
In vivo 
1
HMRS has also been used to assess the presence of a lipid lecithin, a component of 
lung surfactant, in amniotic fluid.  Lecithin has a resonance of 3.2ppm (the same as other Cho 
containing compounds).  Clifton et al analysed in vitro amniotic fluid samples obtained via 
amniocentesis for clinical indications during the second or third trimester.  Resonances were 
detected at 3.2ppm.  In vivo MR spectroscopy was also performed on two of these third 
trimester fetuses.  Prominent resonances at 3.2ppm were found in the lung and amniotic fluid 
of one fetus at 37 weeks gestation, imaged in vivo, possibly indicating the presence of 
surfactant.  The second fetus, also at 37 weeks gestation, did not have a prominent peak at 
3.2ppm in either the lung or amniotic fluid, despite having a surfactant:albumin ratio within 
the normal range indicating sufficient lung maturity[304]. 
 
Kim et al also studied eight third trimester fetuses with 
1
HMRS, using a PRESS sequence 
with an echo time of 144ms, assessing both fetal lung tissue and amniotic fluid.  They were 
unable to obtain spectra from three fetuses.  Lac was identified in the amniotic fluid of 3 
patients.  Lac was assessed due to the fact it had been readily identified in amniotic fluid in 
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ex vivo experiments.  Cho, at 3.2ppm however, was only detected in one fetal lung spectra; 
this patient had undergone breath holding in attempt to minimise the effects of motion[305].  
 
Further work is required for evaluation of MRS in the fetal heart, liver and lungs as numbers 
to date are very small and it has proven extremely difficult to accurately sample from a small 
specific region of interest.   
 
5.1.2 
1
HMRS and IUGR Pregnancies 
There is very little literature on the role of MRS in abnormal pregnancies.  Two studies have 
assessed fetuses with ventricular dilatation [279, 292]; there is one case reported of a twin 
pregnancy with suspected pyruvate dehydrogenase deficiency[306] and three case reports 
from IUGR pregnancies.  The details of these will briefly be outlined below. 
 
Azpurua et al assessed the brain of a 25 week fetus with severe IUGR.  They detected NAA, 
Cho, Cr and Myo-ins as well as Lac placing a 25x25x25mm
3
 voxel below the corpus 
callosum, between the two cerebral hemispheres using an echo time of 135ms.  The fetus was 
subsequently delivered at 29 weeks gestation and followed up to the age of 4 years.  No 
neurological sequelae were noted at this stage[307]. Although the NAA:Cho ratio was 
reported as normal there was no comparison with normal controls.   This group didn’t report 
what the ratio was and didn’t say how they obtained a normal range. 
 
Wolfberg et al investigated the brain of a 33 week fetus with gastroschisis and IUGR.  They 
placed a relatively large 20x20x40 mm
3
 voxel centrally which appears to include basal 
ganglia and white matter using a PRESS sequence at an echo time of 144ms.  They detected 
peaks consistent with the presence of Cho, Cr, and NAA, however, the peak which is labelled 
as Lac was seen at approximately 1.05 to 1.1 and not at 1.3ppm [308]. 
 
Robinson et al performed MRS at 20 weeks gestation on a fetus with severe IUGR.  They 
initially attempted to obtain MRS in both the fetal torso and brain using a PRESS sequence 
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with an echo time of 136ms.  Results were only obtained from the fetal torso.  They were able 
to detect a large Lac peak at 1.3ppm, which they suggested may be reflective of hypoxia, in 
the fetal torso but no further signals.  An intrauterine death was confirmed the next day but it 
is unclear whether the fetus was alive at the time of imaging[309]. 
 
As fetal data is extremely limited at present no other studies/case reports have looked at any 
other pathology relating to aberrant fetal cerebral blood flow, for example in cases of fetal 
anaemia. 
 
However, no study to date has yet conducted a prospective cohort study to assess changes in 
metabolism occurring in IUGR fetuses, specifically in the developing brain compared to 
controls.  IUGR fetuses show a higher incidence of neurodevelopmental sequelae (see 
Chapter 1), despite maintained/increased cerebral blood flow and preserved head growth (see 
Chapter 1).   
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5.2 AIMS OF 1HMRS COMPONENT OF THE STUDY 
 
1 To assess the reproducibility and validity of acquisition of spectroscopy in 
human fetuses. 
2 To assess changes occurring in metabolite ratios in the fetal brain during 
normal in utero development in healthy pregnant volunteers, using three different 
echo times, in order to optimise metabolite detection. 
3 To assess differences in fetal brain metabolite ratios between appropriately 
grown and growth restricted pregnancies at three different echo times. 
4 To investigate the feasibility of obtaining metabolite ratios in other fetal 
tissues including the fetal liver, amniotic fluid and placenta. 
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5.3 METHODS FOR 1HMRS COMPONENT OF THE STUDY 
 
5.3.1 Ethics 
Full ethical approval for the MRI components of this study was obtained from the 
Hammersmith Hospital Research Ethics Committee (REC) number 07/H0707/105.  Patients 
were provided with an information leaflet before agreeing to take part in the study. 
 
5.3.2 Power Calculation 
A neonatal MRS study was used for the power calculation as there are no established normal 
ranges in the fetus[310].  This was performed in conjunction with the Imperial College 
Statistical Advisory Service using the Lenth Power Calculation website 
(http://www.stat.uiowa.edu/~rlenth/Power/) in order to establish a 5% statistical significance.  
The mean and standard deviation of NAA concentrations in neonates was used.  The mean 
and standard deviation of the normal population was 9.21mmol/kg and 1.29mmol/kg 
respectively[310].  A 1 sided t-test with 80% power at a 5% significance level was performed 
which showed that 25 IUGR and 25 normally grown fetuses, or 21 IUGR and 30 
appropriately grown fetuses are required to detect a 10% difference in NAA levels.  
 
5.3.3 Patient Recruitment 
All pregnant women were recruited between June 2007 and January 2010 and only singleton 
pregnancies were included.  Appropriately grown control pregnancies were recruited from the 
main ultrasound department of Queen Charlotte’s and Chelsea Hospital following a normal 
anomaly scan between 20 and 23 weeks gestation.  All women who agreed to participate 
subsequently underwent at least one further ultrasound scan in order to demonstrate normal 
fetal growth. 
 
Fetuses with IUGR were recruited from the Centre for Fetal Care at Queen Charlotte’s and 
Chelsea Hospital.  Fetal growth restriction was defined as in Chapter 3: an estimated fetal 
weight less than the 10th centile, abnormal doppler velocimetry in the umbilical artery (an 
increased pulsatility index above the 95th centile, absent end diastolic flow or reversed end 
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diastolic flow) and evidence of cerebral redistribution (a middle cerebral pulsatility index less 
than the 5th centile) assessed using ultrasound and Doppler velocimetry.  Only fetuses with a 
suspected placental cause of IUGR were included. 
 
Detailed patient demographics were recorded for each patient which included: maternal age, 
height, weight and ethnicity, parity and any existing medical conditions. 
 
5.3.4 MRI and 
1
HMRS Investigations 
Prior to undergoing MR investigations, all patients and volunteers were thoroughly 
counselled, consented and completed a metal checklist to ensure safety of the procedure. 
 
A 1.5T Philips Magnetic Resonance System (Philips Achieva; Philips Medical systems, Best, 
the Netherlands) with a SENSE wrap around 5 channel cardiac coil was used.  This was 
positioned as close as possible to the fetal head which was determined initially by abdominal 
palpation by an obstetrician.  Following acquisition of initial sequences the position of the 
coil was altered if it was not located optimally over the fetal head.   
 
The women were positioned in the scanner with a left lateral tilt in order to minimise 
compression of the inferior vena cava, which may have resulted in both fetal and maternal 
compromise.  Headphones were provided to all women in order to reduce acoustic noise.  No 
maternal sedation was used; however, women were instructed to remain as still as possible 
during image acquisition.  An obstetrician was present for the duration of the scan. 
 
Conventional Magnetic Resonance Imaging was first obtained: T2 weighted ssFSE sequences 
(TE: 98, TR: 1000, Number of Signal Averages (NSA): 2, matrix: 400 × 178, Field of View 
(FOV): 36 – 40cm, 4mm slice thickness: 4mm, slice gap: 0.4mm, acquisition time: 
20seconds) in the axial, sagittal and coronal planes.  These images were visually analysed by 
an experienced radiologist for the presence of normal anatomical features and the presence of 
pathology.  
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5.3.4.1 Fetal Brain 
Following conventional imaging, spectra were obtained by placing a 2x2x2 cm
3
 voxel over 
the central region of the brain encompassing both white and central grey matter; in order to 
maximise the acquisition of brain tissue; this was selected from a survey sequence.  The 
positioning of the voxel is illustrated in Figure 68. 
 
 
Figure 68 MRI in the Coronal Sagittal and Transverse Plane Showing the Correct 
Location of a 20x20x20mm3 Voxel in a Normal Fetal Brain at 24
+6
 Weeks Gestation. 
 
A PRESS sequence was used to acquire the spectra.  PRESS was selected as it has been used 
extensively in fetal imaging, and has strong suppression of signals outside the selected 
volume.  It is less useful at echo times below 19ms; but the shortest echo time used during 
this project was 42ms.  A TR of 1500ms was used.  Data was acquired in blocks of four 
averages and saved independently, allowing elimination of aberrant spectra due to motion 
artefact in the post processing stage. 
 
Water suppression by selective excitation was used to avoid metabolite signals being 
distorted by the large water peak, and, to avoid distortion of the baseline of the spectrum, 
rendering measurement of individual metabolite peaks difficult.  The PRESS sequence was 
224 
 
repeated at three different echo times 136 ms, 270 ms and 42 ms in order to maximise the 
identification of the chemicals of interest (see page 198). 
 
Following spectral acquisition further imaging was obtained to ensure that the fetus had not 
moved significantly.  Data was discarded if there was evidence of significant fetal motion 
between pre and post spectral imaging. 
 
5.3.4.2 Assessment of Non-Neural Tissue 
A small feasibility study was undertaken to assess whether acquisition of interpretable spectra 
from other fetal tissue was possible.  Tissues investigated were: placenta, amniotic fluid and 
fetal liver.  A 2x2x2cm
3
 voxel was positioned in the tissue type selected.  For the placenta the 
voxel was positioned in central placental tissue, for amniotic fluid it was positioned in the 
largest pocket of cord free liquor and for the fetal liver it was placed centrally over liver 
tissue.   
 
Spectra were acquired using a PRESS sequence, TE 136ms, TR 1500ms.  Data was acquired 
in blocks of four averages and saved independently allowing elimination of aberrant spectra 
in the post processing stage.  Water suppression using selective excitation was used.  Imaging 
was repeated post spectral acquisition to ensure that the voxel remained in the tissue being 
investigated. 
 
5.3.5 Post Processing of Spectra 
Post processing of spectra using jMRUI has been discussed in detail in Chapter 4.  After the 
MR examination, datasets were transferred from the MR consol to a Hewlitt Packard personal 
computer.  Once data for all study patients had been acquired, the spectra were blinded and a 
random number assigned to each patient.  Datasets were then post processed using the jMRUI 
software package (see page 198).  Blocks of 32 individual spectra were produced for each 
echo time.  These were each assessed visually and those with a residual water peak that were 
deviant from the other spectra were eliminated.  Remaining spectra were summed. 
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The spectra underwent line broadening and manual phasing.  The water peak was then set to 
4.7ppm in order to reference the spectrum.  The water peak was subsequently removed.  
AMARES was used to create metabolite ratios for NAA:Cho, NAA:Cr, Cho:Cr at an echo 
time of 270ms and 136ms.  At an echo time of 42ms ratios were created for Cho:Cr, Myo-
ins:Cho and Myo-ins:Cr.  After the generation of metabolite ratios for each patient the spectra 
were unblinded. 
 
5.3.6 Ensuring Validity of Results 
Before analysing the datasets a number of measures were taken to ensure validity of the 
techniques being used.  These included: acquiring spectra in blocks during the single 
acquisition and the removal of any aberrant results (discussed above), repeating conventional 
imaging post spectral acquisition to ensure that the fetal head had not moved significantly 
(again discussed above); ensuring reproducibility of spectral acquisition and ensuring 
reproducibility of the post processing stages.  Reproducibility of data acquisition and post 
processing will be outlined below.  Initially Bland Altman plots were calculated, which did 
show good correlation, however correlation co-efficients were used as this was the method 
cited in previous papers. 
 
5.3.6.1 Data acquisition 
In order to ensure reproducibility of results, spectral acquisition was repeated twice on 5 
patients at the beginning and end of the MR examination. 
 
5.3.6.1.1 Methods 
Using echo times of 136ms, 270ms and 42ms spectra were obtained at the beginning of the 
MR investigation and again at the end on 5 patients; these were a combination of healthy 
pregnant volunteers and fetuses with known cerebral pathology.  Prior to spectral acquisition 
on both occasions the voxel was placed in central brain tissue planned from conventional 
imaging.  Conventional imaging was then repeated post spectral acquisition to ensure that no 
significant fetal motion had occurred.  Datasets were then processed as described above to 
create metabolite ratios for NAA:Cho, NAA:Cr and Cho:Cr at echo times of 136ms and 
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270ms and Myo-ins:Cho, Myo-ins:Cr and Cho:Cr at an echo time of 42ms.  The patient 
details were blinded from the investigator during data analysis.  All spectra were analysed by 
the same investigator (LS) to exclude confounding factors of inter-observer variability.  
SPSS, version 17 (Chicago IL) was used to generate an inter class correlation co-efficient and 
the mean and standard deviation between the two metabolite ratio readings. 
 
5.3.6.1.2 Results 
Echo Time Correlation co-efficient 
Mean Percentage Difference    
and                                     
Standard Deviation 
136ms 0.96 (p<0.001) 14.9 (12) 
270ms 0.918 (p<0.001) 23 (27) 
42ms 0.634 (p=0.05) 20 (24) 
  
Table 12 Correlation Co-efficients at Different Echo Times for Spectra Acquired at the 
Beginning and End of Imaging 
 
5.3.6.1.3 Conclusion 
There was significant reproducibility in metabolite ratios to justify using the technique to 
assess differences in metabolite ratios during this study.  However, the mean percentage 
difference between the two scan results was large particularly for the echo time of 270.  
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5.3.6.2 Post Processing of Spectra 
In order to ensure reproducibility of post processing, the same spectra were analysed twice by 
both the same and different investigators thereby validating the post processing stages. 
 
5.3.6.2.1 Methods 
Using an echo time of 136ms spectra were obtained as described above.  Datasets for 8 
patients, a combination of both healthy pregnant volunteers and women with known fetal 
abnormalities, were saved twice, using different numbers, generating 16 spectra in total.  This 
ensured the blinding of patient details from the investigator in addition to confirming the 
source of the spectra (i.e. the same or different patients).  In order to further ensure 
reproducibility of post processing, the same spectra were also analysed twice by two different 
investigators (LS and MA) in order to validate the post processing stages.  Using an echo 
time of 136ms spectra were obtained, as described above.  Datasets were then post processed 
as described above.  Metabolite ratios were created using AMARES for NAA:Cho, NAA:Cr,  
Cho:Cr and Lac:Cho, where detected.  SPSS, version 17 (Chicago IL) was used to generate 
an inter class correlation co-efficient.  Mean and standard deviations for percentage 
difference between metabolite ratios were also generated. 
 
5.3.6.2.2 Results 
Cho, Cr and NAA in all spectra on both occasions and lactate in two of the 8 patients on both 
occasions.  This finding was consistent when spectra where analysed by the same and 
different assessors. 
Intra-Observer 
Variability Correlation 
Co-efficient 
Intra-Observer Mean 
Percentage Difference 
and Standard Deviation 
Inter-Observer 
Variability Correlation 
Co-efficient 
Inter-Observer Mean 
Percentage Difference 
and standard deviation 
0.998 (p<0.001) 3.9 (4.3) 0.868 (p<0.001) 25 (23) 
 
Table 13 Correlation Co-efficients for Intra and Inter Observer Post Processing of 
Spectra 
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5.3.6.2.3 Conclusion 
The post processing steps of spectral analysis is a reproducible technique when performed by 
both the same and different investigators.  However, it was significantly more reproducible 
when spectra are post processed by the same assessor as the mean percentage difference 
between two observers was 25%. 
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5.3.7 Pregnancy Outcome Data 
For all patients and volunteers enrolled in the study any obstetric complications, such as pre-
eclampsia, which developed during pregnancy were noted 
 
Delivery parameters were recorded for each patient and volunteer.  These included: 
intrauterine death/ livebirth, gestation at delivery, sex of infant, mode of delivery, any intra-
partum complications, one and five minute APGAR scores, lowest cord pH at delivery, need 
for resuscitation at delivery and admission to neonatal unit.  Customised birthweight centiles 
were calculated based on delivery and maternal parameters using gestation network, United 
Kingdom edition (http://www.gestation.net/).   
 
Any neonatal complications to the time of discharge from hospital were also recorded.  These 
included: neonatal death, sepsis, respiratory distress syndrome, intraventricular haemorrhage, 
hypoglycaemia, jaundice and gastrointestinal complications. 
 
5.3.8 Statistical Analysis 
Statistical analysis was performed using the SPSS software package version 17 (SPSS 
Chicago, IL, USA). Linear regression analysis was used to adjust for altered metabolite ratios 
with advancing gestational age.  
 
Analysis of covariance was used to assess the effects of metabolite ratios in IUGR when 
corrected for gestational age, as well as the influence of ethnicity, maternal age, sex of fetus 
and maternal BMI on metabolite ratios.  Each metabolite ratio was assessed for normality 
prior to ANCOVA analysis.  ANCOVA is a general linear model with a continuous outcome 
variable being metabolite ratio, and at least one continous predictor (gestation, maternal age 
and BMI) and at least one categorical predictor variable (presence of IUGR, ethnicity and sex 
of fetus). Where data was not normally distributed, original data sets were transformed by 
logging to base 10. 
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Demographic and delivery data was analysed using the t-test where data was normally 
distributed and Mann-Whitney where the criteria for normality were not satisfied, when 
continuous and the Chi-Squared test when categorical.  Independent samples t tests were 
performed to discover if there were significant differences in the gestational age at scan, 
between interpretable and un-interpretable spectra at all three echo times  
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5.4 RESULTS 1HMRS COMPONENT OF THE STUDY 
 
The results section will be separated into each echo time 136ms, 270ms and 42ms.  Delivery 
and outcome parameters will also be reported.  Results of spectral acquisition of non neural 
tissue will then be discussed. 
 
5.4.1 Echo time 136ms 
5.4.1.1 Spectral Acquisition Echo Time 136ms 
28 fetuses with evidence of intrauterine growth restriction (gestational age 20
+3
 to 35
+0 
weeks, 
median 27
+6
) and 46 appropriately grown fetuses (gestational age 22
+0
 to 38
+6
 weeks, median 
29
+5
) were included.  Two appropriately grown and two IUGR fetuses were scanned twice on 
two separate occasions during gestation. 
 
At the time of imaging all growth restricted fetuses with interpretable spectra had an 
estimated fetal weight less than the 10th centile and evidence of cerebral redistribution (MCA 
dopplers lower than the 5th centile). 7 had a raised pulsatility index (greater than the 95th 
centile), 12 had absent end diastolic flow and 2 had reversed end diastolic flow on umbilical 
artery dopplers.  
 
67% of spectra obtained were suitable for analysis.  31 interpretable spectra were obtained 
from appropriately grown control fetuses (20
+0
-37
+5
 weeks gestation, median 30
+0
) and 21 
spectra from IUGR fetuses (20
+3
 to 35
+0
 weeks gestation, median 28
+0
).  The remaining 
spectra were uninterprettable due to excessive fetal motion: these spectra showed evidence of 
abnormal morphology or absence of the water peak, poorly defined metabolite peaks or a 
noisy baseline. 
 
NAA, choline and creatine were identified in all fetuses with interpretable spectra.  An 
example of a typical fetal spectrum produced can be seen in Figure 69.  Lactate was also 
detected in 8 fetuses: 4 appropriately grown and 4 growth restricted fetuses.   
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Figure 69 Spectra from a 24+6 week appropriately grown fetus, illustrating resonances 
for Myo-inositol (3.5ppm), Choline (3.2 ppm), Creatine (3.0ppm), N-acetylaspartate 
(2.0ppm) and Lactate (the bifid inverted peak at 1.3ppm) at an echo time of 136ms. 
 
5.4.1.1 Differences in Spectral Acquisition Depending on Gestational Age at an Echo Time 
of 136ms 
There was no significant difference in the gestational age at scan between fetuses with 
interpretable and un-interpretable spectra.  This was the case for echo times of 136ms, 270ms 
and 42ms (p = 0.591, p = 0.220 and p = 0.622 respectively). 
 
5.4.1.2 Maternal Demographics of Fetuses with Interpretable Spectra Echo Time 136ms 
Maternal demographics for fetuses with interpretable spectra at an echo time of 136ms can be 
seen in Table 14 below. 
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Maternal Characteristic IUGR Appropriately Grown Significance 
Age 
Range 
Median 
 
24-44 
32 
 
18-44 
33 
p=0.039 
BMI 
Range 
Median 
 
18.5-36 
24.5 
 
17-33 
23 
Not significant 
Parity 
0 
1 
2 
3 
>3 
 
53% 
26% 
16% 
5% 
0% 
 
65% 
26% 
9% 
0% 
0% 
Not significant 
Ethnicity 
Caucasian 
Asian 
South East Asian 
Afro carribean 
African 
Other 
53% 
26% 
5% 
5% 
0% 
11% 
 
64% 
16% 
6% 
6% 
6% 
0% 
 
Not significant 
 
Table 14 Maternal Demographics of Fetuses with Interpretable Spectra at an Echo 
Time of 136ms 
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5.4.1.3 Alteration of Metabolite Ratios with Gestational Age in Appropriately Grown 
Fetuses 
From the appropriately grown fetuses, linear regression analysis demonstrated that the 
NAA:Cho ratio increased with advancing gestation (p=0.004) and that the Cho:Cr ratio 
decreased with increasing gestation (p=0.01).  Statistical significance was not reached for the 
NAA:Cr ratio (p=0.658). 
 
 
 
 
p = 0.004 
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p=0.01 
 
 
p= non significant 
 
 
Figure 70 NAA:Cho, Cho:Cr and NAA:Cr Ratios Varying with Gestation in 
Appropriately Grown Fetuses, the Mean and 95% Confidence Intervals are Highlighted 
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5.4.1.4 Differences in Metabolite Ratios Depending on Fetal and Maternal Parameters in 
Appropriately Grown Control Fetuses Echo Time 136ms 
Within the appropriately grown fetuses, differences in metabolite ratios with various fetal and 
maternal parameters were assessed.  There was no statistical difference in any metabolite 
ratio for: sex of infant, maternal ethnicity, maternal age, maternal BMI (see Table 15). 
 
Parameter 
NAA:Cho                                 
p-value 
NAA:Cr                                     
p-value 
Cho:Cr                                      
p-value 
Sex of Infant 0.456 0.533 0.827 
Maternal Ethnicity 0.536 0.812 0.379 
Maternal Age 0.302 0.751 0.657 
Maternal BMI 0.444 0.735 0.504 
 
Table 15 Differences in Metabolite Ratios with Varying Maternal and Fetal 
Characteristics at an Echo Time of 136ms 
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5.4.1.5 Differences in Metabolite Ratios between Appropriately Grown and IUGR Fetuses 
Echo Time 136ms 
The NAA:Cho and NAA:Cr ratios corrected for gestation were significantly lower (p= 
<0.0001 and p=0.002 respectively) in IUGR fetuses than in appropriately grown fetuses.  
There was no significant differences between the AGA and IUGR groups for the Cho:Cr ratio 
(p=0.212). 
 
p=<0.0001 
 
p = 0.002 
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p=ns 
 
 
Figure 71 NAA:Cho, NAA:Cr and Cho:Cr ratios in appropriately grown and growth 
restricted fetuses at an echo time of 136ms 
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5.4.1.6 Differences in Metabolite Ratios Depending on Severity of IUGR Echo Time 136ms 
Although numbers were small, subgroup analysis was performed comparing the NAA:Cho 
and NAA:Cr ratios in IUGR patients with evidence of cerebral redistribution and high PI and 
those with absent or reversed end diastolic flow.  7 fetuses had raised PI and cerebral 
redistribution and 14 had absent or reversed end diastolic flow. 
 
There was no significant difference in the NAA:Cho, NAA:Cr or Cho:Cr ratios with relation 
to the severity of IUGR (p=0.257, 0.414 and 0.302 respectively). 
 
P=0.257 
240 
 
 
P=0.414 
 
P=0.302 
 
Figure 72 Metabolite Ratios in IUGR Fetuses, with Varying Disease Severity 
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5.4.1.7 Outcome Parameters Echo time 136ms 
The details of delivery parameters of both IUGR and appropriately grown fetuses with 
interpretable spectra can be seen in Table 16.  All fetuses categorised as appropriately grown, 
demonstrated no evidence of growth restriction at subsequent ultrasound scans and had 
birthweights greater than the 10th centile.  Fetuses categorised as growth restricted all had 
birthweights less than the 10th centile, supporting the antenatal diagnosis of IUGR. 
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Parameter IUGR Appropriately Grown Significance 
Number of Patients 19 31  
Gestation at Delivery 
Range 
Median 
 
21
+2
-37
+4 
32
+0
 
35
+6
-43
+0
 
39
+5
 
p<0.001 
Sex of Infant 
Girls 
Boys 
Undetermined 
 
74% 
21% 
5% 
 
48% 
52% 
0% 
Not significant 
Birthweight Centile 
Range 
Median 
 
<0.01-9 
<0.01 
 
11-99 
44.0 
 
p<0.001 
Complications in Perinatal Period 
Livebirth 
Intrauterine Death 
Neonatal Death 
Admissions to Neonatal Unit 
Intraventricular Haemorrhage 
Sepsis 
Respiratory Distress 
Necrotising Enterocolitis 
Uncomplicated Neonatal Course 
 
15 
3 
1 
10 
2 
2 
9 
1 
2 
 
31 
0 
0 
0 
0 
0 
0 
0 
0 
 
 
p<0.001 
Table 16 Outcome Parameters of Fetuses with Interpretable Spectra Echo Time 136ms 
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5.4.1.8 Assessment of Metabolite Ratios in IUGR Fetuses with Poor Outcome Echo time 
136ms 
As can be seen in Table 16, 3 fetuses had an intrauterine death and one fetus a neonatal death.  
Numbers are too small for statistical analysis.  However, the scattergraphs below demonstrate 
the NAA:Cho, NAA:Cr and Cho:Cr ratios in fetuses that had a subsequent perinatal death or 
neonatal death compared with all other IUGR fetuses. 
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Figure 73 NAA:Cho and NAA:Cr ratios in IUGR Fetuses with Different Outcomes 
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5.4.1.9 Assessment of IUGR Fetuses with Pregnancies Complicated by Pre-eclampsia, 
Echo Time 136ms 
From the IUGR fetuses, 9 pregnancies were complicated by pre-eclampsia and 12 did not 
develop pre-eclampsia.  There was no statistical difference in NAA:Cho, NAA:Cr or Cho:Cr 
ratios between these groups (p=0.993, 0.515 and 0.870 respectively).  Only two pregnancies 
of the appropriately grown fetuses became complicated by pre-eclampsia so it was not 
possible to determine the effect on metabolite ratios. 
 
5.4.1.10 Lactate Detection in IUGR and Appropriately Grown Fetuses Echo Time 136ms 
8 fetuses had lactate present: 4, of these were appropriately grown and 4 were growth 
restricted.  The details of these 8 fetuses can be seen in Table 17. 
Fetus IUGR 
Gestation at 
1HMRS 
Gestation at 
Delivery 
Outcome 
Perinatal 
Complications 
1 No 24
+6
 43
+0
 Livebirth None 
2 No 25
+0
 37
+0
 Livebirth None 
3 No 29
+5
 36
+4
 Livebirth None 
4 No 37
+5
 37
+5
 Livebirth None 
5 Yes 
Raised PI 
27
+0
 34
+2
 Livebirth None 
6 Yes 
Absent End 
Diastolic Flow 
20
+3
 21
+2
 
Intrauterine 
Death 
 
7 Yes 
Raised PI 
32
+2
 37
+4
 Livebirth None 
8 Yes 
Absent End 
Diastolic Flow 
32
+0
 32
+0
 Livebirth 
Neonatal Unit 
Admission.No 
further 
complications 
Table 17 Outcome of Fetuses with Lactate Present 
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Due to the fact that only 4 growth restricted and 4 appropriately grown fetuses had lactate 
present and the scans took place at different gestational ages it was not feasible to compare 
metabolite ratios between the two groups.  However, there did not appear to be any 
correlation between the presence of lactate in IUGR fetuses and disease severity. 
 
The graphs below identify the NAA:Cho and NAA:Cr ratios of fetuses with lactate present in 
comparison with all other appropriately grown and growth restricted fetuses.   
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Figure 74 NAA:Cho and NAA:Cr Ratios in Fetuses with Lactate Present 
 
5.4.2 Echo Time 270ms 
5.4.2.1 Spectral Acquisition 
28 fetuses with evidence of intrauterine growth restriction (gestational age 20
+3
 to 35
+0 
weeks, 
median 27
+6
) and 45 appropriately grown fetuses (gestational age 22
+0
 to 38
+6
 weeks, median 
29
+5
) were included.  Two appropriately grown and two IUGR fetuses were scanned twice 
during gestation. 
 
At the time of imaging all growth restricted fetuses with interpretable spectra had an 
estimated fetal weight less than the 10th centile and evidence of cerebral redistribution (MCA 
dopplers lower than the 5th centile), 6 had a raised pulsatility index (greater than the 95th 
centile), 14 had absent end diastolic flow and 0 had reversed end diastolic flow on umbilical 
artery dopplers.  
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64% of spectra obtained were suitable for analysis.  29 interpretable spectra were obtained 
from appropriately grown control fetuses (22
+0
 to 37
+5
 weeks gestation, median 31
+3
) and 20 
spectra from IUGR fetuses (20
+3
 to 35
+0
 weeks gestation, median 27
+2
).  The remaining 
spectra were uninterprettable due to excessive fetal motion. 
 
NAA, choline and creatine were identified in all fetuses.  It was not possible to reliably 
identify lactate at an echo time of 270ms as the spectrum was too noisy.  An example is 
shown in Figure 75.  This fetus had a clear lactate present at 136ms (see Figure 69) but it was 
hard to determine at the echo time of 270ms. 
 
 
Figure 75 Fetal Spectra from a Control Pregnancy at an Echo Time of 270ms.  
Resonances are seen for choline (3.2ppm), creatine (3.0ppm) and NAA (2.0ppm).  No 
Lactate Peak is Evident. 
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5.4.2.2 Maternal Demographics of Fetuses with Interpretable Spectra Echo time 270ms 
Maternal demographics of fetuses with interpretable spectra at an echo time of 270ms are 
shown in Table 18. 
Maternal Characteristic IUGR Appropriately Grown Significance 
Age 
Range 
Median 
 
24-40 
32 
 
18-41 
33 
Not significant 
BMI 
Range 
Median 
 
18.5-36 
24.3 
 
17-33 
22 
Not Significant 
Parity 
0 
1 
2 
3 
>3 
 
53% 
32% 
15% 
0% 
 
57% 
35% 
8% 
0% 
Not significant 
Ethnicity 
Caucasian 
Asian 
South east asian 
Afro-carribean 
African 
Other 
 
48% 
21% 
6% 
15% 
10% 
0% 
 
63% 
15% 
11% 
8% 
3% 
0% 
Not significant 
 
Table 18 Maternal Demographics of Fetuses with Interpretable Spectra at an Echo 
Time of 270ms 
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5.4.2.3 Metabolite Ratios in Appropriately Grown Fetuses Echo Time 270ms 
From the appropriately grown fetuses, linear regression analysis demonstrated that the 
NAA:Cho ratio increased with advancing gestation (p=0.008) and that the Cho:Cr ratio 
decreased with increasing gestation (p=0.029).  Statistical significance was not reached for 
the NAA:Cr ratio (p=0.477) ( Figure 76). 
 
 
p= 0.008 
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p= 0.029 
 
 
p=ns 
 
 
Figure 76 NAA:Cho, Cho:Cr and NAA:Cr Ratios Varying with Gestation in 
Appropriately Grown Fetuses, the Mean and 95% Confidence Intervals are Highlighted 
at an Echo Time of 270ms 
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5.4.2.4 Differences in Metabolite Ratios Depending on Fetal and Maternal Parameters in 
Appropriately Grown Control Fetuses Echo Time 270ms 
Within the appropriately grown fetuses, differences in metabolite ratios with various fetal and 
maternal parameters were assessed.  There was no statistical difference in any metabolite 
ratio for: sex of infant, maternal ethnicity, maternal age, maternal BMI (see Table 19). 
 
Parameter 
NAA:Cho        p-
value 
NAA:Cr          p-
value 
Cho:Cr           p-
value 
Sex of Infant 0.409 0.459 0.588 
Maternal Ethnicity 0.954 0.603 0.536 
Maternal Age 0.597 0.617 0.435 
Maternal BMI 0.931 0.122 0.441 
 
Table 19 Maternal and Fetal Demographics of Fetuses with Interpretable Spectra at an 
Echo Time of 270ms 
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5.4.2.5 Differences in Metabolite Ratios between IUGR and Appropriately Grown Fetuses 
Echo Time 270ms 
The NAA:Cho and NAA:Cr ratios corrected for gestation were significantly lower (p= 
<0.001 and p=0.023 respectively) in IUGR fetuses than in appropriately grown fetuses.  
There was no significant differences between the AGA and IUGR groups for the Cho:Cr ratio 
(0.765). 
  
 
 
p=< 0.0001 
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p=0.023 
 
 
P=0.765 
 
 
Figure 77 Metabolite Ratios for NAA:Cho, NAA:Cr and Cho:Cr in Appropriately 
Grown and Growth Restricted Pregnancies at an Echo Time of 270ms 
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5.4.2.6 Differences in Metabolite Ratios Depending on Severity of IUGR Echo Time 270ms 
Although numbers were small, subgroup analysis was performed comparing the NAA:Cho 
and NAA:Cr ratios in IUGR patients with evidence of cerebral redistribution and high PI and 
those with absent or reversed end diastolic flow.  6 fetuses had raised PI and cerebral 
redistribution and 14 had absent or reversed end diastolic flow. 
 
There was no significant difference in the NAA:Cho, NAA:Cr or Cho:Cr ratios with relation 
to the severity of IUGR (p=0.335, 0.605 and 0.073 respectively). 
 
 
p=0.335 
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p= 0.605 
 
 
p=0.073 
 
 
Figure 78 Metabolite Ratios in IUGR Fetuses with Varying Disease Severity at an Echo 
Time of 270ms 
 
5.4.2.7 Outcome Parameters of Fetuses with Interpretable Spectra Echo Time 270ms 
Outcome parameters of fetuses with intpretable spectra at an echo time of 270ms can be seen 
in Table 20 below.  
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Parameter IUGR Appropriately Grown Significance 
Number of Patients 19 28  
Gestation at Delivery 
Range 
Median 
 
 
21
+2
-37
+4
 
30
+1
 
 
35
+6
-43
+0
 
39
+2
 
 
p<0.001 
Sex of Infant 
Girls 
Boys 
Undetermined 
 
25% 
55% 
5% 
 
46% 
54% 
0% 
Not significant 
Birthweight Centile 
Range 
Median 
 
<0.001-9 
<0.001 
 
11-99 
46.5 
 
p<0.001 
Complications in Perinatal Period 
Livebirth 
Intrauterine Death 
Neonatal Death 
Admissions to Neonatal Unit 
Intraventricular Haemorrhage 
Sepsis 
Respiratory Distress 
Necrotising Enterocolitis 
Uncomplicated Neonatal Course 
 
13 
5 
1 
12 
1 
2 
9 
1 
2 
 
28 
0 
0 
0 
0 
0 
0 
0 
28 
 
 
p<0.001 
Table 20 Outcome Parameters of Fetuses with Interpretable Spectra at an Echo Time of 
270ms 
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5.4.2.8 Assessment of Metabolite Ratios in IUGR Fetuses with Poor Outcome Echo Time 
270ms 
As can be seen in Table 20 5 fetuses had an intrauterine death and one fetus had a neonatal 
death.  Numbers are too small for statistical analysis.  However, the scattergraphs below 
demonstrate the NAA:Cho, NAA:Cr and Cho:Cr ratios in fetuses that had a subsequent 
perinatal death compared with all other IUGR fetuses. 
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Figure 79 NAA:Cho, NAA:Cr and Cho:Cr Ratios in IUGR Fetuses with Differing 
Outcome 
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5.4.2.9 Assessment of IUGR Fetuses with Pregnancies Complicated by Pre-eclampsia Echo 
Time 270ms 
8 pregnancies with IUGR fetuses were complicated by pre-eclampsia and 12 did not have 
pre-eclampsia.  There was no statistical difference between growth restricted pregnancies 
with and without pre-eclampsia for the NAA:Cho ratios p=0.147 or Cho:Cr ratios p=0.968.  
At an echo time of 270ms pregnancies complicated by pre-eclampsia had stastically lower 
levels of NAA:Cr p=0.045. 
 
Both echo times of 270ms and 136ms resulted in the same metabolite ratio trends for NAA, 
Choline and Creatine.  Lactate detection however proved to be optimal at an echo time of 
136, this is due to the fact that lactate is inverted at 136ms but positive at 270 which helps to 
distinguish it from lipids and other macromolecules. 
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5.4.3 Echo time 42ms 
5.4.3.1 Spectral Acquisition Echo Time 42ms 
28 fetuses with evidence of intrauterine growth restriction (gestational age 20
+4
 to 35
+0 
weeks, 
median 27
+6
) and 47 appropriately grown fetuses (gestational age 22
+0
 to 38
+6
 weeks, median 
29
+5
) were included.  Two appropriately grown and two IUGR fetuses were scanned twice 
during gestation. 
 
At the time of imaging all growth restricted fetuses with interpretable spectra had an 
estimated fetal weight less than the 10th centile and evidence of cerebral redistribution (MCA 
dopplers lower than the 5th centile). 5 had a raised pulsatility index (greater than the 95th 
centile), 16 had absent end diastolic flow and 1 had reversed end diastolic flow on umbilical 
artery dopplers.  
 
65% of spectra obtained were suitable for analysis.  27 interpretable spectra were obtained 
from appropriately grown control fetuses (23
+0
 to 37
+5
 weeks gestation, median 29
+6
) and 24 
spectra from IUGR fetuses (20
+3
 to 35
+0
 weeks gestation, median 27
+6
).  The remaining 
spectra were uninterprettable. 
 
Choline, creatine and Myo-inositol were identified in all fetuses.  An example of a typical 
fetal spectrum produced can be seen in Figure 80.  It was not possible to identify NAA at the 
echo time of 42ms due to contamination from other metabolite peaks (see Figure 80). 
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Figure 80 Example of a Fetal Spectra from a Control Pregnancy at 32 Weeks Gestation 
at an Echo Time of 42ms.  Resonances can be seen for Myo-inositol 3.5ppm, choline 
3.2ppm and creatine 3.0ppm.  The NAA Peak at 2.0ppm is Contaminated from Signals 
from other Metabolites and is Un-interpretable 
 
5.4.3.2 Maternal Demographics of Fetuses with Interpretable Spectra Echo time 42ms 
Maternal demographics of fetuses with interpretable spectra at an echo time of 42ms can be 
seen in Table 21 below. 
  
Myo-ins 
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Maternal Characteristic IUGR Appropriately Grown Significance 
Age 
Range 
Median 
 
22-44 
31.5 
 
17-44 
32.5 
Not significant 
BMI 
Range 
Median 
 
18.5-36 
24.5 
 
18.5-32 
22.3 
Not significant 
Parity 
0 
1 
2 
3 
>3 
 
12 
6 
3 
1 
0 
 
17 
7 
2 
0 
0 
Not significant 
Ethnicity 
Caucasian 
Asian 
South East Asian 
Afro-carribean 
African 
Other 
 
11 
5 
1 
3 
0 
2 
 
16 
4 
1 
2 
1 
2 
Not significant 
 
Table 21 Maternal Demographics of Fetuses with Interpretable Spectra at an Echo 
Time of 42ms 
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5.4.3.3 Metabolite Ratios in Appropriately Grown Fetuses Echo time 42ms 
From the appropriately grown fetuses, linear regression analysis demonstrated that the 
Cho:Cr ratio and the Myo-ins:Cr ratio decreased with advancing gestation (p=0.001 and p= 
<0.001 respectively).  Statistical significance was not reached for the Myo-ins:Cho ratio, 
although this was extremely borderline (p=0.052) (Figure 81 below). 
 
 
p=0.001 
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p=<0.001 
 
 
p=ns 
 
 
Figure 81 Cho:Cr, Myo-ins:Cr and Myo-ins:Cho Ratios in Appropriately Grown 
Fetuses at an Echo Time of 42ms 
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5.4.3.4 Differences in Metabolite Ratios Depending on Fetal and Maternal Parameters in 
Appropriately Grown Control Fetuses Echo Time 42ms 
Within the appropriately grown fetuses, differences in metabolite ratios with various fetal and 
maternal parameters were assessed.  There was no statistical difference in any metabolite 
ratio for: sex of infant, maternal ethnicity, maternal age, maternal BMI (see Table 22). 
 
Parameter Cho:Crp-value Myo-ins:Crp-value 
Myo-ins:Chop-
value 
Sex of Infant 0.725 0.868 0.362 
Maternal Ethnicity 0.330 0.621 0.665 
Maternal Age 0.411 0.083 0.280 
Maternal BMI 0.673 0.950 0.671 
 
Table 22 Alteration of Metabolite Ratios with Maternal and Fetal Characteristics in 
Appropriately Grown Fetuses at an Echo Time of 42ms 
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5.4.3.5 Differences in Metabolite Ratios between IUGR and Appropriately Grown 
Fetuses Echo Time 42ms 
There was no significant differences between the AGA and IUGR groups for the Cho:Cr 
ratio, Myo-ins:Cr or the Myo-ins:Cho ratio (p=0.168, 0.285 and 0.807 respectively). 
 
 
 
 
p= 0.168 
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p=0.285 
 
 
p=ns 
 
 
 
Figure 82 Cho:Cr, Myo-ins:Cho and Myo-ins:Cr Ratios in Appropriately Grown and 
Growth Restricted Fetuses at an Echo Time of 42ms 
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5.4.3.6 Assessment of Metabolite Ratios in IUGR Fetuses Based on Disease Severity Echo 
Time 42ms 
There was no significant difference in metabolite ratios when IUGR was categorised on the 
basis of antenatal Doppler assessment (positive end diastolic flow versus absent or reversed 
end diastolic flow). 
 
 
 
p = 0.304 
 
270 
 
 
p = 0.201 
 
 
p = 0.ns 
 
 
Figure 83 Metabolite ratios in IUGR fetuses with varying degrees of severity, echo time 
42ms 
5.4.3.7 Outcome Parameters of Fetuses with Interpretable Spectra Echo Time 42ms 
The outcome parameters of fetuses with an interpretable spectra at an echo time of 42ms can 
be seen in Table 23 below. 
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Parameter IUGR Appropriately Grown Significance 
Number of Patients 22 26  
Gestation at Delivery 
Range 
Median 
 
21
+2
-37
+4
 
30
+4
 
35
+6
-43
+0
 
39
+2
 
p<0.001 
Sex of Infant 
Girls 
Boys 
Undetermined 
 
17% 
54% 
8% 
 
50% 
50% 
0% 
p=0.035 
Birthweight Centile 
Range 
Median 
 
<0.001-9 
<0.01 
 
13-99 
51 
p<0.001 
Complications in Perinatal Period 
Livebirth 
Intrauterine Death 
Neonatal Death 
Admissions to Neonatal Unit 
Intraventricular Haemorrhage 
Sepsis 
Respiratory Distress 
Necrotising Enterocolitis 
Uncomplicated Neonatal Course 
 
17 
5 
2 
14 
2 
1 
10 
3 
3 
 
26 
0 
0 
0 
0 
0 
0 
0 
26 
p<0.001 
 
Table 23 Outcome of IUGR Fetuses with Interpretable Spectra at an Echo Time of 
42ms 
272 
 
5.4.3.8 Alteration of Metabolite Ratios with Outcome at an Echo time of 42ms 
As can be seen in Table 23 5 fetuses had an intrauterine death and two fetuses a neonatal 
death.  Numbers are too small for statistical analysis.  However, the scattergraphs below 
demonstrate the Myo-ins:Cho, Myo-ins:Cr and Cho:Cr ratios in fetuses that had a subsequent 
perinatal death compared with all other IUGR fetuses. 
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Figure 84 Metabolite Ratios with Varying Outcomes in IUGR Fetuses, Echo Time 42ms 
5.4.3.9 Assessment of IUGR Fetuses with Pregnancies Complicated by Pre-eclampsia Echo 
Time 42ms 
12 pregnancies with IUGR fetuses were complicated by pre-eclampsia and 16 did not have 
pre-eclampsia.  There was no statistical difference between growth restricted pregnancies 
with and without pre-eclampsia for the Myo-ins:Cho p=0.231, Myo-ins:Cr p=0.744 or the 
Cho:Cr ratio p=0.318. 
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5.4.4 Non Neural Tissue 
5.4.1.1 Placenta 
The placenta was assessed in 7 appropriately grown and 7 growth restricted fetuses.  
However due to excessive noise within the spectra it was not possible to identify any 
metabolite peaks. 
 
Fetus IUGR 
Gestation at 
1HMRS 
Gestation at 
Delivery 
Outcome 
1  no 24
+5
 43
+0
 livebirth 
2  no 25
+0
 37
+0
 livebirth 
3  no 24
+4
 41
+0
 livebirth 
4  no 23
+4
 41
+5
 livebirth 
5  no 27
+0
 39
+5
 livebirth 
6  no 36
+3
 40
+3
 livebirth 
7 no 27
+6
 38
+0
 livebirth 
8  yes 23
+6
 25
+5
 intrauterine death 
9  yes 28
+0
 29
+6
 livebirth 
10  yes 28
+4
 36
+6
 livebirth 
11 yes 35
+0
 36
+6
 livebirth 
12  yes 22
+0
 23
+5
 intrauterine death 
13 yes 30
+4
 34
+1
 livebirth 
14 yes 26
+3
 28
+4
 intrauterine death 
 
Table 24 Details of Fetuses with Placental Spectra 
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An example of a spectrum for a placenta, echo time 136ms can be seen in Figure 85. 
 
 
Figure 85 Example of a Placental Spectra Echo Time 136ms. 
 
5.4.1.2 Liver 
Spectra at an echo time of 136 were taken from 2 IUGR and 2 appropriately grown fetuses.  
The details of these fetuses are illustrated in Table 25.   
 
Fetus IUGR 
Gestation at 
1HMRS 
imaging 
Gestation at 
Delivery 
Birth weight 
centile at 
delivery 
Outcome 
1  no 23
+4
 41
+5
 13 livebirth 
2 no 36
+0
 39
+2
 24 livebirth 
3 yes 32
+4
 33
+0
 <0.1 livebirth 
4 yes 28
+0
 29
+6
 <0.1 livebirth 
 
Table 25 Details of Fetuses with Liver Spectra 
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It was not possible to detect any metabolites in any of these 5 spectra.  An example of a liver 
spectra is given (see Figure 86). 
 
 
Figure 86 Example of a Liver Spectra, Echo Time 136ms 
 
5.4.1.3 Amniotic Fluid 
3 patients had spectra at 136ms taken from a sample of amniotic fluid. 
 
Fetus IUGR 
Gestation at 
1
HMRS 
Gestation at 
Delivery 
Outcome 
1 no 36
+1
 40
+1
 livebirth 
2 no 33
+5
 40
+2
 livebirth 
3 no 27
+2
 39
+2
 livebirth 
 
Table 26 Details of Patients with Amniotic Fluid Spectra  
 
277 
 
No metabolites were evident in any of them.  An example of such a spectra can be seen in 
Figure 87. 
 
 
Figure 87 Example of an Amniotic Fluid Spectra, Echo Time 136ms 
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5.5 DISCUSSION 1HMRS COMPONENT OF THE STUDY 
 
This study has demonstrated that spectral acquisition is a feasible, reproducible technique for 
the metabolic assessment of the fetal brain in utero.  Spectra were successfully obtained from 
67% of fetuses imaged at an echo time of 136ms, 64% of fetuses imaged at 270ms and 65% 
at 42ms.  The success of spectral acquisition was not affected by the gestational age at the 
time of imaging. 
 
Peaks were identified in all fetuses for NAA, Cho and Cr between 20
+3
 and 37
+5
 weeks 
gestation at echo times of both 360ms and 270ms.  At an echo time of 42ms peaks for Cho, 
Cr and Myo-ins were present in all fetuses.  At this echo time it was not possible to identify 
and quantify NAA as the peak was contaminated with signals from other metabolites. 
 
5.5.1 Alteration in Metabolite Ratios with Gestational Age in Appropriately Grown 
Control Fetuses 
In accordance with a previous study, this study has demonstrated that in appropriately grown 
fetuses NAA:Cho ratios increase at echo times of both 136ms and 270ms and Cho:Cr ratios 
decrease from 24
+6
 to 37
+5
 weeks gestation at echo times of 136ms, 270ms and 42ms [249].  
Kok et al, in a group of 35 fetuses found that the NAA:Cr ratio increased and Cho:Cr ratios 
decreased between 30 and 41 weeks gestation.  This group also found that NAA:Cr ratios 
decreased with advancing gestation; however, no alteration in the NAA:Cr ratio during 
gestation using a TE of either 136ms or 270ms was found in this study.  This may be due to 
the fact that the regions of interest sampled within the brain are not comparable between the 
studies and the proportions of grey and white matter sampled are likely to differ: in Kok’s 
study the brain closest to the receiver coil was sampled , whereas this current study sampled 
from a central region of interest.  The NAA:Cho ratio may increase with gestation due to 
increasing NAA levels (attributable the development of dendrites and synapses as well as 
oligodendrocyte proliferation and differentiation) and relatively constant or slightly 
decreasing choline levels (attributable to the high levels required for cell membrane 
formation[251] or increased myelination in late pregnancy[249]).  No alteration in the 
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NAA:Cr ratio may be attributable to NAA levels increasing with gestation but creatine levels 
increasing in proportion. 
 
At an echo time of 42ms the Myo-ins:Cho and Myo-ins:Cr ratio both decreased with 
increasing gestation in the appropriately grown control fetuses.  This is likely to be reflective 
of a decrease in absolute levels of Myo-ins accompanied by a relatively smaller decrease in 
Cho levels and an increase in Cr levels.  Kok et al did assess the difference between Myo -
ins:Cho ratios in a group of 10 hydrocephalic and 36 appropriately grown control fetuses, 
finding a difference between the two groups.  They did not specifically comment on whether 
Myo-ins:Cr ratios decreased with statistical significance with increasing gestation, but a 
reduction is evident from their graph.  Cho:Cr ratios have been found to decrease with 
gestation in other fetal studies at 42ms[249]. 
 
Myo-ins has been shown to be the predominant resonance in the brain spectrum at a short 
echo time e.g. before 28 weeks.  Estimation of absolute levels of Myo-ins in the fetal brain 
have been found to decrease between 22 and 39 weeks by Girard et al (calculated based on 
assumptions of spin relaxation times and brain tissue water content)[251].  This gestational 
range is similar to the one encompassed by this study.  It has been suggested that the high 
levels of Myo-ins early in gestation are attributable in part to the high density of glial cells at 
22 weeks which then progressively decreases [302]. 
 
In contrast to previous fetal studies lactate was detected in the developing brain of 4 control 
fetuses.  The role of lactate in the developing brain has proved controversial.  Lactate is the 
end product of anaerobic glycolysis and animal models have demonstrated that lactate 
accumulates in the fetal brain in cases of acute hypoxia[283].  Human neonates are also 
known to produce lactate in response to hypoxic insults, the level of which correlates with 
poorer neurological outcome[252].  The woman whose fetus had lactate present at 37
+5
 weeks 
gestation ruptured her membranes shortly after 
1
HMRS Imaging and retrospectively reported 
that she had begun to feel tightenings during the scan.  It is therefore likely that she was in 
early labour and transient hypoxaemia may have been responsible for the elevated levels and 
detection of cerebral lactate.  Although every effort was taken to ensure that women were 
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positioned in the scanner with a left lateral tilt in order to avoid compression of the inferior 
vena cava (IVC), it is possible that these four women may have become more supine during 
the scan resulting in vessel compression and compromising fetal oxygenation levels and, 
hence, causing transient hypoxaemia.  Higher fetal oxygenation levels have previously been 
reported in the left lateral position[311]. 
 
However, lactate has also been implicated as a fuel source in the immature brain [285-286].  
Small amounts of lactate have been detected in the apparently normal preterm neonatal brain, 
levels decreasing with advancing gestation[287].  Leth et al performed MRS on 13 
appropriate for gestational age and 10 small for gestational age neonates between 28 and 41 
weeks gestation.  Lactate was detected in all 10 small for gestational age but also 10 of 13 
appropriate for gestational age infants.  Brain lactate ranged from 0.9 to 2.4mmol/kg.  No 
long term follow up was reported in this study[303]; however, Roelants-Van Rijn assessed 26 
appropriately grown and 14 small for gestation preterm neonates: they again detected lactate 
in both groups.  Follow up to 2 years of age was performed and no differences in the 
Griffiths’ developmental quotient were noted[276].   
 
The majority of previous 
1
HMRS studies in healthy fetuses have been undertaken after 30 
weeks gestation[249-250].  Only one study assessed fetuses prior to 30 weeks and maternal 
sedation with flunitrazepam was used[251].  It has previously reported that neonates sedated 
with Pentobarbitol had lower ratios of Lac:Cho and Lac:NAA on brain 
1
HMRS, which was 
purported to be due to a combination of the relative importance of glycolytic energy 
generation in the immature brain coupled with reduced glycolysis which is known to be 
produced by Pentobarbitol[312].  Animal studies have also demonstrated that diazepam can 
provide neuroprotection against oxygen/glucose deprivation-induced injury in rat cortical 
brain slices[313].  The effects of maternal sedation on fetal spectra have not been investigated 
to date.  It is possible that lactate was detected in the apparently normally developing fetal 
brain in this study partly as a consequence of fetuses of a lower gestational age being scanned 
(two of the cases where lactate was detected were less than 28 weeks gestation) and partly 
due to the fact that no maternal sedation was used.  However, it is unclear why lactate was 
present in sufficient levels to be detected in some fetuses but not in others. There was no 
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correlation of fetuses with lactate present with particularly abnormal ratios of NAA:Cho or 
NAA:Cr in comparison with other appropriately grown fetuses.  
 
No difference in any metabolite ratios were found to occur between male or female fetuses, 
or those from different ethnic backgrounds.  All appropriately grown fetuses had a normal 
perinatal period. 
 
5.5.2 Alterations in Metabolite Ratios between Appropriately Grown and Growth 
Restricted Fetuses 
We have demonstrated an alteration in brain metabolism in growth restricted fetuses 
compared with appropriately grown controls using an optimized MRS approach; ratios of 
NAA:Cho and NAA:Cr were significantly lower in growth restricted fetuses than in the 
control population when corrected for gestation at both 136ms and 270ms.  No alteration in 
the Cho:Cr ratios between appropriately grown and growth restricted fetuses was noted at 
either 136ms, 270ms or 42ms. No difference in Myo-ins:Cho or Myo-ins:Cr ratios were 
evident between the two groups at an echo time of 42ms. 
 
5.5.2.1 NAA 
Due to the fact that the Cho:Cr ratios were unchanged between the two groups, the most 
likely explanation for the reduction in NAA:Cho and NAA:Cr ratios is a decrease in levels of 
NAA.  Due to the fact that there was no difference in metabolite ratios, depending on the 
severity of IUGR, these changes appear to occur early in the evolution of the condition. 
 
Previous neonatal studies have not detected a difference in cerebral metabolism between pre-
term small for gestational age and appropriately grown pre-term neonates, specifically 
assessing NAA:Cho, Lac:Cho, Myo-inositol:Cho and Glutamate/glutamine/γ-aminobutyric 
acid:Cho ratios[276].  However, their infants were only described as small for gestational 
age, a statistical definition of birthweight less than the 10
th
 centile, and it is uncertain whether 
these neonates also had evidence of placental insufficiency as no further information was 
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given.  The ex utero environment is also extremely different from the in utero environment 
and this is likely to affect brain metabolism. 
 
The observed reduction in NAA:Cho and NAA:Cr levels in IUGR fetuses may be attributable 
to a reduction in neuronal viability.  However, no overt structural lesions were identified on 
MRI in the IUGR fetuses.  To date no studies in human infants have assessed the 
development of myelination in infants that were growth restricted in utero and did not sustain 
overt white matter injury.   
 
It is also possible, given its association with oligodendrocytes, that a reduction in the 
NAA:Cho and NAA:Cr ratios found in this study may be reflective of delayed rather than 
compromised white matter development.  A rat model has shown that the most critical period 
of myelination when the most rapid changes take place occurs between birth and postnatal 
day 21[314], which encompasses the equivalent human gestational range included in this 
study:  birth/day 0 in the rat is equivalent to 32-34 weeks of fetal gestation and 12 to 13 days 
in the rat is equivalent to a full term neonate[315].  Human studies have also illustrated that 
the most rapid changes occurring during the myelination process occurs between 
midgestation and the end of the second postnatal year[255].  Lower levels of NAA may 
therefore be reflective of an alteration in the myelination process.  A rat model of IUGR 
demonstrated that pups with moderate growth restriction showed features of white matter 
damage, including mild astrogliosis, inflammatory microgliosis and loss of immature 
oligodendrocytes leading to a transient delay in myelination.  Myelination was then restored 
after postnatal day 14 associated with increased density of O4-immunoreactive 
oligodendrocytes and the proliferation of immature oligodendrocytes[155].  In a sheep model 
of IUGR, a reduction in growth and myelination of optic nerve axons observed at term did 
not persist at 2.3 years; again suggesting delayed rather than compromised 
development[154]. To date no studies in human infants have assessed neonates that were 
growth restricted in utero addressing whether postnatal myelination appears delayed and then 
improves.  However, this explanation does not fully address why IUGR fetuses are at risk of 
increased neurodevelopmental sequelae in the absence of additional insults such as infection.  
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The most likely mechanism for low NAA:Cho and NAA:Cr ratios in IUGR fetuses is 
impaired neuronal mitochondrial function/metabolism resulting in decreased production of 
NAA.  NAA is synthesized in neuronal mitochondria from acetyl-CoA and aspartate by N 
Acetyltransferase (Asp-NAT); a process which is dependent on the mitochondrial energy 
state[267].  NAA is then transported to the neuronal cytoplasm and is transferred to 
oligodendrocytes[268].  At this point the acetate portion is used for myelin synthesis and the 
aspartate portion is used for energy production or protein synthesis.  
 
The increase of NAA during the third trimester is likely to reflect development of neuronal 
mitochondria. Indeed, during the corresponding developmental period in rodents there was an 
increased number of mitochondria per cell, mitochondrial proteins, respiratory enzyme 
content per mitochondrion and mitochondrial matrix density as well as crystal volume [316-
319]. 
 
There is evidence to indicate that adaptation to chronic intrauterine hypoxia occurs in IUGR 
fetuses by an increase in glycolytic capacity.  Hypoxia inducible factors transcriptionally 
regulate the expression of a number of genes involved in glycolysis[159].  Cerebral 
mitochondrial gene expression is also altered in growth restricted rat pups[157]; mRNA 
levels of four mitochondrial proteins were increased in IUGR rat fetuses.  The number of 
mitochondria profiles has also been found to have increased by 20% per unit area in the 
visual cortex, mitochondria appearing condensed with an increased electron density of the 
matrix[158].  These alterations may be an attempt to compensate for the reduced efficiency of 
aerobic metabolism in individual mitochondria.   
 
In addition to alterations in mitochondria, the hypoxic, acidotic, hypoglycaemic intrauterine 
environment[320] lacking in amino acids[66] associated with IUGR may result in a reduction 
in availability of acetyl-CoA[321] and aspartate[66].  They may preferentially be utilized for 
energy production as opposed to being converted into NAA.  This would lead to a decrease of 
NAA in both neurons and oligodendroglia.   
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Although numbers are small, there does not appear to be any correlation between particularly 
low NAA:Cho or NAA:Cr ratios and poor short term outcome.  At an echo time of 136ms 
NAA:Cho and NAA:Cr ratios were unchanged in IUGR fetuses with pregnancies with and 
without pre-eclampsia.  However, at an echo time of 270ms NAA:Cr ratios were significantly 
lower (p=0.045).  This may reflect an additional risk of pre-eclampsia to neuronal 
mitochondria in IUGR pregnancies, perhaps mediated by additional inflammatory cells found 
in pre-eclamptic pregnancies[40].  However, it may be an aberrant result, as numbers in the 
two groups are small at present: 8 pre-eclamptic and 12 non pre-eclamptic pregnancies.  The 
result was also unconfirmed at a shorter echo time of 136ms.  Correlations of spectroscopy 
findings with long term outcome measures such as congition will need to be performed. 
 
5.5.2.2 Myo-inositol 
Myo-ins is regarded as an astrocyte marker and is thought to play an integral role in the 
osmotic regulation of cells.  Levels have been reported to increase in acute brain injury in the 
adult brain [322] and after acute hypoxic-ischaemic injury in the neonatal brain[282].  This 
was proposed to be attributable to upregulation of the SMIT transporter following hypoxia-
ischaemia and acidosis[282].   
 
This study has demonstrated no difference in either Myo-ins:Cho or Myo-ins:Cr ratios 
between appropriately grown and growth restricted fetuses.  This may be attributable to the 
fact that IUGR is a chronic condition with preserved cerebral blood flow.  Although some 
fetuses show evidence of hypoxia and acidosis at cordocentesis, this is not inevitably the 
case[57]. 
 
Increased Myo-inositol has also been reported in chronic stage perinatal white matter injury 
(defined by either cystic or haemorrhagic lesions) in preterm infants, thought to be due to 
increased astroglia[282].  In a recent publication, Bassen et al reported a reduction in mature 
cortical astrocytes in a rabbit model of IUGR [152].  In contrast, Nitsos et al did not find a 
statistical difference in cortical astrocytes number in the guinea pig IUGR model and noted 
astrocytes proliferation in perivascular regions[153].  Differences between these findings are 
likely to be attributable to the fact that in the rabbit model, IUGR was induced in the 3
rd
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trimester by means of partial uterine artery ligation, whereas in the guinea pig model IUGR 
was induced earlier in gestation and involved complete uterine artery ligation, thus reflecting 
increased disease severity.   
 
It is becoming increasingly apparent that early and late onset IUGR have disparate 
pathophysiologies[17].  Fetuses in this 
1
HMRS study all developed IUGR prior to 34 weeks, 
which represents early onset disease.  The finding of comparable Myo-ins:Cho and Myo-
ins:Cr between appropriately grown and growth restricted fetuses is also likely to reflect the 
fact that cortical astrocyte numbers are unchanged between the two groups, in accordance 
with the findings of Nitsos et al[153].   
 
5.5.2.3 Lactate 
Lactate was detected in four IUGR fetuses.  Their outcome was variable, one having an 
intrauterine death, one was delivered preterm and was admitted to the neonatal unit, and two 
further fetuses had uncomplicated perinatal periods.   
 
No 
1
HMRS studies have been conducted in the preterm neonatal brain with evidence of true 
in utero growth restriction.  Two case reports of IUGR fetuses have previously been 
published which report the presence of lactate in the fetal brain using 
1
HMRS[307-308].  
They both hypothesised that this may be due to hypoxia related to placental insufficiency.  
However, although associated with increased susceptibility to acute perinatal hypoxic brain 
injury, IUGR is a chronic condition.  Significant hypoxia-ischaemia is required before the 
brain converts from aerobic to anaerobic metabolism. Non cerebral tissue may have lower 
thresholds for lactate generation, resulting in increased fetal blood lactate levels[323].  
Soothill et al reported mean peripheral lactate concentrations in the umbilical vein in 2
nd
 
trimester fetuses to be 1.1 +/-0.25 mmol/kg[323].  As lactate is also able to cross the 
immature blood-brain barrier, it is feasible that lactate may transfer into the brain if levels are 
higher in the blood than in the extracellular space of the brain.  Some of the brain lactate 
detected may consequently be generated from non cerebral tissue.   
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Increased cerebral lactate during hypoxia may actually be neuroprotective in growth 
restricted fetuses.  A piglet model has shown that growth restricted piglets with high brain 
lactate on 
1
HMRS had similar levels of apoptosis to normal weight piglets when exposed to 
an acute hypoxic insult.  Growth restricted piglets with lower levels of lactate had increased 
apoptotic injury[162].  This may indicate that growth restricted fetuses adapt to their 
intrauterine environment with increased glycolytic function.  Consequently the IUGR fetuses 
may mount a large response to a minor degree of hypoxia, thereby resulting in elevated levels 
of cerebral lactate. 
 
There was no correlation of fetuses with lactate present with particularly abnormal ratios of 
NAA:Cho, NAA:Cr in comparison with other IUGR fetuses.  The fact that lactate was 
identified in both growth restricted and appropriately grown fetuses implies that it is not 
simply a marker of acute hypoxia. 
 
5.5.2.4 Choline and Creatine 
Although Cho:Cr ratios are unchanged between appropriately grown and growth restricted 
fetuses it is also possible that alterations in Cho and Cr levels may be occurring.  Creatine 
constitutes high energy reserves of cells and increased levels may reflect increased 
myelination [258].  A reduction in creatine levels has been reported in acute hypoxia[265].  
However, even if a similar phenomenon occurs in chronic hypoxia associated with IUGR an 
even greater reduction in NAA levels would be required in order to result in a decreased 
NAA:Cr ratio.  Due to the fact that Cr and phosphocreatine constitute the high energy 
reserves of a cell, an increase in levels of Cr may indicate increased demand from gliosis 
and/or remyelination[264]; levels are decreased in acute hypoxic encepahlopathy[265]. 
 
A reduction in choline levels, which has been observed in some fetal studies in appropriately 
grown fetuses, has been attributed to accelerated pre-myelination in the third trimester.  
During the process of myelination phospholipids, then sphingomyelin (also containing 
choline), galactocerebrosides and glycoproteins are detected as phospholipid concentrations 
are concurrently decreased[251].  Reductions in choline levels may therefore be reflective of 
high substrate levels required for the formation of cell membranes with levels reducing as 
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incorporation of lipids has occurred.  One possible mechanism by which a reduction in NAA 
may occur in IUGR fetuses is a delay in myelination.  If this is the case choline levels may 
also be expected to be increased.  This would further accentuate the NAA:Cho ratio 
difference between IUGR and appropriately grown fetuses.  However, this is unlikely as no 
alterations in the Cho:Cr,or Myo-ins:Cho ratios were observed, and if choline levels were 
significantly deranged both Myo-ins and Cr levels would have to be altered as well. 
 
5.5.3 Limitations 
As discussed in Chapter 4, 
1
HMRS in the fetus is hampered by low signal to noise and fetal 
movement.  It is also very difficult to assess a particular area of the fetal brain, such as, 
specifically white or grey matter, partly due to the relatively large size of the voxel necessary 
to obtain sufficient signal to noise, but also due to small fetal movements which may take 
place during the spectral acquisition.  Attempts have been made to overcome this by re-
imaging the brain to identify the position of the fetus post acquisition, but small movements 
may not be accounted for in this manner. 
 
  
288 
 
5.5.4 Non neural tissue 
5.5.4.1 Placenta 
The placenta was assessed in 7 IUGR and 7 appropriately grown fetuses, however, no 
metabolites were readily identified.  Free creatine is known to be present in the placenta and 
maternal levels can influence those in the fetus[324].  Large amounts of choline are also 
delivered to the fetus via the placenta during pregnancy.  Lactate may also be present in the 
placenta as it has been proposed that the placental maternal circulation provides an efficient 
mechanism to remove excess lactate in the prenatal period[306].   
 
These metabolites may not have been detected due to the fact that the placenta is a large 
organ and metabolism within it may not be uniform.  Positioning of the voxel may have 
therefore been responsible for the results.  However, more plausible is the lack of choline, 
creatine and lactate detection was due to excess noise in the spectra rendering interpretation 
difficult. This may be caused by the large amount of blood within the placenta.  Blood 
contains large amounts of iron, which interferes with the T2 relaxation time.  Also if the 
voxel was positioned over large blood vessels the spectra may have had increased noise and it 
may have been harder to detect small amounts of lactate, choline or creatine. 
 
5.5.4.2 Liver 
Obtaining spectra from the fetal liver proved to be very difficult.  Creatine is transported 
through the placenta from the maternal circulation and studies on animal models have 
demonstrated free phosphatidylcholine and phosphorylcholine are present in the fetal 
liver[325].  Despite this no choline compounds or creatine were detected in the 4 livers 
assessed.  This is probably due to the small size of the fetal liver and poor signal to noise.  
Another group did assess the fetal liver with a short echo time.  They detected the presence of 
lipids but no other resonances[293]. 
 
5.5.4.3 Amniotic fluid 
Lecithin is a choline containing compound and consequently produces a resonance at 3.2ppm 
on 
1
HMRS.  Other fetal studies have demonstrated its presence in some fetuses during the 
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third trimester but not all, despite having surfactant:albumin ratios within the normal range 
(indicating sufficient lung maturity)[304]. 
 
The three fetuses whose amniotic fluid was assessed in this study were 27
+5
, 33
+2
 and 36
+1
 
weeks gestation.  It is possible that lecithin was not present at this stage of gestation; 
however, the spectrum produced was very noisy and difficult to interpret.  Further assessment 
of large numbers of pregnancies will be required to establish whether detection is feasible. 
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5.6 Conclusions 
 
This study has demonstrated that 
1
HMRS is a feasible technique in the fetus to assess the 
metabolic profile of the developing brain.  NAA:Cr ratios increase and Cho:Cr, Myo-ins:Cr 
ratios decrease with increasing gestation in appropriately grown fetuses.  NAA:Cho and 
NAA:Cr ratios are lower in growth restricted fetuses, which may be reflective of 
mitochondrial impairment.  Lactate has been identified in the fetal brain in both growth 
restricted and appropriately grown fetuses, indicating that it is not simply a marker of acute 
hypoxia.  It has been possible to identify lactate in the fetal placenta, but spectra are noisy 
and of poor quality which is likely to be due to the high concentration of blood within the 
placenta.  Spectra from the fetal liver and amniotic fluid were difficult to interpret. 
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CHAPTER 6 – ASSESSMENT OF THE RELATIONSHIP BETWEEN CEREBRAL 
VOLUME BLOOD FLOW AND THE METABOLIC PROFILE OF THE 
DEVELOPING BRAIN  
 
6.1 INTRODUCTION 
 
Chapter 3 has demonstrated, in accordance with previous studies, that cerebral volume blood 
flow is maintained and is indeed increased in IUGR fetuses in comparison to the 
appropriately grown control group.  Chapter 5 has revealed that metabolite ratios are 
deranged in IUGR fetuses: NAA:Cho and NAA:Cr ratios being significantly reduced. 
 
Abrupt increases in cerebral flow have been shown to be detrimental in adults following left 
ventricular assist device implantation.  Abrupt restoration of cerebral flow has been thought 
to overwhelm cerebral auto regulatory capacity which may increase the risk for haemorrhage 
or cerebral oedema[326].  However, this hyper-perfusion is on a background of chronically 
hypo-perfused cerebral vasculature.  Hyper-perfusion injuries have also been shown to be 
associated with a period of energy failure following acute hypoxia in neonates[327].  IUGR, 
is, however, a more chronic condition with cerebral hypoperfusion occurring as a peri-
terminal event as opposed to a precursor to hyper-perfusion.  It is also unknown whether this 
increased volume blood flow is conferring some degree of neuroprotection or may in part be 
responsible for the increased neurodevelopmental sequelae observed in IUGR infants. 
 
Chapter 5 has discussed why altered mitochondrial function is the most likely mechanism by 
which aberrations in NAA:Cho and NAA:Cr result in IUGR fetuses, the relationship between 
cerebral volume blood flow and metabolite ratios will be explored in more detail in the fetal 
brain. 
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6.2 AIMS 
 
1) To correlate volumetric blood flow in the middle cerebral artery with the NAA:Cho 
and NAA:Cr ratios in both appropriately grown and growth restricted fetuses. 
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6.3  METHODS 
 
All patients were recruited between June 2007 and January 2010 and only singleton 
pregnancies were included.  Appropriately grown fetuses were recruited following a normal 
anomally scan between 19 and 23 weeks gestation.  IUGR fetuses were recruited from the 
Centre for Fetal Care and were offered an amniocentesis and TORCH screen to exclude 
fetuses with congenital infection or karyotype abnormalities.  IUGR was defined as an 
estimated fetal weight below the 10
th
 centile.  Maternal demographics of all women were 
recorded as described previously. 
 
Appropriately grown fetuses underwent assessment of biometry, estimation of fetal weight, 
amniotic fluid index and volume blood flow in the middle cerebral artery (as described in 
Chapter 3).  All IUGR fetuses underwent MRS of the fetal brain within 24 hours of the 
ultrasound assessment.  All appropriately control fetuses underwent ultrasound assessments 
within 5 days of the MRS scan.  MRS was performed in accordance with the protocol 
described in Chapter 5.  Only an echo time of 136ms was performed as this echo time proved 
optimal for the detection of lactate and assessing differences in NAA:Cho and NAA:Cr 
ratios. 
 
ANCOVA analysis was used to assess the interactions between volume blood flow in the 
middle cerebral artery, gestation, presence of IUGR and the NAA:Cho and NAA:Cr Ratios.  
Regression analysis was used to assess the relationship of volume blood flow with gestation 
in appropriately grown control fetuses.  During this part of the analysis the effects of head 
circumference on the metabolite ratios. 
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6.4 RESULTS 
 
21 appropriately grown and (24
+1
 to 36
+5
 weeks gestation, median 30
+1
 weeks) 20 IUGR 
fetuses (20
+5
 to 36
+0
 weeks gestation, median 28
+0
 weeks) were assessed.  19 interpretable 
spectra were obtained from appropriately grown fetuses (24
+1
 to 36
+5
 weeks gestation, 
median 30
+1
 weeks) and 19 spectra from IUGR fetuses (20
+5
 to 36
+0
 weeks gestation, median 
28
+0
 weeks.) 
 
Median volume blood flow in appropriately grown fetuses was 76cc/min (range 15-
294cc/min) and 173cc/min (range 52-386cc/min) in IUGR fetuses (see Figure 88).  In the 
appropriately grown control fetuses, volume blood flow in the middle cerebral artery 
increased with increasing gestation (p=0.017). Volume blood flow was significantly higher in 
IUGR fetuses (p=0.01) when both gestational age and estimated fetal weight were accounted 
for. 
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Figure 88 Volume Blood Flow in the Middle Cerebral Artery of Appropriately Grown 
and Growth Restricted Fetuses that Underwent 1HMRS 
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6.4.1 Demographics 
Maternal demographics of fetuses with interpretable spectra at and volume blood flow 
assessment in the middle cerebral artery can be seen in Table 27. 
Maternal Characteristic IUGR Appropriately Grown Significance 
Age 
Range 
Median 
 
19-44 
31 
 
17-44 
32 
Not significant 
BMI 
Range 
Median 
 
18.5-36 
24.5 
 
19-33 
22.6 
Not significant 
Parity 
0 
1 
2 
3 
>3 
 
60% 
20% 
15% 
5% 
0% 
 
68.4% 
26.3% 
5.3% 
0% 
0% 
Not significant 
Ethnicity 
Caucasian 
Asian 
South East Asian 
Afro-carribean 
African 
Other 
 
50% 
30% 
5% 
5% 
0% 
10% 
 
57.9% 
10.5% 
10.5% 
5.3% 
5.3% 
5.3% 
Not significant 
 
Table 27 Maternal Demographics of Women with Appropriately Grown and Growth 
Restricted Fetuses with Interpretable Spectra 
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6.4.2 NAA:Cr Ratios 
As was the case in Chapter 5, there was no correlation between the NAA:Cr ratio and 
increasing gestational age (p=0.281).  For the NAA:Cr ratio, there remained a significant 
correlation (p=0.045) between the presence of IUGR and NAA:Cr ratios:  NAA:Cr ratios 
were significantly lower in IUGR fetuses.  When incorporated into the model there was no 
effect of the NAA:Cr ratio with the head circumference measured by ultrasound (p= 0.57). 
 
There was no significant correlation between middle cerebral artery volume blood flow and 
NAA:Cr ratios, when alterations due to gestational age and the presence of IUGR were 
accounted for (p=0.274).  When the IUGR fetuses alone were analysed, accounting for the 
effects of altering metabolite ratios with increasing gestation there was still no correlation 
between NAA:Cr ratios and volume blood flow in the middle cerebral artery (p=0.123). 
 
6.4.3 NAA:Cho Ratios 
As was the case in Chapter 5, there was a positive correlation between the NAA:Cho ratio 
and increasing gestational age (p=0.002).  There remained a significant correlation (p=0.011) 
between the presence of IUGR and NAA:Cho ratios:  NAA:Cho ratios were significantly 
lower in IUGR fetuses.  When incorporated into the model there was no association between 
head circumference and metabolite ratio (p=0.147) 
 
There was no significant correlation between middle cerebral artery volume blood flow and 
NAA:Cho ratios, when alterations due to gestational age and the presence of IUGR were 
accounted for (p=0.808).  When the IUGR fetuses alone were analysed, accounting for the 
effects of altering metabolite ratios with increasing gestation there was still no correlation 
between NAA:Cho ratios and volume blood flow in the middle cerebral artery (p=0.887). 
 
6.4.4 Outcome Parameters 
The outcome parameters of fetuses that had assessment of volume blood flow in the middle 
cerebral artery and 
1
HMRS can be seen in Table 28 below.  
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Parameter IUGR Appropriately Grown Significance 
Number of Patients 19 19  
Gestation at Delivery 
Range 
Median 
 
21
+2
-37
+4
 
32
+0
 
36
+5
-43
+0
 
40
+1
 
p<0.001 
Sex of Infant 
Girls 
Boys 
Undetermined 
 
74% 
21% 
5% 
 
58% 
42% 
0% 
Not significant 
 
Birthweight Centile 
Range 
Median 
 
<0.01-9 
<0.01 
 
<0.01-99 
35 
p<0.001 
Complications in Perinatal Period 
Livebirth 
Intrauterine Death 
Neonatal Death 
Admissions to Neonatal Unit 
Intraventricular Haemorrhage 
Sepsis 
Respiratory Distress 
Necrotising Enterocolitis 
Uncomplicated Neonatal Course 
 
17 
2 
1 
16 
3 
3 
11 
1 
2 
19 
0 
0 
0 
0 
0 
0 
0 
19 
p<0.001 
Table 28 Outcome Parameters of Fetuses that had Assessment of Volume Blood Flow in 
the Middle Cerebral Artery and 
1
HMRS 
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Two fetuses that were in the appropriately grown control group had birth centiles less than 
the 10
th
 centile.  However, they both maintained constant growth curves and showed no 
evidence of placental insufficiency. 
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6.5 DISCUSSION 
 
It has been demonstrated in accordance with findings from Chapters 3 and 5 that NAA:Cho 
and NAA:Cr ratios were significantly lower in IUGR fetuses than in the control population.  
Interestingly there was no association between the HC and metabolite ratios, gestation 
appeared to be a more significant factor.  Volume blood flow was significantly higher in 
IUGR fetuses.  There was no correlation between volume blood flow and metabolite ratios, 
either as the population as a whole or specifically within the IUGR fetuses.   
 
No previous studies, either in animal models or in the human fetal population have assessed 
the relationship between the metabolic profile of the developing brain and cerebral blood 
flow.  Studies have, however, been performed in adults with severe traumatic brain injury, 
simultaneously assessing cerebral blood flow and NAA levels.  It was demonstrated that in 
patients with a reduction in the NAA:Cr ratio, blood flow was well above ischaemic 
thresholds[328].  Although it is possible that an ischemic event due to hypo-perfusion at the 
time of the initial insult may have occurred resulting in neuronal death, other studies have 
shown that the majority of such patients do not survive after a severe ischaemic insult such as 
this[329].  This group therefore proposed that mitochondrial injury as opposed to neuronal 
death was responsible for the observed reduction in NAA levels. 
 
IUGR is a chronic condition and although it is possible that acute fluctuations in cerebral 
blood flow may be superimposed on this chronic process, all growth restricted fetuses 
included in this part of the study maintained the brain sparing reflex and had increased 
cerebral blood flow on all ultrasound examinations both prior and subsequent to the Magnetic 
Resonance Imaging.  The fact that there was no correlation between volume blood flow in the 
middle cerebral artery and metabolite ratios in either appropriately grown or growth restricted 
fetuses in this study implies that increased cerebral flow is unlikely to be responsible for 
derangements of metabolite ratios.  As suggested in Chapter 5, the most likely explanation for 
a reduction in NAA:Cho and NAA:Cr ratios in IUGR fetuses is an  alteration in the cerebral 
mitochondrial profile in IUGR fetuses. 
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An alteration in cerebral mitochondrial gene expression has been demonstrated in growth 
restricted rat pups[157].  Four important mitochondrial proteins, NADH-ubiquinone 
oxireductase subunit 4, subunit C of the F1F0-ATPase and the adenine nucleotide transporters 
1 and 2 were found to be increased in comparison to control animals.  Individual 
mitochondria also appeared abnormal in the visual cortex in a sheep model of IUGR with an 
increased density of the inner matrix[158].  An increased number of mitochondria profiles per 
unit area was also reported by this group[158].  These alterations may be an attempt to 
compensate for the reduced efficiency of aerobic metabolism in individual mitochondria.   
 
The abnormal intrauterine environment associated with IUGR has already been shown to 
have a long term impact on cellular energy metabolism in the pancreas.  In a rat model of 
IUGR, reactive oxygen species production and oxidative stress increased in IUGR islets.  It 
was found that mitochondrial DNA point mutations accumulated with age and were 
associated with decreased mitochondrial DNA content and reduced expression of 
mitochondria encoded genes in IUGR islets.  This mitochondrial dysfunction resulted in an 
impairment of insulin secretion[180].  This provides an explanation for the increased 
incidence of insulin resistance in both children and adults who were growth restricted in 
utero[330-331] despite the fact that hypoglycaemia acidosis and hypoxia resolve in the early 
perinatal period. 
 
An abnormal cerebral mitochondrial profile has already been observed in the IUGR rat model 
postnatally: cerebral mitochondrial/nuclear DNA ratios, mitochondrial marker protein levels 
and cerebral mRNA levels of mitochondrial proteins were diminished in IUGR juvenile pups 
indicating mitochondrial function is abnormal even after the hypoxic intrauterine 
environment has been removed.  Mitochondrial dysfunction may also render the IUGR brain 
more susceptible to additional insults associated with prematurity such as infection and 
hypoxia-ischaemia associated with delivery.   
 
No fetuses in this component of the study, or indeed any of the IUGR fetuses that underwent 
1
HMRS experienced a loss of compensatory blood flow, as described previously[124].  
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However, this would be extremely interesting to assess the effect on NAA metabolite ratios, 
whether they are even lower due to super-imposed acute ischaemia and neuronal loss.  
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CHAPTER 7 – OVERALL CONCLUSIONS 
 
7.1 DISCUSSION 
 
IUGR is a prevalent and serious obstetric condition associated with significant perinatal 
morbidity and mortality[1].  A phenomenon known as ‘brain sparing’ is thought to exist in 
pregnancies complicated by growth restriction, whereby blood is preferentially diverted to 
supply the fetal brain, at the expense of other ‘non essential’ organs such as the kidneys, 
gastrointestinal tract and lower extremities.  Much of the initial research regarding the brain 
sparing phenomenon and circulatory changes occurring in growth restricted fetuses was 
performed on animal models.  Most of these studies actually involved short periods up to 48 
hours of hypoxia and was therefore not accurately modelling the more chronic condition of 
IUGR[103, 108] and despite this supposedly neuroprotective adaptation, children that were 
growth restricted in utero have a higher incidence of neurodevelopmental sequelae[3].   
 
At present there are no effective therapeutic strategies for treating pregnancies complicated 
by IUGR, and clinical management involves assessing the optimal timing of delivery.  This 
study therefore aimed to understand the pathophysiology of this elusive condition in more 
detail, using non-invasive imaging modalities of high resolution ultrasound, Doppler 
velocimetry and power Doppler to calculate volumetric blood flow in the IUGR fetus as well 
as investigating the metabolic status of the apparently structurally normal developing brain in 
IUGR fetuses using Magnetic Resonance Spectroscopy.  Table 29 summarises the main aims 
and findings of this thesis. 
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Imaging Modality Aims Main Findings 
Ultrasound To assess changes in volume blood flow in 
IUGR fetuses compared with appropriately 
grown fetuses in the umbilical artery, middle 
cerebral artery and renal artery.  Following 
interim analysis, additional vessels were also 
assessed: descending and ascending aorta, 
femoral and carotid arteries. 
Volume blood flow per kg is 
increased in IUGR fetuses in the 
umbilical, middle cerebral artery, 
renal artery, carotid artery and 
ascending aorta in IUGR fetuses.  
There was no difference in volume 
blood flow in the descending aorta. 
To assess differences in vessel diameter 
between appropriately grown and growth 
restricted fetuses in the above vessels. 
All vessels had an increased 
diameter when standardised for 
fetal weight in IUGR fetuses in 
comparison with controls 
Magnetic Resonance 
Spectroscopy 
To assess changes occurring in metabolite 
ratios of the developing brain during normal in 
utero development. 
 
 
 
 
NAA:Cho ratios increase with 
increasing GA. 
Cho:Cr ratios and Myo-ins:Cr 
ratios decrease with increasing GA. 
No relationship between Myo-
ins:Cho and NAA:Cr with GA 
To assess differences in brain metabolite ratios 
between appropriately grown and growth 
restricted pregnancies at three different echo 
times. 
 
NAA:Cho ratios and NAA:Cr 
ratios are lower in IUGR fetuses 
than in controls. 
No differences in Cho:Cr, Myo-
ins:Cho or Myo-ins:Cr ratios 
between IUGR and control fetuses 
 
To investigate the feasibility of obtaining 
metabolite ratios in other fetal tissues including 
the fetal liver, amniotic fluid and placenta. 
 
Obtaining spectra from fetal liver, 
placenta and amniotic fluid was 
unfeasible in this study 
Ultrasound and 
Magnetic 
Spectroscopy 
To correlate volume blood flow in the middle 
cerebral artery with the metabolic profile of the 
developing brain in both appropriately grown 
and growth restricted fetuses. 
 
There was no correlation between 
volume blood flow in the middle 
cerebral artery and NAA:Cho or 
NAA:Cr ratios. 
 
Table 29 Main Aims and Results of Study 
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This study has longitudinally assessed 150 appropriately grown fetuses between 16
+1
 and 
39
+6
 weeks gestation and 78 growth restricted fetuses between 20
+0
 and 39
+2
 weeks gestation 
using power Doppler in order to calculate vessel diameter, Doppler velocimetry and Volume 
Blood Flow.  Initially, three vessels commonly used in clinical practice, the umbilical artery, 
middle cerebral artery and renal arteries were assessed.  However, due to preliminary 
findings further vessels were also analysed including the ascending and descending aorta, 
internal carotid and femoral arteries. 
 
In accordance with previous studies, a decrease in the PI of the middle cerebral artery, 
ascending aorta and internal carotid were noted in the IUGR cohort in comparison with 
appropriately grown controls and an increase in the PI of the descending aorta and umbilical 
artery.  These findings are all in accordance with previous publications[100] and such results 
have been cited in support of the brain sparing phenomenon.  No difference in renal artery PI 
was observed between the two groups, which is consistent with some previously published 
studies[138-139].  An increase in the PI of the femoral artery was observed in IUGR fetuses, 
which is in contrast to existing literature[140]; this may be related to the small size and 
difficulty in identification of the femoral vessel and poor insonation angle.  Nevertheless, 
Doppler velocimetry is only an indirect assessment of blood flow and consequently volume 
blood flow was calculated using knowledge of the vessel diameter and peak systolic velocity. 
 
Vessel diameter, when standardised for fetal weight, was significantly greater in IUGR 
fetuses in the ascending aorta, internal carotid and middle cerebral arteries, which would be 
in accordance with the brain sparing phenomenon; however, the umbilical arteries, 
descending aorta and femoral arteries also had an increase in vessel diameter when 
standardised for fetal weight.  This is in contrast to previous understanding of the 
pathophysiology of IUGR where it has been assumed that peripheral vasoconstriction occurs 
in order to maintain perfusion to ‘essential’ organs such as the heart and brain.   
 
In accordance with the brain sparing phenomenon, volume blood flow was increased in the 
middle cerebral artery, ascending aorta and internal carotid artery.  In contrast with previous 
assumptions of preferential cerebral redistribution of blood flow, no alteration was found in 
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volume blood flow in the descending aorta between appropriately grown and growth 
restricted fetuses.  Indeed an increase in volume blood flow was also found in the umbilical 
and renal and femoral arteries when standardised for fetal weight.   
 
These findings may be attributable to an alteration in the balance of circulating vasoactive 
factors in IUGR fetuses, resulting in generalised vasodilation, increasing blood flow and 
thereby maintaining tissue perfusion (see Chapter 3).  An alteration in the structure, 
composition and innervation of blood vessels may also in part be responsible for these 
findings (see Chapter 3).  However, it must also be taken into account that measurement of 
small vessels, even utilising power Doppler, is difficult, and when calculating volume blood 
flow mean velocity is calculated by halving the peak systolic velocity, thus not taking into 
account varying diastolic flow.  The angle of insonation is also very important when 
calculating Doppler velocimetry measurements.  Although all measurements were kept below 
60
o
, vessels where the angle of insonation was closer to zero such as the middle cerebral, 
renal and umbilical arteries, are likely to provide more accurate estimation of volume blood 
flow. 
 
Another interesting result to emerge from this study is that early and late onset IUGR may 
vary in their pathophysiology.  It is increasingly being reported that early and late pre-
eclampsia have disparate pathophysiologies[332].  Early onset disease has been reported to 
be associated with abnormal placentation with abnormal remodelling of maternal spiral 
arteries postulated to be attributable to a defective maternal immune response to trophoblasts.  
Abnormal endothelial activation and the maternal inflammatory response then results in 
maternal manifestations of pre-eclampsia[332].  Late onset pre-eclampsia has been proposed 
to have a separate pathology: maternal factors such as cardiovascular and metabolic disorders 
may result in the activation of placental and systemic inflammation and oxidative stress[332].  
Angiogenic factors have also been reported to be abnormal in fetuses with early onset (pre 34 
weeks) pre-eclampsia but not those with later onset disease (post 34 weeks)[170].  
 
IUGR is also a disease which is also thought to be attributable to abnormal placentation and 
many cases of IUGR and pre-eclampsia occur concomitantly, particularly when the 
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conditions manifest prior to 34 weeks gestation.  It is therefore feasible that two separate 
disorders, early and late onset, also occur in growth restricted fetuses.  It has already been 
reported that early onset IUGR is associated with abnormal development of the villous tree 
which can result from a severe reduction in uterine blood flow.  A reduction in branching 
angiogenesis and decreased placental vascularisation results in a reduction in villi number 
with poor capillary formation.  Peripheral villi which contain slender unbranched and 
uncoiled capillary loops have also been reported.  This results in a reduction in surface area 
available for maternal-fetal nutrient transport[17].  A lack of oxygen extraction and 
consumption by the IUGR fetus means that the oxygen content of maternal blood exiting the 
placenta is close to arterial values.  Increased PlGF versus VEGF expression has been found 
in early onset IUGR fetuses which further perpetuates a reduction in non branching 
angiogenesis and abnormal villous tree formation[23].  Late onset IUGR, however, 
demonstrates increased branching angiogenesis secondary to deficient remodelling of the 
spiral arteries.  Uteroplacental hypoxia is thought to be due to increased expression of factors 
which stimulate branching angiogenesis[17].  IUGR in late pregnancy is also associated with 
increased maturation of the placenta (Grannum grade 2 or 3) and a 40% increase in capillary 
fraction volume[31].   
 
No fetuses that developed IUGR in this study subsequent to 34 weeks gestation had absent 
end diastolic flow in the umbilical artery, possibly due to increased branching angiogenesis 
within the placenta, and there did not appear to be any significant difference in volume blood 
flow, when standardised for fetal weight, between late onset IUGRs and the control 
population, whereas early onset IUGR had significantly increased volume blood flow in the 
umbilical artery.  Although volume blood flow was increased overall in the middle cerebral 
artery, even in IUGR fetuses with no evidence of cerebral redistribution on Doppler 
velocimetry, fetuses with late onset IUGR had no evidence of increased cerebral blood flow 
when standardised for fetal weight, whereas early onset IUGR fetuses had significantly 
increased volume blood flow.  Despite the fact that numbers were small in this subgroup 
analysis, further investigation is warranted, particularly with the association of an increased 
risk of cerebral palsy in IUGR fetuses delivered after 33 weeks gestation[3]. 
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The next component of the study assessed the metabolic profile of the developing brain in 46 
appropriately grown  fetuses between 22
+0
 and 38
+6
 weeks gestation and 28 growth restricted 
fetuses between 20
+3
 and 35
+0
 weeks gestation utilising the technique of 
1
HMRS.  It was 
demonstrated that this technique was a feasible reproducible modality with which to 
investigate the metabolic profile of the fetal brain in vivo.  The appropriately grown 
population was first assessed and it was demonstrated that ratios of metabolites NAA:Cho 
increased with increasing gestational age and Cho:Cr decreased with advancing gestation at 
echo times of 136ms and 270ms.  At a shorter echo time the Myo-ins:Cr and Cho:Cr 
decreased with advancing gestation. 
 
These findings may be attributable to: increasing levels of NAA during development which 
may be reflective of synaptic complexity and increased myelination, as well as, reflecting 
development of neuronal mitochondria; decreasing levels of choline due to the high levels 
required for cell membrane formation [282]and increased myelination [249] with advancing 
gestation; decreasing myo-inositol levels as the highest density of glial cells is between 22 
and 28 weeks gestation[302]; stable Cr levels[249]. 
 
The metabolic profile of the fetal brain of IUGR fetuses was compared with that of 
appropriately grown fetuses.  A demonstrable alteration in brain metabolism was evident: 
IUGR fetuses had significantly lower NAA:Cho and NAA:Cr ratios.  This is most likely to be 
reflective of reduced NAA levels.  NAA has been proposed to be a neuronal marker; however 
it is also present in oligodendrocytes[274] and is known to be synthesised in mitochondria.  
Mitochondrial function has been reported to be abnormal in multiple tissues in growth 
restricted fetuses including the brain [156-157, 183].  This may be an attempt to compensate 
for abnormal substrate supply and is a response to metabolic stresses associated with IUGR.  
It is, therefore, likely that alterations in mitochondrial function may be responsible for the 
deranged NAA:Cho and NAA:Cr ratios found in this study.  No alterations were noted in 
Cho:Cr, Myo-ins:Cr or Myo-ins:Cho ratios.  All IUGR fetuses in this part of the study 
developed IUGR prior to 34 weeks gestation and are therefore likely to represent early onset 
IUGR. 
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To investigate the fact that increased blood flow to the developing brain associated with 
IUGR has been reported to be ‘brain sparing’, the relationship between volume blood flow 
and NAA:Cho and NAA:Cr ratios in appropriately grown and growth restricted fetuses was 
investigated.  There was no relationship between volume blood flow and these metabolite 
ratios.  IUGR is a chronic condition and although it is possible that acute fluctuations in 
cerebral blood flow may be superimposed on this chronic process, all growth fetuses included 
in this part of the study maintained the brain sparing reflex.  The fact that there was no 
correlation between volume blood flow in the middle cerebral artery and metabolite ratios in 
either appropriately grown or growth restricted fetuses in this study implies that increased 
cerebral flow is unlikely to be responsible for derangements of metabolite ratios.  This further 
supports an alteration in the cerebral mitochondrial profile being responsible for the reduced 
NAA:Cho and NAA:Cr ratios observed in IUGR fetuses.   
 
An abnormal mitochondrial profile has also been proposed as an explanation as to why 
individuals that were growth restricted in utero are more susceptible to the metabolic 
syndrome in later life.  In a rat model of IUGR the abnormal intrauterine environment has 
been shown to have a long term impact on cellular energy metabolism in the pancreas.  It was 
found that mitochondrial DNA point mutations accumulated with age and were associated 
with decreased mitochondrial DNA content and reduced expression of mitochondria encoded 
genes in IUGR islets which resulted in an impairment of insulin secretion[180].  This 
provides an explanation for the increased incidence of insulin resistance in both children and 
adults who were growth restricted in utero[330-331] despite the fact that hypoglycaemia 
acidosis and hypoxia resolve in the early perinatal period.  It is therefore possible that 
mitochondrial dysfunction may also be associated with the neurodevelopmental sequelae 
observed in individuals that were growth restricted in utero in the absence of overt structural 
neurological lesions.   
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7.2 FUTURE WORK 
 
7.2.1 Ultrasound Component of the Study 
7.2.1.1 Assessment of Vasoactive Factors in Umbilical Cord Blood 
To assess the relationship between circulating vasoactive factors and vessel diameter, 
umbilical cord blood samples of various factors could be assessed, including adrenomedullin, 
endothelin-1, angiotensin II, renin, nitric oxide derivatives, thromboxane A2 and prostacyclin 
in appropriately grown and growth restricted pregnancies.  Vessel diameters could be 
measured using power Doppler immediately prior to Caesarean section delivery in IUGR 
fetuses and umbilical vein and artery cord blood collected at delivery.  The control group 
would be harder to obtain, as elective Caesarean sections commonly occur at term.  
Consequently, it would first be necessary to assess whether these factors alter with increasing 
gestation in the appropriately grown control population (and whether mode of delivery also 
affects concentrations). 
 
7.2.1.2 Assessment of Vessel Diameters in Systole and Diastole 
Although systolic diameters have been found to be significantly increased in IUGR fetuses in 
comparison with appropriately grown controls when standardised for fetal weight, diastolic 
diameters were not assessed during this study.  Diastolic diameters may also alter in IUGR 
fetuses partly as a consequence of altered vessel recoil due to altered vessel composition. 
 
7.2.1.3 Pathology Specimens of IUGR Fetuses 
The vessel composition of IUGR fetuses could be assessed at post-mortem examination.  
Quantification of elastin and collagen in multiple fetal vessels in fetuses that had been 
assessed with ultrasound prior to intrauterine death could be undertaken.  However, only a 
small number of early onset IUGR fetuses that die in utero are likely to have been serially 
assessed and obtaining consent from such patients may also prove difficult.  Secondly, a 
suitable control group of appropriately grown fetuses is impossible to obtain in this situation.  
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7.2.2 
1
HMRS Component of the Study 
7.2.2.1 Technique of 1HMRS 
Further work is required to optimise scanning techniques.  Possibilities exist to counteract the 
effects of maternal respiration.  These include Navigator echo sequences which have been 
used to successfully obtain cardiac spectra in adults and a similar technique may be utilised in 
fetal spectroscopy[333].  At present the use of higher magnetic field strength in fetal studies 
has been limited to animal models[334].  However, in the future the use of a 3T MRI scanner 
may facilitate a reduction in acquisition time, superior signal to noise ratio and increased 
spectral separation and resolution.  This may also facilitate sampling more specific areas on 
the fetal brain facilitated by a smaller voxel size. 
 
7.2.2.2 Carbon/phosphorous spectroscopy 
Other nuclei can be utilised in MRS e.g. carbon and phosphorous.  However, these require 
specific coils that may not be available on commercial clinical scanners.   Animal studies 
using 
31
P (Phosphorus) MRS to assess cerebral energy metabolism have been performed.  
31
P 
MRS can be used to measure phosphorous metabolites involved in cerebral energy 
metabolism, such as, phosphocreatine, inorganic phosphate and Adenosine Triphosphate.  
Van Cappellen et al studied cerebral energy metabolism during impaired oxygen supply in 
fetal sheep.  They found that with low arterial pH, phosphocreatine and nucleoside 
triphosphate levels were decreased significantly and at a pH of below 7 nucleoside 
triphosphates disappeared.  This was associated with subsequent fetal death[335].  
13
C 
(Carbon) MRS has also been performed and used to perform dynamic analysis of metabolite 
flux rates in vivo.  Lapidot et al used 
13
C MRS to assess fetal metabolism in a rabbit model of 
diabetes[336].  
13C MRS has also been used to assess Alzheimer’s, Canavan’s disease, 
mitochondrial and hepatic encephalopathy, epilepsy and normal brain development in human 
studies[337]. 
 
7.2.2.3 Assessment of N-acetylaspartate in Animal Models 
Given the association between a supposed reduction in NAA levels and IUGR fetuses these 
findings should be translated to an animal model. MRS will be undertaken on the IUGR rat 
brain. If this confirms a reduction in NAA levels mitochondrial function will be assessed.  
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This work in collaboration with Professor Pierre Gressens and Professor Henrik Hagberg, 
IRDB Imperial College has already commenced.  If mitochondrial abnormalities are 
confirmed, this may provide a future therapeutic target and 
1
HMRS may provide a clinical 
method for assessing treatment response. 
 
7.2.3 All Components of the Study 
7.2.3.1 Outcome Parameters 
The most important aspect to both components of this study is to correlate these findings of 
altered vessel diameter, volume blood flow and metabolic profile with both short and long 
term outcome.  This may prove challenging as some of the adverse neurodevelopmental 
sequelae associated with IUGR, such as cerebral palsy, occur infrequently in the population 
and consequently a suitably powered study would require very large numbers.  Follow up 
would have to be at least until school age, as this is when some of the more subtle 
developmental differences in children who were growth restricted in utero become apparent.  
To detect associations between alterations in vessel diameter and volume blood flow and 
cardiovascular disease would require large numbers and follow up into late adulthood which 
may not prove feasible. 
 
7.2.3.2 Subgroup Analysis 
This study has demonstrated that the pathophysiology of early onset IUGR (prior to 34 
weeks) is likely to be different from that of late onset IUGR (after 34 weeks).  This could be 
further investigated by analyzing the metabolic profile of the developing brain in late onset 
IUGR fetuses as well as increasing the numbers in the late onset IUGR subgroup for 
ultrasound components of the study in order to assess true significance.  Increased subgroup 
analysis of IUGR fetuses with positive end diastolic flow, absent end diastolic flow, reversed 
end diastolic flow in the umbilical cord and those fetuses with venous changes should also be 
investigated.  This would again require increased numbers. 
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Appendix 
 
 
Pulsatility Index in the Descending Aorta in Appropriately Grown and Growth Restricted 
Fetuses ( p<0.001) 
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Peak Systolic Velocity in the Descending Aorta in Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Vessel Diameter in the Descending Aorta in Appropriately Grown and Growth Restricted 
Fetuses (p=ns) 
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Vessel Diameter per Kilgram in the Descending Aorta in Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Volume Blood Flow in the Descending Aorta in Appropriately Grown and Growth Restricted 
Fetuses (p<0.001) 
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Volume Blood Flow per Kilogram in the Descending Aorta in Appropriately Grown and 
Growth Restricted Fetuses (p=ns) 
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Pulsatility Index in the Ascending Aorta in Appropriately Grown and Growth Restricted 
Fetuses (p<0.001) 
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Peak Systolic Velocity in the Ascending Aorta in Appropriately Grown and Growth 
Restricted Fetuses (p=ns) 
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Vessel Diameter in the Ascending Aorta in Appropriately Grown and Growth Restricted 
Fetuses (p=0.003) 
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Vessel Diameter per Kilogram in the Ascending Aorta in Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Volume Blood Flow in the Ascending Aorta in Appropriately Grown and Growth Restricted 
Fetuses (p=0.043) 
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Volume Blood Flow per Kilogram in the Ascending Aorta in Appropriately Grown and 
Growth Restricted Fetuses (p<0.001) 
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Pulsatility Index of the Internal Carotid Artery in Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Peak Systolic Velocity in the Internal Carotid Artery in Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Vessel Diameter in the Internal Carotid Artery in Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Vessel Diameter per Kilogram in the Internal Carotid Artery in Appropriately Grown and 
Growth Restricted Fetuses (p<0.001) 
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Volume Blood Flow in the Internal Carotid Artery in Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Volume Blood Flow per Kilogram in the Internal Carotid Artery in Appropriately Grown and 
Growth Restricted Fetuses (p<0.001) 
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Pulsatility Index in the Femoral Artery in Appropriately Grown and Growth Restricted 
Fetuses (p=0.009) 
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Peak Systolic Velocity in the Femoral Artery in Appropriately Grown and Growth Restricted 
Pregnancies (p<0.001) 
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Vessel Diameter in the Femoral Artery in Appropriately Grown and Growth Restricted 
Fetuses (p<0.001) 
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Vessel Diameter per Kilogram in the Femoral Artery of Appropriately Grown and Growth 
Restricted Fetuses (p<0.001) 
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Volume Blood Flow in the Femoral Artery in Appropriately Grown and Growth Restricted 
Fetuses (p=ns) 
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Volume Blood Flow per Kilogram in the Femoral Artery in Appropriately Grown and 
Growth Restricted Fetuses (p=0.001) 
 
 
 
 
 
 
 
